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With	  chronic	  liver	  disease	  rising,	  the	  need	  to	  stage	  of	  liver	  disease	  and	  fibrosis	  accurately	  is	  
paramount	   as	   it	   helps	   guide	   therapy	   and	   informs	  prognosis.	   Liver	   biopsy	   is	   a	   flawed	   gold	  
standard,	  associated	  with	  morbidity	  and	  mortality.	  Application	  of	  simple	  non-­‐invasive	  tests	  
to	   assess	   fibrosis	   could	   provide	   a	   safe	   way	   of	   identifying	   patients	   in	   greatest	   need	   of	  
intervention	  and	  of	  monitoring	  response	  to	  therapy.	  
	  
I	   have	   shown	   in	   this	   thesis	   that	   transient	   elastography	   is	   an	   excellent	   tool	   for	   ruling	   out	  
significant	   fibrosis	   in	   patients	  with	   chronic	   liver	   disease.	   It	   is	   easy	   to	   learn	   and	   successful	  
scanning	  correlates	  well	  with	  histological	  liver	  fibrosis.	  
I	   have	   also	   shown	   that	   Use	   of	   APRI	  with	   a	   cut	   off	   of	   >1.5-­‐2	   and	   Fib-­‐4	   >3.25	   can	   provide	  
prognostic	  value	  for	  overall	  and	  liver-­‐related	  mortality	  in	  patients	  with	  viral	  hepatitis.	  
Finally	   I	   have	   assessed	   a	   range	   of	   potential	   new	   biomarkers	   showing	   that	   combining	  
measuring	   serum	   levels	   of	   the	   chemokine	   CXCL10	   and	   the	   endothelial	   adhesion	   receptor	  
VAP-­‐1	  can	  increase	  the	  correlation	  strength	  with	  fibrosis	  stage.	  Using	  morphometric	  analysis	  
of	   liver	   fibrosis	   I	   show	   that	   the	   same	  markers	   can	   be	   linked	   to	   quantitatively	   measured	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  laboratory	  practice	  
GCSF	  granulocyte	  colony-­‐stimulating	  factor	  
GMCSF	  granulocyte	  macrophage	  colony-­‐stimulating	  factor	  
GP130	  Gylcoprotein	  130	  
HBV	  –	  Hepatitis	  B,	  	  
HCC,	  hepatocellular	  carcinoma;	  	  
HCV	  –	  Hepatitis	  C	  virus,	  	  
HGF	  Hepatocyte	  Growth	  Factor	  
HIV-­‐	  Human	  Immunodeficiency	  virus,	  	  
HOMA-­‐IR	  Homeostatic	  Model	  Assessment	  of	  Insulin	  Resistance	  
HR	  Hazard	  Ratio	  
HSC	  Hepatic	  stellate	  cells	  
I-­‐TAC	  Interferon-­‐inducible	  T	  cell	  alpha	  chemoattractant	  




IP10	  Serum	  Interferon-­‐gamma-­‐inducible	  protein	  10	  
IQR,	  interquartile	  range;	  	  
IR	  Insulin	  Resistance	  
ITU	  –	  Intensive	  care,	  	  
JNK	  c-­‐Jun	  N-­‐terminal	  kinase	  
LKK	  I	  kappa	  B	  kinase	  
LSM	  –	  Liver	  stiffness	  measurement,	  	  
LSM,	  liver	  stiffness	  measurement;	  
MCP-­‐1	  monocyte	  chemotactic	  protein	  -­‐1	  
MMP	  matrix	  metalloproteinase	  	  
MRE	  magnetic	  resonance	  elastography	  
MRI	  Magnetic	  Resonance	  Imaging	  
MRS	  Magnetic	  resonance	  spectrography	  
NAFLD	  –	  Non-­‐alcoholic	  fatty	  liver	  disease,	  	  
NASH	  Non-­‐alcoholic	  steatohepatitis	  
NK	  Natural	  killer	  
NOS	  nitric	  oxide	  species	  
NPV,	  negative	  predictive	  value;	  	  
OR	  Odds	  ratio	  
P-­‐Prospective,	  	  
P3Np	  N-­‐terminal	  procollagen	  3	  peptide	  
PAI-­‐1	  plasminogen	  activator	  inhibitor	  1	  
PBC,	  primary	  biliary	  cirrhosis,	  	  
PDGF	  platelet	  derived	  growth	  factor	  
PPV,	  positive	  predictive	  value;	  	  
PSC	  –	  primary	  sclerosing	  cholangitis,	  	  
R-­‐Retrospective	  
RANTES	  Regulated	  upon	  Activation,	  Normal	  T	  cell	  Expressed	  and	  Secreted	  
RFA	  radio-­‐frequency	  ablation	  
ROC,	  receiver	  operating	  characteristic;	  	  
ROS	  reactive	  oxygen	  species	  
RR	  relative	  risk	  
SD	  Standard	  deviation	  
SE	  Standard	  Error	  
SMA	  smooth	  muscle	  actin	  
TE,	  transient	  elastography	  
TG	  Triglyceride	  
TGF-­‐	  β	  transforming	  growth	  factor	  –beta	  
TGF-­‐α	  transforming	  growth	  factor	  alpha	  
TIMP	  tissue	  inhibitor	  of	  metalloproteinase	  
TNF-­‐	  α	  tumour	  necrosis	  factor	  –	  alpha	  
TPA	  tissue	  plasminogen	  activator	  
TRAIL	  TNF	  –	  related	  apoptosis	  inducing	  ligand	  
VAP-­‐1	  Vascular	  Adhesion	  Protein	  1	  






Worldwide,	  liver	  related	  morbidity	  and	  mortality	  continue	  to	  rise.	  It	  is	  the	  5th	  highest	  cause	  
of	  death	  in	  the	  UK	  (Office	  National	  Statistics)	  
 
 
Figure	  1-­‐1	  Increasing	  Liver	  Mortality	  –	  data	  from	  ONS	  
	  
Cirrhosis	  is	  a	  pathological	  process	  common	  to	  all	  causes	  of	  chronic	  liver	  disease.	  The	  exact	  
point	   when	   fibrosis	   becomes	   irreversible	   is	   difficult	   to	   define	   and	   the	   underlying	  
mechanisms	  are	  not	  completely	  understood.	  Cirrhosis	  has	  major	  effects	  on	  the	  liver	  causing	  
a	   disordered	   architecture	   leading	   to	   portal	   hypertension.	   This	   manifests	   itself	   as	   varices,	  
ascites	  and	  encephalopathy.	  Cirrhosis	  also	  has	  the	  potential	  to	  develop	  into	  hepatocellular	  
carcinoma	  (HCC)	  in	  3%	  per	  year	  in	  HBV	  and	  HCV	  with	  similar	  risk	  in	  alcoholic	  liver	  disease.	  In	  
patients	  with	   iron	  overload	   and	   cirrhosis,	   this	   can	   rise	   as	   high	   as	   7%	  per	   year.	   Risk	  drops	  
with	  venesection	  but	  not	  back	  to	  baseline.	  In	  contrast,	  patients	  with	  autoimmune	  hepatitis	  
related	   cirrhosis	   have	   a	   very	   low	   risk	   of	   HCC	   development(Ryder,	   2003).	   Patients	   with	  
1 CHAPTER	  1:	  GENERAL	  INTRODUCTION	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established	   cirrhosis	   can	   remain	   free	   of	   clinical	   symptoms	   for	  many	   years,	   in	   which	   case	  
they	  are	  said	  to	  have	  compensated	  cirrhosis.	  The	  rate	  at	  which	  both	  fibrosis	  and	  subsequent	  
decompensation	  develop	  are	  determined	  by	  environmental	  and	  genetic	  factors	  which	  helps	  
to	  explain	  the	  broad	  spectrum	  of	  response	  to	  the	  same	  aetiological	  agent	   in	  patients	  with	  
chronic	   liver	  diseases(Bataller	  and	  Brenner,	  2005).	  Patients	  with	  self-­‐limiting	  acute	  disease	  
such	   as	   hepatitis	   A	   do	   not	   usually	   develop	   scarring	   despite	   activation	   of	   inflammatory	  
pathways	  and	  scarring	  only	  develops	  if	  the	  injury	  becomes	  chronic	  and	  persists.	  
The	   development	   of	   clinical	   complications	   of	   portal	   hypertension	   or	   symptoms	   and	   the	  
development	   of	   HCC	   are	   associated	   with	   a	   much	   worse	   outcome	   as	   illustrated	  











Figure	  1-­‐2	  Chart	  showing	  worsening	  prognosis	  after	  decompensation	  (from	  D’Amico	  et	  al,	  
J	  Hep	  2006)	  	  
	  
Liver	   transplantation	   is	   currently	   the	   only	   curative	   treatment	   for	   end	   stage	   chronic	   liver	  
disease.	  Its	  high	  demand	  has	  not	  been	  matched	  by	  a	  rise	  in	  liver	  donations	  leading	  to	  high	  
levels	  of	  mortality	  on	  the	  waiting	   list	  and	  those	  who	  receive	  a	   liver	  transplant	  require	   life-­‐
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long	   immunosuppression	   with	   the	   consequent	   risks	   of	   infection	   cancer	   and	   increased	  




1.2 Normal	  liver	  architecture	  
 
A	   fibrocollagenous	   capsule	   surrounds	   the	   liver	   with	   connective	   tissue	   (stroma)	   extending	  
into	   it	   as	   septa,	   which	   contain	   the	   vasculature	   and	   ducts	   of	   the	   liver.	   The	   stroma	   thus	  
divides	   the	   liver	   into	   lobules	   and	   allows	   for	   an	   ordered	   architecture	   supporting	   veins,	  
arteries	   and	   a	  biliary	   system.	   This	   architecture	  becomes	  disrupted	   in	   fibrotic	   liver	   disease	  
with	   consequent	   effects	   on	   the	   flow	   of	   blood	   and	   bile	   in	   and	   through	   the	   liver.	   The	  
replacement	  of	  normal	  liver	  cells	  with	  scar	  tissue	  also	  has	  functional	  consequences	  that	  can	  
result	  in	  liver	  failure	  if	  the	  mass	  of	  functional	  liver	  cells	  falls	  below	  a	  threshold.	  






Taken from https://courses.stu.qmul.ac.uk/smd/kb/microanatomy/d/alimentary/answers/index.htm 
 








Taken from https://courses.stu.qmul.ac.uk/smd/kb/microanatomy/d/alimentary/answers/index.htm 
Figure	   1-­‐4	  Alternative	   view	  of	   normal	   liver	   architecture	   showing	   portal	   tract,	   sinusoidal	  




1.3 What	  is	  the	  process	  behind	  liver	  fibrosis?	  
 
Repetitive	  injury	  in	  the	  liver	  stimulates	  an	  inflammatory	  response,	  which	  attempts	  to	  clear	  
the	   instigating	   factor,	   for	   example	   a	   virally	   infected	   hepatocyte,	   and	   then	   heal	   the	   injury	  
through	  fibrogenesis	  to	  maintain	  hepatic	   integrity.	  Liver	   fibrogenesis	  occurs	   in	  the	  context	  
of	   a	   chronic	   inflammatory	   response,	  which	   leads	   to	  myofibroblast	  proliferation,	   increased	  
production	  of	  extracellular	  matrix	  and	  parenchymal	  cell	  proliferation	  as	  part	  of	  a	  process	  of	  
scar	   formation	   and	   regeneration	   that	   replaces	   hepatocytes	   lost	   through	   necrosis	   or	  
apoptosis.	   In	  the	  wound	  healing	  response,	   increased	  extracellular	  matrix	  (ECM)	  deposition	  
occurs	   and	   this	   is	   a	   normal	   appropriate	   response.	   The	   constituents	   of	   this	  matrix	   include	  
basement	   membrane	   and	   interstitial	   collagens,	   proteoglycans,	   elastin	   and	   matrix	  
glycoproteins	   such	   as	   fibronectin	   and	   laminin.	   In	   normal	   liver	   fibril	   forming	   collagens	   are	  
physiological.	   Types	   1,	   3	   and	   5	   are	   found	   in	   the	   capsule,	   around	   large	   vessels	   and	   in	   the	  
portal	  areas(Friedman,	  2008)	  
	  
Types	  3	  and	  4	  collagens	  with	  fibronectin	  accumulate	  early	  in	  liver	  injury	  in	  the	  space	  of	  Disse	  
and	  over	  time	  greater	  amounts	  of	  type	  1	  and	  4	  collagen	  together	  with	  elastin	  and	  laminin	  re	  
deposited	  as	  the	  injury	  becomes	  sustained	  and	  chronic.	  Although	  all	  4	  types	  of	  collagen	  are	  
increased	  by	  3-­‐10	  fold,	  the	  proportion	  of	  type	  1	  collagen	   in	  chronic	   liver	  disease	   increases	  
the	  most.	   The	  maturity	   of	   the	   fibrosis	   can	   therefore	   be	   assessed	   using	   knowledge	   of	   the	  
different	   types	   of	   ECM	   deposited	   together	   with	   the	   amount	   of	   crosslinking	   observed.	  
Recently	  it	  was	  shown	  that	  elastin	  accumulation	  in	  liver	  injury	  occurs	  not	  only	  as	  a	  result	  of	  
increased	   synthesis	   but	   also	   as	   a	   failure	   of	   matrix	   metalloproteinase	   (MMP)	   -­‐12	   derived	  
degradation(Pellicoro	  et	  al.,	  2012).	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1.4 Development	  of	  cirrhosis	  
 
Wound	  healing	  is	  a	  complicated	  process,	  which	  involves	  matric	  deposition,	  degradation	  and	  
remodelling.	   Excessive	   accumulation	   of	   the	   ECM	   occurs	   in	   persisting	   hepatic	   injury	  
associated	   with	   dysregulated	   regeneration.	   This	   leads	   to	   disruption	   of	   normal	   tissue	  
architecture	   and	   loss	   of	   function.	   Subsequent	   development	   of	   nodules	   of	   regenerating	  
hepatocytes	   surrounded	   by	   scar	   tissue	   defines	   cirrhosis.	   An	   imbalance	   between	  
fibrinogenesis	  and	  fibrinolysis	  leads	  to	  scar	  formation.	  Fibrogenesis	  is	  the	  production	  of	  ECM	  
whereas	  fibrinolysis	  is	  the	  breakdown	  of	  ECM	  by	  matrix	  metalloproteinases.	  Fibrinogenesis	  
is	   usually	   insidious	   taking	   many	   years	   for	   cirrhosis	   to	   manifest	   other	   than	   in	   special	  
situations	  such	  as	  neonatal	  liver	  disease.	  	  
There	  are	  many	  different	  causes	  of	  liver	  injury	  with	  different	  patterns	  of	  damage	  reflecting	  
the	   site	   of	   injury	   (e.g.	   biliary,	   perisiunsoidal	   or	   peri	   central).	   	   However	   the	   underlying	  
processes	   are	   similar	   and	   chronic	   inflammation	   is	   central	   to	   the	   process	   of	   fibrogenesis	  





1.5 Crosslinking	  and	  development	  of	  advance	  cirrhosis	  
 
Crosslinking	  of	  collagen	  and	  maturation	  of	   the	  scar	  with	   increasing	   levels	  of	  elastin	  occurs	  
via	  the	  action	  of	  lysyl	  oxidase	  and	  tissue	  transglutaminase.	  In	  animal	  models	  the	  reversibility	  
of	   fibrosis	   is	   dependent	   upon	   this	   level	   of	   cross-­‐linking	   and	   increased	   septal	   thickness	   /	  
smaller	  nodules	  are	  associated	  with	  poor	  outcomes	  (Nagula	  et	  al.,	  2006).	  
 
1.5.1 Why	  is	  cirrhosis	  important?	  
As	   mentioned	   above,	   the	   disruption	   to	   the	   liver	   in	   cirrhosis	   presents	   structural	   and	  
physiological	  problems	  to	  the	  patient.	  Patients	  with	  cirrhosis	  often	  have	  portal	  hypertension	  
as	   a	   result	   of	   intrahepatic	   resistance	   and	   increased	   portal	   blood	   flow.	   The	   resistance	   to	  
blood	  flow	  is	  due	  to	  the	  fact	  that	  the	  normally	  compliant	  liver	  cannot	  respond	  to	  increased	  
portal	   blood	   flow	  by	  distending	  because	   the	   scar	   and	   regenerative	   nodules	   compress	   the	  
vasculature.	  This	  manifests	  as	  varices,	  ascites	  and	  splenomegaly.	  
Replacement	  of	  hepatocytes	  with	  scar	  tissue	  reduces	  the	  functional	  mass	  of	  liver	  tissue	  and	  
leads	  to	  liver	  failure	  with	  reduced	  formation	  of	  essential	  proteins	  involved	  in	  clotting	  as	  well	  
as	  reducing	  the	  liver’s	  ability	  to	  filter	  splanchnic	  blood.	  In	  patients	  with	  cirrhosis	  and	  varices,	  




1.6 Cell	  death	  
 
Apoptosis	  maintains	   tissue	   homeostasis	   and	   health	   by	   counterbalancing	   cell	   proliferation	  
and	   eliminating	   damaged	   and	   or	   old	   cells.	   Liver	   injury	   frequently	   results	   in	   hepatic	   cell	  
apoptosis.	  Any	  imbalance	  of	  this	  process	  will	  lead	  to	  liver	  pathology.	  	  
Apoptosis	  can	  be	  triggered	  by	  several	   intra	  and	  extra	  cellular	  triggers.	   Intracellular	  triggers	  
include	   DNA	   damage	   that	   results	   in	   mitochondrial	   permeability	   and	   the	   release	   of	   pro-­‐
apoptotic	   factors.	   Extracellular	   signals	   are	   mediated	   through	   cell	   surface	   receptors	  
particularly	  those	  belonging	  to	  the	  tumour	  necrosis	  factor	  receptor	  superfamily	  hat	  can	  be	  
activated	  by	   their	   ligands	   including	  TNF-­‐	  α	   ,	   TNF	   related	  apoptosis	   inducing	   ligand	   (TRAIL)	  
CD40L	  and	  Fas	  ligand	  (FasL)(Malhi	  et	  al.,	  2010).	  In	  particular,	  activation	  of	  Fas	  and	  TNF-­‐R1	  is	  
associated	   with	   hepatocyte	   apoptosis	   in	   a	   wide	   variety	   of	   liver	   diseases,	   including	   viral	  
hepatitis,	   fulminant	   hepatic	   failure,	   cholestatic	   liver	   disease,	   alcoholic	   hepatitis,	   non-­‐
alcoholic	   fatty	   liver	   disease	   (NAFLD)	   and	   non-­‐alcoholic	   steatohepatitis	   (NASH),	   Wilsons'	  
disease	  and	  ischemia-­‐reperfusion	  injury(Akazawa	  and	  Gores,	  2007).	  Kupffer	  cells	  are	  located	  
in	  the	  hepatic	  sinusoids	  and	  from	  a	  component	  of	  the	  reticuloendothelial	  system.	  	  They	  take	  
up	   particulate	   and	   bacterial	   products	   from	   the	   portal	   blood	   and	   can	   secrete	   an	   array	   of	  
cytokines	   that	   modulate	   local	   inflammatory	   responses.	   Clearance	   of	   apoptotic	   bodies	   by	  
Kupffer	   cells	   triggers	   their	   release	  of	  profibrogenic	   cytokines	   such	  as	   transforming	  growth	  
factor	   -­‐beta	   (TGF-­‐	   β)	   and	   TNF-­‐	   α.	   Hepatic	   stellate	   cells	   which	   are	   located	   beneath	   the	  
sinusoidal	   endothelium	  within	   hepatic	   sinusoids	   are	   also	   able	   to	   engulf	   apoptotic	   bodies	  
derived	  from	  hepatocytes	  leading	  to	  their	  production	  of	  TGF-­‐β	  and	  type	  1	  collagen(Canbay	  




Other	  forms	  of	  cell	  death	  include	  necrosis	  and	  autophagy.	  Extensive	  hepatocyte	  necrosis	  is	  a	  
feature	   of	   ischaemic	   injury,	   associated	   with	   excessive	   reactive	   oxygen	   species	   (ROS)	  
production,	   paracetamol	   poisoning	   and	   fulminant	   liver	   failure.	   The	   cytochrome	   P450	   2E1	  
(CYP2E1)	  has	  an	  important	  role	  in	  the	  generation	  of	  ROS(Nieto	  et	  al.,	  2003).	  Hepatic	  stellate	  
cells	   (HSCs)	  cultured	   in	   the	  presence	  of	  CYP2E1-­‐overexpressing	   (E47)	  HepG2	  cells	  produce	  
more	  collagen.	  This	  may	  help	  to	  explain	  in	  part	  the	  pathogenesis	  of	  alcoholic	  liver	  disease	  as	  
CYP2E1	  is	  induced	  by	  alcohol.	  	  
Autophagy	   is	  a	  catabolic	  process	  dependent	  on	   lysosomes	  for	  execution	  and	  occurs	  under	  




1.7 What	  cells	  are	  involved	  and	  how	  is	  the	  process	  regulated?	  
 
Several	   lineages	   of	   fibroblasts	   are	   implicated	   in	   fibrogenesis	   including	   stellate	   cells	   portal	  
fibroblasts	   and	   bone	  marrow	   derived	   fibroblasts.	   	   	   Differentiated	  myofibroblasts	   are	   the	  
main	  source	  of	  excessive	  ECM	  production,	  but	  their	  origin	  is	  unresolved	  and	  several	  distinct	  
myofibroblast	   precursors	   have	   been	   described	   and	   are	   summarised	   in	   the	   figure	  
below(Brenner	  et	  al.,	  2010).	  
 
1.7.1 Resident	  Cells	  
The	  most	  accepted	  myofibroblast	  progenitors	  are	  HSCs	  located	  in	  the	  space	  of	  Disse	  below	  
the	  sinusoidal	  endothelium	  where	  they	  act	  as	  pericytes.	  HSCs	  are	  also	  known	  as	   lipocytes,	  
Ito	  cells,	  or	  peri-­‐sinusoidal	  cells.	  They	  represent	  a	  major	  reservoir	  of	  vitamin	  A	  in	  the	  human	  
body.	  In	  response	  to	  cytokines	  and	  growth	  factors	  released	  during	  injury	  quiescent	  stellate	  
cells	   transform	   into	  an	  activated	  state	  during	  which	   they	  secrete	  extra	  cellular	  matrix	  and	  
express	   smooth	  muscle	   actin	   (α-­‐SMA),	  which	   although	   not	   tissue	   specific	   can	   be	   used	   to	  
identify	   activated	  myofibroblasts	  with	   contractile	  properties.	   The	   contractile	  properties	  of	  
HSCs	  regulate	  portal	  resistance	  and	  blood	  flow	  as	  mentioned	  earlier.	  Activated	  stellate	  cells	  
produce	   cytokines,	   chemokines	   such	   as	   monocyte	   chemotactic	   protein	   -­‐1	   (MCP-­‐1)	   and	  
growth	   factors	   including	   and	   increase	   their	   expression	   of	   platelet	   derived	   growth	   factor	  
(PDGF)	   receptor	  and	  TGF-­‐β	   receptors.	   Loss	  of	   intracellular	   retinoid	   is	   a	  notable	   feature	  of	  
stellate	  cell	  activation,	  but	  it	  is	  uncertain	  if	  this	  is	  required	  for	  their	  activation.	  
Other	  sources	  of	   liver	  myofibroblasts	   include	  portal	  fibroblasts	  and	  second	  layer	  fibroblast	  
located	  around	  the	  centrolobular	  vein.	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1.7.2 Epithelial	  mesenchymal	  transition	  (EMT)	  	  
This	   is	  a	   second	  potential	   (and	  controversial)	   source	  of	   fibroblasts	  or	  myofibroblasts.	  EMT	  
proposes	  that	  hepatocytes	  and	  cholangiocytes	  can	  differentiate	  into	  fibroblast	  like	  cells	  that	  
lay	   down	   matrix.	   	   	   EMT	   occurs	   when	   epithelial	   cells	   lose	   key	   epithelial	   characteristics	  
becoming	  more	  motile	  and	  in	  some	  cases	  fibrogenic.	  Demonstrating	  this	  change	  is	  difficult	  
however	  because	  of	  a	  lack	  of	  definitive	  markers	  and	  doubts	  over	  the	  specificity	  of	  previous	  
markers	  such	  as	  fibroblast-­‐specific	  protein	  1	  (FSP1	  also	  known	  as	  S100A4)	  which	  has	  been	  
used	   to	  define	  EMT	   in	  vivo(Osterreicher	  et	  al.,	   2011).	  Recently	  Taura	  et	  al	   suggested	   that	  
hepatocyte	   EMT	   seen	   in	   vitro	   is	   a	   function	   of	   the	   combination	   of	   TGF-­‐b	   treatment	   and	  
culture	  conditions	  which	  is	  not	  seen	  in	  vivo(Taura	  et	  al.,	  2010).	  However,	  before	  discounting	  
EMT	   it	   should	  be	  noted	   that	   the	  murine	  carbon	   tetrachloride	   (CCl4)	  model	  used	  does	  not	  
accurately	  model	  human	  disease.	  
The	   question	   of	   cholangiocyte	   EMT	   is	   also	   open	   to	   question.	   Several	   groups	   looking	   at	  
human	   and	   animal	   models	   have	   reported	   that	   cholangiocytes	   in	   fibrotic	   livers	   coexpress	  
multiple	   epithelial	   and	   mesenchymal	   markers,	   suggesting	   that	   they	   were	   likely	   to	   be	  
undergoing	   EMT(Wells,	   2010).	   However	   lineage	   tracing	   of	   cells	   in	   vivo	   suggests	   that	   very	  
little	   EMT	   occurs	   in	   either	   hepatocytes	   or	   cholangiocytes.	   After	   inducing	   liver	   fibrosis	   by	  
varying	   means,	   no	   resultant	   myofibroblast	   originated	   from	   genetically	   marked	   epithelial	  
cells(Chu	  et	  al.,	  2011,	  Kisseleva	  and	  Brenner,	  2011).	  
 
1.7.3 BM	  derived	  cells	  
Fibrocytes	   are	   a	   population	   of	   CD45+	   leukocytes	   derived	   from	   the	   bone	  marrow	   and	   are	  
inactive	  mesenchymal	  cells.	   In	  culture	   they	  can	  differentiate	   into	  myofibroblasts	  and	  have	  
been	   implicated	   in	   fibrogenesis	   in	   the	   skin,	   kidneys,	   lungs	   and	   liver.	   Upon	   injury	   they	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migrate	   to	   the	   site	  of	   injury	  and	  once	   there	   they	   secrete	  TGF-­‐B	  and	  MCP-­‐1	   that	  promote	  
ECM	  deposition.	  The	  contribution	  of	  fibrocytes	  to	  the	  myofibroblast	  population	  is	  minor	  at	  






1.8 Important	  cytokines	  in	  liver	  fibrosis	  
 
These	  molecules	  are	  important	  mediators	  of	  the	  activation	  of	  stellate	  cells	  and	  can	  be	  split	  
into	  two	  classes(Tsukamoto,	  1999,	  Friedman,	  2000)	  
	  
Broadly	  speaking	  the	  relevant	  mitogenic	  (stimulate	  cell	  proliferation)	  cytokines	  are:	  
PDGF	  	  











PDGF	   is	   the	  most	  potent	  mitogen	  for	  HSCs	  and	  other	  cells	  of	  mesenchymal	  origin.	   It	   is	  up	  
regulated	   in	   the	   fibrotic	   liver.	   There	   are	   4	   subtypes	   (A-­‐D)	   and	   two	   structurally	   related	  
tyrosine	   kinase	   receptors:	   PGDFR-­‐α	   and	   PDGFR-­‐β.	   Injury	   is	   associated	   with	   increased	  
autocrine	  PGDF	  and	  up	  regulated	  PDGF-­‐R.	  Inhibition	  of	  PDGF	  attenuates	  liver	  fibrinogenesis	  
experimentally	  by	  reducing	  alpha-­‐SMA	  and	  Type	  1	  collagen	  expression(Borkham-­‐Kamphorst	  




CCL2	   (MCP-­‐1)	   is	  a	   chemokine	   that	   is	  up	   regulated	  during	  hepatic	   inflammation	  and	  which	  
recruits	   monocytes	   and	   macrophages	   to	   sites	   of	   inflammation	   through	   its	   activation	   of	  
chemokine	   receptor	   (CCR)	   2.	   Elevated	   levels	   correlate	   with	   the	   number	   of	   leukocytes	  
infiltrating	  portal	  tracts	  in	  one	  study(Marra	  F	  and	  M,	  1998)	  
	  
TGF-­‐α	  and	  Il-­‐1	  
TGF-­‐α	  is	  produced	  by	  macrophages	  and	  induces	  epithelial	  development.	  It	  is	  closely	  related	  
to	  epidermal	  growth	   factor	   (EGF).	   It	  acts	   synergistically	  with	   IL-­‐1(Dinarello,	  2000)	  which	   is	  
rapidly	   expressed	   in	   response	   to	   tissue	   injury.	   Il-­‐1	   is	   an	   important	   participant	  with	   other	  
cytokines	  in	  controlling	  the	  progression	  of	  liver	  injury	  to	  fibrosis.	  	  
	  
TNF-­‐α	  	  
TNF-­‐α	   activates	   several	   intracellular	   pathways	   to	   regulate	   cell	   death,	   proliferation	   and	  
inflammation.	   It	   also	   contributes	   to	   hepatocyte	   proliferation	   and	   liver	   regeneration.	   It	   is	  
secreted	  by	  macrophages	  and	  to	  a	  lesser	  extent	  fibroblasts	  and	  acts	  via	  two	  receptors	  TNF-­‐
R1	  and	  TNF-­‐R2.	  The	  dichotomous	  nature	  of	  action	  is	  dependent	  on	  one	  pathway	  inactivating	  
the	  other.	  The	  process	  of	   regulation	   involves	   the	   I	  kappa	  B	  kinase	   (IKK),	  ROS	  and	  c-­‐Jun	  N-­‐
terminal	  kinase	  (JNK)	  pathways	  and	   is	  summarised	   in	  a	  review	  by	  Schwabe	  et	  al.(Schwabe	  








TGFB1	   is	   a	   highly	   profibrogenic	   cytokine	   	   with	   mitogenic	   properties.	   	   It	   is	   produced	   by	  
multiple	   liver	   cell	   types	   including	   stellate	   cells,	   Kupffer	   cells,	   hepatocytes	   and	  
cholangiocytes.	   TGFB1	   is	   critical	   for	   the	   proliferation	   and	   activation	   of	   fibrogenic	  
myofibroblasts.	   There	   are	  many	   sources,	   but	   autocrine	   expression	   is	   the	  most	   important.	  
Perhaps	  surprisingly,	  as	  the	  degree	  of	  liver	  fibrosis	  increases,	  levels	  of	  TGFB1	  are	  observed	  
to	   decrease	   with	   a	   corresponding	   elevation	   in	   HGF(Imbert-­‐Bismut	   et	   al.,	   2001)	   and	   over	  
expression	  of	  HGF	  in	  cell	  lines	  supresses	  increases	  of	  TGFB1(Ueki	  et	  al.,	  1999).	  
The	   therapeutic	   inhibition	   of	   TGF-­‐B	   is	   complicated	   by	   the	   potential	   for	   promoting	  
inflammation	  and	  cancer	  or	  reducing	  apoptosis.	   
 
1.8.3 Anti-­‐fibrotic	  cytokines	  
 
Interferon	  gamma	  (IFN-­‐ γ)	  
This	   cytokine	   is	   widely	   know	   for	   its	   anti-­‐viral	   properties	   and	   can	   directly	   inhibit	   viral	  
replication.	  It	  is	  produced	  by	  natural	  killer	  (NK)	  cells	  and	  subsets	  of	  T	  cells	  	  
Interferon	  gamma	  has	  been	  shown	  to	  decrease	  collagen	  synthesis	  as	  well	  as	   inhibiting	  the	  
activation	   of	   HSCs(Baroni	   et	   al.,	   1996).	   It	   also	   reduces	   the	   expression	   of	   type	   1	   and	   4	  
collagen	   and	   fibronectin	   in	   HSCs	   in	   vitro.	   An	   RCT	   of	   therapy	   in	   HCV	   patients	   showed	   no	  







This	   anti-­‐inflammatory	   cytokine	   is	   released	   by	  monocytes,	   some	   populations	   of	   dendritic	  
cells,	   macrophages	   and	   subsets	   of	   T	   cells.	   It	   down	   regulates	   production	   of	   inflammatory	  
cytokines	  such	  as	  Il-­‐1	  as	  well	  as	  profibrogenic	  cytokines	  such	  as	  TGF-­‐B.	  Il-­‐10	  deficient	  mice	  
show	  increased	  susceptibility	  to	  hepatic	  fibrosis	  due	  to	  CCL4	  and	  helminthic	  infection	  (Louis	  
et	   al.,	   1998,	  Mentink-­‐Kane	  et	   al.,	   2011).	   In	  humans	  with	  hepatitis	  C	   virus	   (HCV)	   infection,	  
administration	   of	   IL-­‐10	   was	   shown	   in	   a	   pilot	   study	   to	   reduce	   hepatic	   inflammation	   and	  
fibrosis(Nelson	  et	  al.,	  2000).	  Several	  years	   later,	  however	  this	  study	  showed	  that	  although	  
fibrosis	   improved,	   viral	   loads	   increased	   due	   to	   alterations	   in	   immunologic	   viral	  
suppression(Nelson	  et	  al.,	  2003).	  
	  
Hepatocyte	  Growth	  Factor	  (HGF)	   	  
HGF	   in	  animal	  models	  has	  been	  shown	  to	  have	  antifibrotic	  effects	   through	  suppression	  of	  
TGF-­‐beta	  mediated	  transcription	  of	  type	  1	  collagen	  and	  activated	  HSCs(Ozaki	  et	  al.,	  2002).	  




1.9 Diseases	  associated	  with	  liver	  fibrosis	  
The	  pattern	  of	  damage	  to	  the	  liver	  and	  the	  symptoms	  experienced	  depend	  on	  the	  aetiology	  
of	  the	  disease	  and	  also	  the	  type	  of	  cell	  targeted	  by	  the	  liver	  injury.	  	  
	  
Fatty	  liver	  disease	  
Non-­‐alcoholic	  fatty	  liver	  disease	  (NAFLD)	  represents	  a	  spectrum	  of	  disease	  ranging	  from	  the	  
most	  benign	  hepatic	  steatosis	  through	  to	  steatohepatitis	  with	  in	  some	  cases	  progression	  to	  
fibrosis	   and	   cirrhosis.	   	   It	   is	   a	   manifestation	   of	   the	   metabolic	   syndrome	   associated	   with	  
diabetes,	  dyslipidaemia	  and	  obesity	  and	  the	  prevalence	  is	  rising	  along	  side	  the	  rise	  in	  obesity	  
and	  diabetes.	   It	  now	  represents	  a	  major	  cause	  of	   liver	  disease	  worldwide	  and	  perhaps	  the	  
most	   common	   type	   of	   liver	   disease	   in	   western	   countries(de	   Alwis	   and	   Day,	   2008).	   The	  
diagnosis	   cannot	   be	   made	   on	   histology	   alone	   because	   the	   histological	   features	   are	  
indistinguishable	  from	  alcoholic	  liver	  disease.	  
Non-­‐alcoholic	   steatohepatitis	   (NASH)	   is	   characterised	   by	   a	   spectrum	   of	   inflammation,	  
apoptosis/	  necrosis	  and	   fibrosis.	   It	   is	  highly	   likely	   that	   insulin	   resistance	   is	   instrumental	   in	  
the	  pathogenesis	  of	  NASH,	  but	  how	  this	  triggers	  steatohepatitis	  is	  unknown.	  Progression	  to	  
steatohepatitis	  and	  fibrosis	  depends	  on	  inflammatory	  pathways	  activated	  by	  free	  fatty	  acids	  
(FFA),	   inflammatory	   cytokines	   and	   adipokines,	   oxidative	   stress	   and	   mitochondrial	  
dysfunction	  in	  a	  complex	  interplay	  with	  genetic	  predisposition	  (Dowman	  et	  al.,	  2010).	  
Histologically,	  steatohepatitis	  is	  characterized	  by	  steatosis	  with	  mixed	  lobular	  inflammation	  
and	   hepatocyte	   ballooning	   (±Mallory’s	   hyaline)	   in	   the	   presence	   or	   absence	   of	   fibrosis.	  





Alcoholic	  liver	  disease	  (ALD)	  
Steatosis	   and	   steatohepatitis	   seen	   in	   alcoholic	   liver	   disease	   are	   histologically	  
indistinguishable	  form	  the	  changes	  seen	  in	  NAFLD	  and	  thus	  the	  diagnosis	  rest	  on	  evidence	  
of	  alcohol	  excess.	  
Alcohol	   induces	  an	   increase	   in	   lipid	  peroxidation	  by	  enhancing	   the	  production	  of	  ROS	  and	  
decreasing	  the	  level	  of	  endogenous	  antioxidants(Ishii	  et	  al.,	  1997).	  	  
The	   break	   down	   of	   alcohol	   within	   hepatocytes	   produces	   ROS	   and	   acetaldehyde,	   both	   of	  
which	  have	  pro-­‐fibrotic	  properties	  on	  HSCs	  via	  a	  paracrine	  mechanism(Purohit	  and	  Brenner,	  
2006).	  	  
The	   inflammatory	   response	   to	   alcohol	   is	   not	   however	   universal	   and	   likely	   to	   be	  
multifactorial	  as	  with	  NAFLD,	  i.e.	  with	  environmental	  and	  genetic	  predisposition.	  
Interestingly	   alcohol	   actually	   has	   a	   damping	   effect	   on	   NK	   cells	   (which	   themselves	   kill	  
activated	  stellate	  cells).	  This	  could	  account	  for	  the	  accelerated	  nature	  of	  fibrosis	  seen	  upon	  
cessation	  of	  alcohol	  intake.(Jeong	  et	  al.,	  2008)	  
	  
Cholestatic	  liver	  disease	  
Extrahepatic	   cholestasis	   is	   due	   to	   bile	   duct	   obstruction.	   Classically	   this	   is	   associated	  with	  
oedema,	  proliferation	  of	  bile	  ductular	  structures	  and	  a	  neutrophilic	  ±lymphocytic	  /	  plasma	  
cell	   infiltrate.	   This	   reaction	   is	   known	   as	   a	   ductular	   reaction	   and	   is	   common	   in	   biliary	  
obstruction.	  	  
	  
Intrahepatic	   cholestasis	  may	   be	   drug	   or	   toxin	   related,	   genetic	   due	   to	   functional	   bile	   flow	  
impairment	   (e.g.	   mutation	   of	   bile	   salt	   transport	   proteins)	   and	   due	   to	   immune	   mediated	  
destruction	   of	   small	   intrahepatic	   ducts	   by	   primary	   sclerosing	   cholangitis	   (PSC),	   primary	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biliary	  cirrhosis	  (PBC)	  PBC	  and	  other	  vanishing	  bile	  duct	  syndromes.	   	   In	  PBC	  the	  damage	  is	  
immune	  related	  and	  associated	  with	  a	  T	  cell	  infiltrate	  of	  intrahepatic	  bile	  ducts.	  This	  process	  
leads	  to	  bile	  duct	  destruction	  and	  ductopenia.	  The	  process	  if	  left	  unchecked	  leads	  to	  portal	  
tract	  expansion	  by	  fibrosis	  with	  ultimately	  portal	  bridging(Jones,	  2007).	  	  
	  
	  
Chronic	  Viral	  Infection	  
The	  pathogenesis	  of	   chronic	  viral	   induced	   fibrosis	   is	  poorly	  understood	  due	   to	   the	   lack	  of	  
animal	  models	  of	  chronic	  viral	  hepatitis	  infection.	  HCV	  eludes	  the	  host	  immune	  system	  and	  
infects	  hepatocytes.	  This	  leads	  to	  a	  slow	  process	  of	  hepatocyte	  injury	  with	  oxidative	  stress	  
and	   apoptosis	   leading	   to	   HSC	   activation	   and	   ECM	   deposition.	   Typically	   parenchyma	  
inflammation	   is	   seen	  on	  histological	   examination	  although	   this	  may	  be	  modest	   consistent	  




1.10 Matrix	  Degradation	  
 
Stellate	  cells	  express	  metalloproteinases	  required	  for	  matrix	  degradation	   including	  MMP-­‐2	  
and	  MMP3.	  Markedly	  increased	  expression	  of	  MMP-­‐2	  is	  characteristic	  of	  cirrhosis(Benyon	  et	  
al.,	   1996).	   Degradation	   of	   ECM	   hastens	   its	   replacement	   by	   fibril-­‐forming	   collagen,	   which	  
further	  activates	  stellate	  cell	  growth	  and	  MMP-­‐2	  production.	  The	  collagenases	  are	  inhibited	  
by	  tissue	  inhibitor	  of	  metalloproteinase	  1	  and	  2	  (TIMP-­‐1	  and	  2).	  The	  increased	  expression	  of	  
TIMPs	  shifts	  the	  balance	  of	  extracellular	  matrix	  towards	  deposition	  of	  collagen	  and	  fibrosis.	  
This	  up	  regulation	  requires	  activated	  stellate	  cells	  as	  the	  relevant	  receptors	  are	  not	  seen	  on	  
quiescent	  HSCs.	  Sustained	  TIMP-­‐1	  expression	  is	  a	  key	  reason	  for	  progressive	  fibrosis	  and	  its	  





1.11 Reversion	  to	  quiescence?	  
 
Removing	  the	  underlying	  cause	  of	   liver	   injury	   is	  the	  most	  effective	  way	  to	  prevent	  fibrosis	  
such	   as	   in	   haemochromatosis	   or	  Wilsons	   disease	   or	   alcoholic	   liver	   disease.	   Cirrhosis	   had	  
traditionally	  been	  considered	  an	  irreversible	  state	  but	  recent	  evidence	  has	  shown	  that	  the	  
development	  of	   fibrosis	   is	   dynamic	   and	  potentially	   reversible	   depending	  on	   the	   extent	   of	  
cross-­‐linked	  elastin	  and	  collagen.	  Resolution	  of	   liver	  fibrosis	   is	  associated	  with	  reversion	  of	  
activated	   HSCs	   to	   quiescence	   or	   perhaps	   by	   altering	   the	   balance	   of	   proliferation	   to	   cell	  
death	  (apoptosis).	  Stellate	  cells	  apoptosis	  has	  been	  observed	   in	  rats	  recovering	  from	  CCL4	  
injury(Iredale	  et	  al.,	  1998).	  Degradation	  of	  matrix	  appears	  also	  to	  promote	  HSC	  apoptosis.	  In	  
vitro	   cells	   treated	   with	   MMP-­‐9	   stimulate	   HSC	   apoptosis(Zhou	   et	   al.,	   2004)Treatment	   of	  
these	  cells	  with	  TIMP-­‐1	  exerts	  and	  anti-­‐apoptotic	  effect	  by	  inhibiting	  MMP	  activity(Murphy	  
et	   al.,	   2002).	   The	   activated	   stellate	   cell	   by	   secretion	   of	   collagen	   and	   TIMP	   protects	   itself	  
against	   apoptosis,	   but	   the	   default	   pathway	   for	   HSC	   may	   be	   for	   them	   to	   undergo	  
apoptosis(Issa	  et	  al.,	  2001).	  With	  resolution	  of	  fibrosis,	  the	  HSC	  survival	  signals	  are	  removed	  
and	   they	   undergo	   apoptosis,	   further	   reducing	   TIMP,	   increasing	   MMP	   and	   leading	   to	  






1.12 Liver	  biopsy	  and	  its	  flaws	  
 
Liver	   biopsy	   allows	   a	   physician	   to	   make	   a	   diagnosis	   and	   assess	   the	   severity	   of	   the	   liver	  
disease	  including	  inflammation,	  necrosis,	  steatosis	  or	  deposits	  of	  iron	  and	  copper	  as	  well	  as	  
fibrosis	   and	   architectural	   changes.	   	   Liver	   biopsy	   is	   however	   not	   without	   its	   limitations.	  
Several	  scoring	  systems	  are	  used	  to	  assess	  fibrosis	  but	  they	  are	  all	  flawed	  because	  the	  score	  
represents	   numerical	   shorthand	   for	   a	   categorical	   assignment.	   It	   thus	   neither	   represents	  
integers	  nor	  numerical	  measurements	  along	  a	  continuum	  in	  a	  mathematical	  sense	  (Standish	  
et	  al.,	  2006).	  The	  scoring	  system	  is	  a	  pathologist’s	  way	  of	  describing	  more	  than	  just	  fibrosis.	  
It	   contains	   a	   mixture	   of	   features	   and	   at	   higher	   stages	   can	   represent	   more	   architectural	  
change	   and	   nodularity	   rather	   than	   the	   amount	   of	   fibrous	   tissue;	   hence	   the	   degree	   of	  
collagen	   seen	   in	   similar	   staged	  biopsies	  may	  vary.	   	   It	   is	   thus	   incorrect	   to	  assume	   that	   the	  
scoring	  system	  is	  describing	  a	  continuous	  variable	  (fibrosis)	  using	  a	  categorical	  system	  and	  
that	  the	  stages	  assume	  linearity	  in	  progression	  of	  fibrosis,	  which	  does	  not	  reflect	  the	  disease	  
progression.	  
Liver	  biopsy	  is	  associated	  with	  pain	  (20%	  of	  cases)	  (Cadranel	  et	  al.,	  2000)	  and	  rarely	  major	  
side	   effects	   such	   as	   bleeding	   and	   infection	   (in	   3%(Piccinino	   et	   al.,	   1986).	   	   Furthermore,	   it	  
only	  samples	  a	  small	  portion	  of	  the	  liver	  (1/50,000)	  and	  interpretation	  of	  histology	  is	  open	  
to	  intra	  and	  inter-­‐observer	  error(Bedossa	  et	  al.,	  2003).	  Pathologists	  have	  to	  assess	  the	  >1kg	  
liver	  based	  on	  a	  piece	  of	   tissues	  weighing	  10-­‐15mg	  hence	  patchy	  disease	  may	  be	  over	  or	  
under	   reported	  due	   to	   variations	   between	   lobules(Rosenberg	   et	   al.,	   2004).	   	  One	   study	  of	  
HCV	   patients	   assessed	   biopsies	   taken	   from	   the	   left	   and	   right	   liver	   lobes	   laparoscopically.	  
33%	  of	  patients	  had	  at	  least	  one	  stage	  difference	  between	  the	  lobes	  and	  that	  sampling	  error	  
could	  lead	  to	  under	  diagnosing	  of	  cirrhosis	  in	  14.5%	  of	  the	  patients.	  This	  would	  have	  major	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implications	  for	  the	  patient	  in	  terms	  of	  management	  and	  follow	  up(Regev	  et	  al.,	  2002).	  This	  
is	  perhaps	  where	  serum	  based	  scoring	  systems	  may	  in	  future	  be	  more	  widely	  utilised.	  
 
1.12.1 What	  makes	  an	  “adequate”	  liver	  biopsy?	  
 
Until	  recently,	  a	  liver	  biopsy	  containing	  six	  portal	  tracts	  satisfied	  histopathologists(Bravo	  et	  
al.,	   2001).	   Recently	   the	   American	   Association	   for	   the	   Study	   of	   Liver	   Disease	   released	  
guidelines	   on	   what	   constitutes	   an	   adequate	   biopsy.	   This	   was	   >20mm	   in	   length	   and	   >11	  
portal	  tracts(Rockey	  et	  al.,	  2009).	  To	  achieve	  this	  it	  is	  likely	  that	  3	  or	  4	  passes	  are	  needed.	  
Recent	  UK	   data	   has	   suggested	   that	   only	   4%	  of	   samples	  measured	   20mm	  or	  more	   and	   of	  
those,	  2%	  had	  11	  or	  more	  complete	  portal	  tracts(Naseer	  et	  al.,	  2011).	   It	  was	  also	  noted	  in	  
the	   recent	  paper	  by	  Boursier	   as	  part	  of	   a	  multicentre	   study	   looking	  at	  1785	  patients	   that	  
liver	   biopsy	   length	   had	   no	   influence	   on	   the	   diagnostic	   accuracy	   of	   non-­‐invasive	  
markers(Boursier	  et	  al.,	  2012a).	  
 
1.12.2 Repetitive	  liver	  biopsy	  
 
Despite	   the	   good	   correlation	   between	   fibrosis	   staging	   and	   specific	   outcomes	   (time	   to	  
develop	  cirrhosis,	  time	  to	  develop	  clinical	  decompensation),	  the	  progression	  of	  liver	  fibrosis	  
over	   time	   is	   commonly	   not	   linear(Hintermann	   et	   al.,	   2010)	   hence	   the	   need	   for	   repeated	  
measurements	   to	   give	   an	   idea	   of	   disease	   behaviour.	   	   It	   is	   neither	   practical	   nor	   ethical	   to	  
undertake	   frequently	   repeated	   liver	   biopsies	   for	   monitoring	   of	   disease	   progression	   or	  
regression	  due	  to	  the	  reasons	  mentioned	  above.	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1.13 Collagen	  Proportionate	  analysis	  to	  quantify	  fibrosis	  
 
Collagen	  proportional	  area	  (CPA)	   is	  a	  quantitative	  digital	   image	  analysis	  and	  was	  shown	   in	  
2009	  to	  correlate	  with	  Ishak	  staging	  (r=0.47;	  p<0.001).	  For	  significant	  fibrosis	  (Ishak	  >2),	  the	  
AUROC	  for	  CPA	  was	  0.84	  with	  a	  cut	  off	  of	  6%	  giving	  78%	  sensitivity	  and	  80%	  specificity.	  For	  
severe	  fibrosis	  (Ishak	  5+6),	  the	  AUROC	  was	  0.9	  with	  a	  CPA	  value	  of	  9%	  giving	  78%	  sensitivity	  
and	   88%	   specificity(Calvaruso	   et	   al.,	   2009).	   	   The	   absolute	   values	   of	   collagen	   seen	   are	  
summarised	  in	  an	  excellent	  review	  by	  Standish	  in	  the	  figure	  below.	  What	  is	  noted	  is	  that	  the	  
increasing	  stage	  of	  fibrosis	  compared	  to	  Ishak	  stage	  of	  disease	  is	  not	  linear	  (Standish	  et	  al.,	  
2006).	   The	   paper	   also	   illustrates	   that	   within	   each	   histological	   stage	   there	   may	   be	   great	  
differences	   in	   CPA.	   Two	   biopsies	   may	   be	   Ishak	   stage	   6	   (cirrhotic)	   due	   to	   parenchymal	  
nodules	  surrounded	  by	  fibrous	  tissue,	  but	  the	  proportion	  of	  collagen	  might	  differ	  vastly.	  The	  
paper	  shows	  two	  cirrhotic	  biopsies	  with	  CPAs	  of12%	  and	  27%	  respectively.	  	  
 





Figure	  1-­‐6	  Collagen	  proportional	  area	  vs.	  Ishak	  fibrosis	  stage	  
	  
The	  accuracy	  of	  CPA	  of	  stained	  biopsy	  samples	   is	  dependent	  upon	  biopsy	  size.	  Recently,	   It	  
was	  shown	  that	  when	  compared	  to	  a	  tissue	  block,	  biopsy	  samples	  22-­‐28mm	  in	  length	  give	  a	  
90%	  probability	  of	  CPA	  being	  within	  5%	  of	  the	  block’s	  CPA.	  For	  biopsies	  12-­‐15mm	  in	  length,	  
this	  drops	   to	  75%(Hall	   et	  al.,	   2013).	   Since	   the	  median	  biopsy	   length	  was	  23mm	   it	   is	   likely	  









1.14 Limits	  of	  Non-­‐invasive	  markers	  
 
There	  is	  a	  resistance	  to	  the	  adoption	  of	  non-­‐invasive	  markers	  for	  diagnosing	  fibrosis	  due	  to	  
the	   lack	   of	   well-­‐designed	   studies	   assessing	   the	   various	   methods.	  Where	   studies	   do	   exist	  
there	  is	  a	  perceived	  lack	  of	  external	  validation	  especially	  as	  the	  number	  of	  tests	  is	  constantly	  
expanding	  leaving	  little	  time	  to	  validate	  and	  test	  them	  in	  clinical	  practice.	  Another	  concern	  
as	  mentioned	   above	   is	   the	   fact	   the	   gold	   standard	   (liver	   biopsy)	   is	   not	   ideal	   and	  prone	   to	  
error,	  which	  makes	  benchmarking	  new	  markers	   difficult.	   	  Other	   drawbacks	   are	   that	  most	  
current	  markers	  do	  not	  reflect	  liver	  fibrosis	  but	  necroinflammation	  and	  injury.	  There	  is	  also	  
a	   paucity	   of	   data	   on	   using	   the	   models	   to	   monitor	   response	   to	   treatment	   or	   change	   in	  
disease	  burden	  over	   time.	   	  Other	  weaknesses	   include	   intra-­‐laboratory	  variations	   in	   serum	  
marker	  assays	  with	  different	  reference	  ranges.	  
As	   discussed	   below	   a	   further	  weakness	   is	   that	  most	   of	   the	   studies	   (as	  mentioned	   above)	  
compare	   groups	   of	   patients	   at	   the	   extremes	   of	   disease.	   Studies	   usually	   quote	   that	   the	  
marker	   can	   differentiate	   minimal	   or	   no	   fibrosis	   from	   cirrhosis,	   but	   that	   assessing	  






1.15 Assessing	  liver	  fibrosis	  
 
Any	  new	  method	  of	  assessing	  liver	  fibrosis	  must	  be	  judged	  against	  liver	  biopsy.	  Due	  to	  the	  
misclassification	   rate	   of	   biopsy,	   it	   becomes	   impossible	   to	   achieve	   a	   perfect	   concordance	  
with	   an	   area	   under	   receiver	   operating	   characteristic	   (AUROC)	   of	   1.	   	   Assuming	   that	   liver	  
biopsy	   has	   a	   sensitivity	   and	   specificity	   of	   >90%	   and	   the	   prevalence	   of	   fibrosis	   of	   ~40%,	   a	  
perfect	  non-­‐invasive	  test	  would	  only	  reach	  and	  AUROC	  of	  0.9(Mehta	  et	  al.,	  2009)	  .	  Another	  
consideration	   is	   that	   fibrosis	   in	   a	   liver	   biopsy	   is	   assessed	   by	   architectural	   changes	   rather	  
than	   the	  amount	  of	   fibrosis	   therefore	  assuming	  a	  direct	  correlation	  between	  non-­‐invasive	  
value	  and	  fibrosis	  stage	  may	  be	  incorrect(Ratziu,	  2010).	  
The	  next	  question	  pertaining	  to	  diagnosing	  fibrosis	  remains	  the	  ability	  of	  various	  markers	  to	  
accurately	  predict	  the	  different	  stages	  of	  fibrosis.	  Most	  biomarkers	  currently	  available	  (see	  
below)	  are	  accurate	  at	  identifying	  patients	  with	  significant	  fibrosis.	  This	  is	  critical,	  as	  patients	  






1.16 The	  ideal	  liver	  fibrosis	  biomarker	  
 
An	  ideal	  liver	  fibrosis	  marker	  should	  have	  the	  following	  characteristics:	  (Rossi	  et	  al.,	  2007)	  
• Liver	  specific	  
• Readily	   available	   and	   standardised	   between	   all	   laboratories	   performing	   diagnostic	  
biochemistry	  /	  haematology	  
• Not	  subject	  to	  false	  positive	  results,	  for	  example	  due	  to	  inflammation	  
• Identifies	  the	  stage	  of	  fibrosis	  
 
 
1.16.1 Development	  of	  non-­‐invasive	  liver	  fibrosis	  biomarkers	  
 
Serum	  markers	  for	  the	  prediction	  of	  fibrosis	  generally	  fall	  in	  to	  two	  categories.	  	  
The	   Indirect	  markers	  are	  a	  mixture	  of	   commonly	  observed	  biochemical	   abnormalities	  and	  
clinical	  observations	  seen	  in	  liver	  disease,	  which	  evaluate	  synthetic	  dysfunction.	  They	  don’t	  
however	   assess	   fibrogenic	   cell	   changes.	   More	   recently,	   a	   greater	   understanding	   of	   the	  
process	   behind	   liver	   fibrosis	   has	   prompted	   researchers	   to	   look	   at	   alternative	  
markers(Martínez	  et	  al.,	  2011)	  Direct	  markers	  use	  the	  fact	  the	  fibrinogenesis	  and	  fibrinolysis	  
generate	  peptides	  that	  can	  be	  measured	  in	  the	  peripheral	  circulation.	  It	  is	  noteworthy	  that	  
TIMPs	  also	  appears	  in	  the	  circulation	  and	  their	  assay	  is	  part	  of	  some	  tests	  of	  fibrinogenesis.	  
One	  caveat	  is	  that	  the	  peptides	  are	  also	  seen	  in	  tissue	  inflammation.	  
	  
Identification	  of	   hepatic	   stellate	   cells	  was	   a	   key	  development	   in	   understanding	   the	   liver’s	  
response	   to	   injury.	   Activation	   of	   hepatic	   stellate	   cells	   is	   the	   primary	   event	   in	   hepatic	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fibrogenesis.	   Quiescent	   cells	   transform	   into	   proliferative,	   fibrogenic,	   and	   contractile	  
myofibroblasts.	  Fibrosis	  evolves	  when	  the	  balance	  between	  extracellular	  matrix	  degradation	  
and	  production	  is	  disrupted(Bataller	  and	  Brenner,	  2001).	  	  Of	  note,	  even	  though	  fibrosis	  is	  a	  
local	  reaction	  of	  the	  liver	  to	  chronic	  injury,	  serum	  levels	  of	  fibrogenic	  cytokines,	  extracellular	  
matrix	   proteins,	   and	   degradation	   products	   are	   markedly	   increased	   in	   cases	   of	   advanced	  
fibrosis	  (bridging	  fibrosis	  or	  cirrhosis).	  Identification	  of	  these	  markers	  is	  therefore	  becoming	  
of	  more	  interest(Martínez	  et	  al.,	  2011).	  It	  also	  helps	  to	  explain	  why	  fibrosis	  biomarkers	  lack	  
sensitivity	  and	  specificity	  in	  the	  initial	  stages	  of	  liver	  fibrosis	  as	  they	  are	  affected	  by	  fibrosis	  
in	  other	  organs	  and	  renal	  problems.	  	  
The	   most	   common	   markers	   used	   in	   current	   assays	   involve	   measuring	   products	   of	  
extracellular	   matrix	   synthesis	   or	   degradation	   and	   the	   enzymes	   that	   regulate	   their	  
production	   or	  modification:	   hyaluronic	   acid,	   serum	   collagenases,	   TIMP,	   and	   profibrogenic	  
cytokines	  such	  as	  TGF-­‐ β1	  (Rosenberg	  et	  al.,	  2004)	  or	  measure	  inflammatory	  markers	  such	  







1.17 Current	  biomarkers	  
 
1.17.1 Indirect	  markers	  
Several	  biomarkers	  have	  been	  developed	  to	  look	  at	  fibrosis	  stage	  have	  been	  described	  using	  
various	  combinations	  of	  tests	  listed	  below:	  
APRI	  (AST	  to	  platelet	  ratio	  index):	  Aspartate	  transaminase	  (AST)	  and	  platelets	  
FIB-­‐4:	  alanine	  aminotransferase	  (ALT)	  and	  age	  
AST:	  ALT	  ratio	  
	  
APRI	  
The	   APRI	   is	   calculated	   as	   (AST/upper	   limit	   of	   normal)/platelet	   count	   (109/l)	   x100.	   AST	  
measures	   liver	   injury	   and	   the	   platelet	   count	   is	   an	   indicator	   of	   splenomegaly	   and	   portal	  
hypertension.	  	  The	  sensitivity	  and	  specificity	  are	  dependant	  upon	  the	  cut	  off	  used	  and	  this	  
varies	  from	  <0.5	  to	  >2.0.	  It	  has	  been	  validated	  in	  HCV	  patients	  in	  a	  recent	  meta-­‐analysis,	  but	  
with	  only	  modest	  accuracy.	  For	  significant	  fibrosis,	  severe	  fibrosis	  and	  cirrhosis,	  the	  AUROC	  
for	  APRI	  were	  0.77,	  0.8	  and	  0.83	  respectively(Lin	  et	  al.,	  2011).	  This	  meta-­‐analysis	  highlights	  
the	   issue	   of	   papers	   quoting	   different	   cut	   off	   but	   suggests	   that	   an	   optimal	   cut-­‐off	   for	  
sensitivity	  and	  specificity	  is	  0.7	  with	  NPV	  of	  79%	  and	  PPV	  of	  70%	  for	  significant	  fibrosis.	  
	  
Fib-­‐4	  was	  first	  described	  in	  2006	  by	  Sterling	  et	  al	  in	  an	  HCV	  cohort	  and	  is	  calculated	  as	  age	  
[years]	  ×	  AST	  [IU/L]/platelet	  count	  [expressed	  as	  platelets	  ×	  109/L]	  ×	  (ALT1/2[IU/L])(Sterling	  et	  
al.,	  2006)	  The	  AUROC	  of	  the	  index	  was	  0.765	  for	  differentiation	  between	  Ishak	  stage	  0-­‐3	  and	  
4-­‐6.	   At	   a	   cutoff	   of	   <1.45	   in	   the	   validation	   set,	   the	   negative	   predictive	   value	   to	   exclude	  
advanced	   fibrosis	   (stage	   4-­‐6)	  was	   90%	  with	   a	   sensitivity	   of	   70%.	  A	   cut-­‐off	   of	  >3.25	   had	   a	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positive	  predictive	  value	  of	  65%	  and	  a	   specificity	  of	  97%.	  Using	   these	  cutoffs,	   the	  authors	  
state	   that	   87%of	   the	   198	   patients	   with	   FIB-­‐4	   values	   outside	   1.45-­‐3.25	   would	   have	   been	  
correctly	  classified,	  and	  liver	  biopsy	  could	  be	  avoided	  in	  71%	  of	  the	  validation	  group.	  Similar	  
values	  were	  found	  in	  a	  French	  cohort	  a	  few	  years	  later(Vallet-­‐Pichard	  et	  al.,	  2007).	  
	  
AST:	  ALT	  
AST	   and	   ALT	   are	   enzymes	   both	   released	   into	   the	   circulation	   following	   damage	   to	  
hepatocytes.	  The	  ratio	  between	  the	  two	  has	  been	  validated	  in	  several	  diseases,	  particularly	  
ALD	  and	  NAFLD	   to	  correlate	  with	   severity	  of	  hepatitis	  and	   risk	  of	   fibrosis.	  A	  cut	  of	  >1	  has	  
been	  proposed	  as	  a	   test	  of	   cirrhosis	  with	  a	  100%	  positive	  predictive	  value	   (PPV).	  The	   test	  
had	  a	  46.7	  –	  53.2%	  sensitivity	  and	  a	  negative	  predictive	  value	  (NPV)	  of	  80.7	  -­‐88.1%(Sheth	  et	  
al.,	  1998,	  Park	  et	  al.,	  2000)	  
	  
Forns	  
The	  Forns	  score	  was	  developed	  in	  2002	  using	  an	  HCV	  cohort	  (Forns	  et	  al.,	  2002).	  Using	  a	  cut	  
off	   of	   <4.2,	   the	   presence	   of	   significant	   fibrosis	   (F2-­‐F4)	   could	   be	   excluded	  with	   an	  NPV	   of	  
96%.	  The	  AUROC	  was	  0.86.	  It	  is	  calculated	  as:	  7.811	  -­‐	  3.131	  ×	  ln	  [number	  of	  platelets	  (10⁹/l)]	  
×	  0.781	  ln	  [GGTP	  (U/L)]	  +	  3.467	  ×	  ln	  [age	  (years)]	  -­‐	  0.014	  [cholesterol	  (mg/dl)].	  This	  value	  is	  
similar	  to	  that	  found	  a	  few	  years	  later	  in	  another	  HCV	  cohort	  of	  228	  patients.	  The	  AUROC	  for	  








Is	   secreted	   by	   stellate	   cells	   and	   hepatocytes	   and	   is	   a	  major	   plasma	   protein.	   It	   is	   a	   broad	  
inhibitor	   of	   endoproteases	   and	   elevated	   serum	   levels	   are	   seen	   in	   liver	   disease	   which	  
correlate	  with	  the	  degree	  of	  liver	  fibrosis(Naveau	  et	  al.,	  1994).	  
	  
Apolipoprotein	  A1	  
This	  protein	  is	  the	  major	  component	  of	  HDL	  and	  levels	  are	  negatively	  correlated	  with	  liver	  
fibrosis(Poynard	   et	   al.,	   1991);	   it	   is	   also	   altered	   in	   poorly	   controlled	   diabetes,	   nephrotic	  
syndrome	  and	  smoking.	  
	  
Haptoglobin	  
This	   is	   an	   acute	   phase	   serum	   protein	   that	   binds	   free	   haemoglobin	   and	   is	   elevated	   in	  
inflammatory	   conditions.	   Reduced	   levels	   are	   observed	   in	   later	   stages	   of	   fibrosis(Imbert-­‐
Bismut	  et	  al.,	  2001).	  
 
1.17.2 Direct	  markers	  
 
1.17.2.1 Glycoproteins	  and	  polysaccharides	  
Hyalauronic	  acid	  	  
This	  is	  a	  glycosaminoglycan	  present	  in	  extracellular	  matrix	  including	  the	  liver	  but	  also	  other	  
tissues	   notably	   the	   joints;	   it	   is	   found	   in	   serum	   and	   synovial	   fluid.	   It	   is	   an	   essential	  
component	   of	   the	   ECM	   and	   it	   is	   produced	   in	   the	   liver	   by	   stellate	   cells	   and	   degraded	   by	  
hepatic	   sinusoidal	   endothelial	   cells.	   Levels	   correlate	   well	   with	   the	   degree	   of	   fibrosis	   in	  
ALD(Stickel	  et	  al.,	  2003)	  and	  HCV(McHutchison	  et	  al.,	  2000).	  The	  increase	  in	  serum	  is	  due	  to	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a	  combination	  of	  reduced	  hepatic	  sinusoidal	  clearance	  and	  increased	  hepatic	  production	  (or	  
both).	  
	  
1.17.2.2 Collagen	  markers	  
Several	  markers	  fit	   into	  this	  category	  such	  as	  N-­‐terminal	  procollagen	  3	  peptide	  (P3NP)	  and	  
laminin.	  Elevated	  levels	  of	  P3NP	  are	  observed	  in	  various	  liver	  diseases	  such	  as	  HCV,	  ALD	  and	  
NAFLD(Rosenberg	  et	  al.,	  2004,	  Nojgaard	  et	  al.,	  2003).	  
	  
1.17.2.3 Collagenases	  and	  their	  inhibitors	  
MMP	  
MMPs	  are	  enzymes	  involved	  in	  collagen	  degradation	  and	  tissue	  remodelling.	  Levels	  of	  TIMP	  
correlate	  with	  fibrosis	  stage(Leroy	  et	  al.,	  2004).	  
	  
1.17.3 Commercially	  available	  biomarker	  combination	  tests	  
Fibrotest:	   α2-­‐macroglobulin,	   apolipoprotein	   A1,	   haptoglobin,	   gamma	   glutamyl	  
transpeptidase	   and	   total	   bilirubin.	   (Fibromax	   adds	   AST,	   ALT,	   fasting	   glucose,	   total	  
cholesterol	  and	  triglyceride	  to	  this	  panel)	  
Fibrometer:	   platelets,	   hyalauronic	   acid	   or	   gamma	   glutamyl	   transpeptidase,	   prothrombin	  
index,	  AST	  and	  α2-­‐macroglobulin.	  
Hepascore:	  α2-­‐macroglobulin,	  hyalauronic	  acid	  and	  gamma	  glutamyl	  transferase	  







This	   model	   was	   first	   described	   in	   2001	   in	   HCV	   patients(Imbert-­‐Bismut	   et	   al.,	   2001).	   It	   is	  
licenced	  to	  biopredictive	  (www.biopredictive.com).	  	  
FibroTestTM,(Poynard	   et	   al.,	   2007)	   SteatoTestTM	   (Poynard	   et	   al.,	   2005)and	   NashTestTM	  
(Poynard	   et	   al.,	   2006)	   are	   three	   simple	   blood	   test	   panels	   that	   have	   been	   developed	   to	  
provide	  a	  non-­‐invasive	  estimate	  of	  liver	  fibrosis,	  steatosis	  and	  steatohepatitis,	  respectively.	  
The	  FibroMax	  TM	  (Biopredictive,	  Paris,	  France)	  is	  the	  combination	  of	  these	  three	  blood	  test	  
panels	   on	   the	   same	   result	   sheet	   and	   provides	   researchers	   and	   physicians	   with	   a	  
simultaneous	   and	   complete	   estimation	   of	   liver	   injury	   in	   NAFLD(Morra	   et	   al.,	   2007).	   	   The	  
FibroMaxTM	   combines	   10	   serum	  markers	  with	   the	   age,	   sex,	   height	   (m)	   and	  weight	   (kg)	   of	  
each	  patient;	  
Fibrotest	   has	   been	   validated	   in	   patients	   with	   HCV,	   HBV,	   ALD	   and	   NAFLD	   in	   a	   meta-­‐
analysis.(Halfon	   et	   al.,	   2008).	   AUROC	   for	   the	   diagnosis	   of	   bridging	   fibrosis	   (F2/F3/F4	   vs.	  
F0/F1)	   was	   0.82	   *0.83-­‐0.86),	   0.831	   *0.78-­‐0.83),	   0.87	   (0.82-­‐0.92)	   and	   0.84	   (0.76-­‐0.92)	  
respectively.	  	  
The	  reliability	  of	  results	  has	  been	  shown	  to	  depend	  on	  local	  laboratory	  compliance	  with	  the	  
pre-­‐analytical	  and	  analytical	  conditions	  recommended	  by	  the	  quality	  chart	  of	  BioPredictive.	  	  
	  
Fibrometer	  
This	  was	   first	  proposed	   in	  2005	  following	  a	  study	  by	  Cales	  et	  al	   in	  a	  viral	  hepatitis	  cohort.	  
When	  compared	  to	  ELF,	  APRI,	  Forns	  and	  Fibrotest	  it	  outperformed	  them(Cales	  et	  al.,	  2005)	  
The	   same	   author	   has	   also	   looked	   at	   the	   use	   of	   Fibrometer	   in	   HIV	   and	   HCV	   co-­‐infected	  
patients	  (HIV/HCV),	  noting	  that	  diagnostic	  accuracy	  in	  co-­‐infected	  patients	  is	  diminished	  by	  
the	  presence	  of	  HIV	  when	  compared	  to	  original	  studies	  of	  mono-­‐infected	  patients(Cales	  et	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al.,	   2010).	   More	   recently,	   Boursier	   showed	   that	   a	   combination	   of	   Fibroscan	   (described	  
below)	  and	  Fibrometer	  gave	  a	  diagnostic	  accuracy	  of	  86.7%;	  this	  has	  been	  introduced	  into	  a	  




This	   scoring	   system	  was	   first	   described	   in	   2005(Adams	   et	   al.,	   2005)	   in	   an	   HCV	   cohort.	   A	  
score	   >0.5	   provided	   a	   specificity	   and	   sensitivity	   of	   89%	   and	   63%	   for	   significant	   fibrosis,	  
whereas	  scores	  <0.5	  had	  74%	  specificity	  and	  88%	  sensitivity	  for	  advanced	  fibrosis.	  The	  score	  
was	  further	  validated	  in	  2009.	  Again	  an	  HCV	  cohort	  was	  used(Becker	  et	  al.,	  2009).	  A	  cutoff	  
score	  of	  >0.55	  was	  best	  for	  predicting	  significant	  fibrosis,	  with	  a	  sensitivity	  and	  specificity	  of	  
82%	  and	  65%	  and	  positive	   and	  negative	   predictive	   values	   of	   70%	  and	  78%.	   The	   ability	   of	  
Hepascore	  to	  predict	  significant	  fibrosis	  (F2–4)	  as	  determined	  by	  the	  AUROC	  was	  similar	  in	  
training	  (0.83)	  and	  validation	  sets	  (0.81)	  
	  
ELF	  
ELF	   accurately	  predicts	  moderate	   to	   severe	   fibrosis	   in	   several	   aetiology	   in	   several	   chronic	  
liver	   diseases.	   It	   was	   first	   described	   in	   2004(Rosenberg	   et	   al.,	   2004)	   and	   revised	   in	   2009	  
when	   it	   was	   shown	   that	   for	   chronic	   HCV	   the	   pooled	   AUROC	   for	   prediction	   of	   Ishak	   4-­‐6	  
fibrosis	   was	   0.85	   (0.81-­‐0.89)	   (Parkes	   et	   al.,	   2011).	   In	   PBC,	   ELF	   predicts	   cirrhosis	   with	   an	  
AUROC	  of	  0.76	  (0.63-­‐0.89)	  or	  significant	  fibrosis	  with	  an	  AUROC	  of	  0.75	  (0.67-­‐0.82).(Mayo	  et	  
al.,	  2008)	   In	  NAFLD,	  ELF	  can	  predict	  severe	  fibrosis,	  moderate	  fibrosis	  and	  no	  fibrosis	  with	  
AUROCs	  of	  0.90,	  0.82	  and	  0.76	  respectively.(Guha	  et	  al.,	  2008).	  




Ultrasound,	   magnetic	   resonance	   imaging	   (MRI)	   and	   computed	   tomography	   (CT)	   have	   all	  
studied	   as	  methods	   of	   assessing	   liver	   fibrosis.	   CT	   and	  MRI	   have	   had	   some	   success	   in	   the	  
non-­‐invasive	   evaluation	  of	   fibrosis	   in	   cardiomyopathy(Nagueh	   and	  Mahmarian,	   2006)	   and	  
interstitial	  lung	  disease(Lutterbey	  et	  al.,	  2007)	  leading	  to	  their	  study	  in	  liver	  disease.	  
Imaging	  of	  the	  liver	  has	  evolved	  rapidly	  in	  the	  last	  10-­‐20	  years	  and	  MRI,	  high	  resolution	  CT	  
and	   high	   definition	   US	   can	   all	   identify	   changes	   in	   the	   liver	   parenchyma	   consistent	   with	  
cirrhosis.	  Portal	  hypertension	  can	  be	  evaluated	  by	  the	  presence	  of	  splenomegaly,	  collateral	  




Ultrasound	  provides	   rapid	   inexpensive	   information	  about	  hepatic	  architecture.	   It	   is	  widely	  
available.	  Cirrhotic	  livers	  have	  a	  typical	  appearance	  of	  nodularity	  and	  often	  show	  increased	  
echogenicity.	   Doppler	   ultrasonography	   allows	   operators	   to	   gain	   information	   about	   the	  
hepatic	  vasculature	  and	  changes	  in	  blood	  flow	  associated	  with	  portal	  hypertension	  or	  loss	  of	  
vessel	   patency.	   Newer	   liver	   imaging	   techniques	   such	   as	   contrast	   enhanced	  
ultrasound(Bolondi	  et	  al.,	  2007)	  are	  not	  yet	  in	  mainstream	  use.	  
	  
	  
Fibroscan	  (Transient	  Elastography	  (TE)	  /Liver	  stiffness	  measurement	  (LSM))	  
Currently,	  Fibroscan	  is	  the	  most	  commonly	  used	  method	  of	  assessing	  liver	  fibrosis.	  	  
A	  vibration	  of	  low	  frequency	  and	  mild	  amplitude	  is	  transmitted	  into	  the	  tissue	  inducing	  an	  
elastic	  shear	  wave	  that	  propagates	  within	  the	  liver.	  Pulse	  echo	  ultrasonic	  acquisitions	  then	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follow	   the	   shear	  wave	  and	  measure	   its	   speed.	   The	  harder	   the	   tissue,	   the	   faster	   the	  wave	  
propagates.	  The	  stiffness	  of	  the	  tissue	  is	  then	  measured	  in	  kilopascals.	  	  
It	  is	  a	  rapid	  and	  reproducible	  way	  of	  assessing	  liver	  stiffness,	  which	  has	  the	  advantage	  over	  
biopsy	  of	  a	  lower	  sampling	  error	  by	  virtue	  of	  the	  fact	  that	  it	  assesses	  a	  larger	  area	  of	  liver.	  
Unfortunately	   it	   is	   not	   without	   problems.	   Extrahepatic	   cholestasis,	   liver	   injury	   and	  
inflammation	   can	   all	   affect	   the	   reading.	   Usability	   is	   also	   affected	   by	   obesity	   and	   small	  
intracostal	  space	  both	  of	  which	  can	  affect	  the	  reproducibility	  and	  accuracy	  of	  readings.	  It	  is	  
however	   excellent	   at	   diagnosing	   liver	   cirrhosis(Sandrin	   et	   al.,	   2003,	   Friedrich-­‐Rust	   et	   al.,	  
2008b)	  	  
The	   use	   of	   two	   or	   more	   non-­‐invasive	   methods	   increases	   the	   diagnostic	   accuracy	   of	   an	  
individual	  assay(Castéra	  et	  al.,	  2010b).	  	  Recently	  controlled	  attenuation	  parameter	  (CAP)	  has	  
been	  introduced	  by	  Echosens®	  who	  manufacture	  the	  scanners.	   It	   is	  a	  tool	  for	  non-­‐invasive	  
assessment	   and	   quantification	   of	   steatosis.	   It	  works	   by	  measuring	   the	   attenuation	   of	   the	  
ultrasound	  wave.	  This	  corresponds	  to	  a	  decrease	   in	  ultrasound	  wave	  amplitude.	  Published	  
data	  shows	  it	  to	  have	  an	  AUROC	  of	  0.91	  and	  0.95	  for	  the	  detection	  of	  more	  than	  10%	  or	  33%	  
steatosis	  respectively(Sasso	  et	  al.,	  2010).	  
 
Recently	  LSM	  values	  have	  been	  shown	  to	  correlate	  with	  portal	  hypertension	  as	  measured	  by	  
hepatic	  venous	  pressure	  gradient	  (HPVG)(Vizzutti	  et	  al.,	  2007).	  This	  means	  that	  potentially	  
LSM	   could	   be	   used	   to	   screen	   liver	   patients	   for	   portal	   hypertension	  without	   the	   need	   for	  
endoscopic	  surveillance,	  but	  is	  yet	  to	  be	  adopted	  into	  mainstream	  practice.	  Splenic	  stiffness	  
has	  also	  been	  measured	  using	  TE	   to	  predict	   the	  presence	   (but	  not	   grade)	  of	  oesophageal	  





Several	   advances	   have	  been	  made	   recently	   using	  MRI.	   These	   involve	  magnetic	   resonance	  
elastography	   (MRE)(Huwart	   et	   al.,	   2006),	   contrast	   enhanced	  MRI	   and	   diffusion	   weighted	  
MRI.	   The	   advantage	   of	   MRE	   over	   Fibroscan	   is	   that	   potentially	   the	   whole	   liver	   can	   be	  
assessed,	   there	   is	   no	   acoustic	   window	   requirement	   (rib	   spaces)	   and	   the	   technique	   is	  
operator	   independent.	   MR	   is	   however	   expensive	   and	   time	   consuming	   compared	   to	  
Fibroscan.	   Diffusion	  weighted	  MRI(Taouli	   et	   al.,	   2007)calculates	   the	   diffusion	   of	  water	   by	  
quantifying	   the	   apparent	   diffusion	   coefficient,	   which	   is	   reduced	   in	   worsening	   fibrosis	  
through	  to	  cirrhosis.	  
Magnetic	   resonance	   spectrography	   (MRS)	   is	   another	   use	   of	   MRI	   that	   allows	   accurate	  
assessment	   of	   hepatic	   fat	   content	  without	   the	   need	   to	   biopsy(Friedrich-­‐Rust	   et	   al.,	   2010,	  





1.19 Future	  Directions	  
Non-­‐invasive	   assessment	   is	   still	   in	   its	   infancy.	   Despite	   many	   research	   studies	   that	   link	  
current	  biomarkers	   to	   fibrosis	   stage	   few	  have	  been	  accepted	   into	   routine	   clinical	  practice	  
partly	  because	  of	  the	  lack	  of	  a	  reliable	  gold	  standard.	  Further	  studies	  are	  needed	  to	  assess	  
specific	   patient	   cohorts	   with	   validation	   cohorts	   confirming	   the	   findings	   in	   other	   centres.	  
Currently	  non-­‐invasive	  markers	  have	  an	  unclear	  role	  in	  assessing	  liver	  fibrosis	  but	  as	  more	  is	  
known	   about	   the	   diagnostic	   accuracy	   of	   these	  markers,	   the	   role	   of	   liver	   biopsy	   to	   stage	  






1.20 Link	  to	  research	  in	  this	  thesis	  
Chapter	   2(Corbett	   et	   al.,	   2013)	   details	   a	   study	   performed	   in	   the	   local	   hospital	   (Queen	  
Elizabeth	  Birmingham)	   looking	  at	   the	   correlation	  of	   LSM	  and	   Ishak	   fibrosis	   stage.	  We	  also	  
used	  this	  study	  to	  analyse	  the	  learning	  curve	  required	  to	  become	  competent	  at	  scanning.	  
Chapter	  3	  is	  a	  meta-­‐analysis	  of	  common	  liver	  fibrosis	  biomarkers	  to	  determine	  whether	  they	  
can	  predict	  clinical	  end	  points,	  which	  many	  would	  argue,	  is	  of	  more	  importance	  than	  fibrosis	  
which	   could	   be	   viewed	   as	   a	   surrogate	   end	   point.	   Although	   the	   markers	   have	   all	   been	  
validated	  in	  assessing	  the	  degree	  of	  liver	  fibrosis,	  data	  on	  their	  ability	  to	  predict	  outcomes	  is	  
less	  widely	  available.	  
Chapter	  4	  reports	  the	  potential	  of	  a	  panel	  of	  non-­‐invasive	  biomarkers	  to	  predict	  fibrosis	  on	  
liver	  biopsy.	  	  The	  “Non	  Invasive	  Biomarkers	  of	  Liver	  Fibrosis”	  study	  (NOBLES)	  was	  set	  up	  to	  
try	  and	  clarify	  the	  role	  of	  potential	  new	  serum	  liver	  biomarkers	  in	  a	  prospectively	  collected	  
cohort	  of	  patients	  attending	  for	  liver	  biopsy.	  Commonly	  used	  indirect	  markers	  are	  assessed	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2.1 Abstract	  	  
 
Background	   &	   Aims:	   The	   diagnostic	   accuracy	   of	   transient	   elastography	   (TE)	   and	   the	  
importance	  of	  the	  validity	  criteria	   in	  day-­‐to-­‐day	  UK	  clinical	  practice	  remains	  unknown.	  Our	  
study	  aims	  to	  address	  this.	  
Methods:	   We	   retrospectively	   analysed	   the	   validity	   criteria	   (includes	   ≥10	   successful	  
acquisitions,	   success	   rate	   ≥60%	   and	   IQR/median	   <30%)	   and	   accuracy	   of	   liver	   stiffness	  
measurements	   (LSM)	  performed	  by	  multiple	  operators	  under	  routine	  clinical	  conditions	  at	  
the	  University	  Hospital	  Birmingham,	  UK	  (2008-­‐2011).	  	  
Results:	   2311	   LSM	   were	   performed.	   153	   (6.6%)	   were	   compared	   with	   liver	   biopsy.	   The	  
correlation	  between	  LSM	  and	  modified-­‐Ishak	  fibrosis	  stage	  was	  superior	   in	  patients	  with	  a	  
valid	  LSM	  (n=97)	  compared	  to	  those	  with	  an	  invalid	  LSM	  (n=56)	  (rs	  0.577	  vs.	  0.259;	  p=0.022	  
and	   the	   AUROC	   for	   significant	   fibrosis	   was	   greater	   when	   LSM	   was	   valid	   (0.83	   vs.	   0.66;	  
p=0.048).	  Using	  an	  8	  kPa	  cut-­‐off,	  the	  negative	  predictive	  value	  of	  valid	  LSM	  was	  superior	  to	  
invalid	   LSM	   for	   the	   detection	   of	   significant	   (84%	   vs	   71%)	   and	   advanced	   fibrosis	   (100%	   vs	  
93%).	   Learning	   curve	   analysis	   highlighted	   that	   the	   greatest	   improvement	   in	   LSM	   validity	  
rates	  occurs	  in	  the	  operators	  first	  10	  LSM,	  reaching	  64.7%	  validity	  by	  50	  LSM.	  
Conclusion:	  TE	  requires	  minimal	  training	  (≥10	  observed)	  and	  when	  valid	  is	  an	  accurate	  tool	  
for	  excluding	  advanced	   liver	   fibrosis.	  To	  ensure	  the	  diagnostic	  accuracy	  the	  recommended	  








Identification	  of	  patients	  with	  significant	   liver	   fibrosis	   is	   important	   to	  determine	  prognosis	  
and	   to	   aid	   clinical	   decision-­‐making,	   with	   regards	   to	   prioritising	   therapeutic	   options	   and	  
monitoring	   for	  disease	  complications	   (i.e.	  HCC,	  gastro-­‐oesophageal	  varices).	  However,	  due	  
to	   the	   fact	   that	  most	   patients	   with	   chronic	   liver	   disease	   remain	   asymptomatic	   until	   liver	  
function	   is	  compromised,	  establishing	  the	  presence	  and	  severity	  of	   liver	  fibrosis	  remains	  a	  
clinical	   challenge.	   This	   is	   further	   compounded	   by	   the	   problems	   of	   liver	   biopsy,	   which	   is	  
widely	  regarded	  as	  a	  sub-­‐optimal	  ‘gold-­‐standard’	  due	  to	  its	  invasive	  nature,	  sampling	  error,	  
inter-­‐observer	   variability	   and	   the	   reluctance	   of	   patients	   to	   undergo	   repeat	   biopsy	   for	  
disease	   monitoring(Bravo	   et	   al.,	   2001)	   Consequently,	   over	   the	   last	   decade	   non-­‐invasive,	  
cheaper	   tools	   for	   identifying	   liver	   fibrosis	  have	  been	  developed(Rockey	  and	  Bissell,	  2006),	  
and	   one	   in	   particular	   transient	   elastography	   (TE)	   (Fibroscan,	   Echosens;	   France)	   has	   been	  
widely	  adopted	  into	  clinical	  practice.	  
	  
TE	  provides	  a	  rapid	  measurement	  of	   liver	  stiffness	  by	  the	  bedside	  and	  has	  been	  shown	  to	  
accurately	   correlate	   with	   histological	   fibrosis	   (in	   particular	   cirrhosis)	   in	   several	   disease	  
aetiologies(Tsochatzis	   et	   al.,	   2011,	   Friedrich-­‐Rust	   et	   al.,	   2008b,	   Talwalkar	   et	   al.,	   2007).	  
Subsequently,	   TE	   has	   gained	   widespread	   use	   as	   a	   research	   tool	   and	   in	   certain	   specialist	  
centres	   as	   a	   routine	   clinical	   tool.	   The	   manufacturer	   recommends	   that	   all	   the	   following	  
criteria	  have	   to	  be	  met	   to	  consider	   the	   liver	   stiffness	  measurement	   (LSM)	  as	  valid:	  1)	  ≥10	  
successful	   acquisitions,	   2)	   success	   rate	   ≥60%,	   and	   3)	   interquartile	   range	   (IQR)/median(M)	  
ratio	  <0.30(Castéra	  et	  al.,	  2010a).	  However,	  the	  importance	  of	  complying	  with	  these	  validity	  
criteria	   has	   never	   been	   demonstrated	   in	   ‘real-­‐world’	   clinical	   practice,	   as	   no	   study	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(retrospective	  or	  prospective)	   to	  date	  has	   shown	   that	  obtaining	  all	   three	  of	   these	   criteria	  
improves	   diagnostic	   accuracy	   (Lucidarme	   et	   al.,	   2009,	  Myers	   et	   al.,	   2010).	   	   Furthermore,	  
since	  the	  introduction	  of	  TE	  in	  the	  UK	  in	  2005,	  there	  has	  been	  a	  paucity	  of	  published	  data	  
from	  day-­‐to-­‐day	  clinical	  practice.	  
	  
Between	  2008	  (first	  introduced)	  and	  2011,	  hepatologists	  at	  the	  Queen	  Elizabeth	  University	  
Hospital	   Birmingham	   (UK)	   performed	   2311	   TE	   examinations	   as	   part	   of	   the	   clinical	  
assessment	  of	  patients	  attending	  the	  liver	  outpatients	  department.	  Our	  study	  has	  analysed	  
the	   performance	   of	   TE	   in	   day-­‐to-­‐day	   clinical	   practice	   in	   this	   retrospective	   cohort	   and	  
examines	  the	  importance	  of	  adhering	  to	  the	  recommended	  LSM	  validity	  criteria.	  In	  addition,	  







2.3.1 Study	  Population:	  
	  
Consecutive	  adult	  patients,	  who	  underwent	  liver	  TE	  as	  part	  of	  a	  routine	  liver	  outpatient	  visit	  
at	  the	  Queen	  Elizabeth	  Hospital,	  Birmingham,	  UK	  between	  August	  2008	  and	  July	  2011,	  were	  
retrospectively	  studied.	  The	  decision	  to	  perform	  TE	  and	  to	  refer	  for	  a	  liver	  biopsy	  was	  made	  
on	  clinical	  grounds	  by	  the	  specialist	  hepatologist	  in	  clinic	  (consultant	  or	  specialist	  registrar).	  
Patients	  with	   suspected	   chronic	   liver	  disease	  of	   any	   aetiology	  were	   included.	   Institutional	  
Review	  Board	  approval	  was	  not	  required.	  
 
2.3.2 Liver	  Stiffness	  Measurement:	  
 
Between	   the	   study	  dates,	   either	   a	   consultant	  hepatologist	  or	   a	   specialist	   trainee	   registrar	  
performed	   the	   TE	   examination	  during	   the	  outpatient	   clinic	   visit.	   In	   our	   unit,	   all	   operators	  
underwent	  a	  certified	  training	  session	   (4	  hour)	  with	  an	  Echosens	  consultant	  prior	   to	  using	  
the	   M-­‐probe	   and/or	   XL-­‐probe	   in	   the	   clinical	   setting.	   Prior	   to	   certification,	   the	   operators	  
performed	  3	  TE	  examinations	  on	  volunteers	  with	  the	  Echosens	  consultant	  in	  attendance	  to	  
determine	  if	  the	  application	  of	  the	  TE	  probe	  and	  interpretation	  of	  the	  LSM	  were	  correct.	  
	  
TE	   was	   performed	   using	   either	   the	   M-­‐probe	   (3.5	   Hz	   frequency)	   or	   XL-­‐probe	   (2.5	   Hz	  
frequency)	   with	   the	   Fibroscan®	   502	   machine	   (Echosens,	   France).	   The	   manufacturer	  
recommends	  that	  the	  XL	  probe	  should	  be	  used	  in	  patients	  with	  a	  skin-­‐capsular	  distance	  >2.5	  
cm	  (measured	  by	  sonographic	  imaging).	  Due	  to	  the	  time	  constraints	  in	  liver	  clinic,	  operators	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were	  advised	  to	  use	  the	  XL-­‐probe	  in	  patients	  with	  a	  measured	  BMI	  >	  30	  Kg/m2	  (Myers	  et	  al.,	  
2012).	   In	  May	   2011,	   our	   unit	   began	   using	   the	   Fibroscan®	   502	   Touch	   (Echosens,	   France),	  
which	   has	   a	   built-­‐in	   automated	   indicator	   that	   recommends	   the	   probe	   best	   suited	   to	   the	  
patient’s	  morphology.	  In	  accordance	  with	  manufacturer’s	  guidance,	  all	  TE	  examinations	  are	  
performed	  in	  our	  clinics	  with	  the	  patient	  lying	  in	  the	  dorsal	  decubitus	  position	  with	  the	  right	  
arm	  extended.	  The	  tip	  of	  the	  transducer	  probe	  (covered	  with	  coupling	  gel)	  is	  placed	  on	  the	  
skin	   in	  an	   intercostal	  space	  overlying	  the	  right	   lobe	  of	   the	   liver.	  A	  time-­‐motion	  ultrasound	  
image	  allows	  the	  operator	  to	   locate	  a	  portion	  of	   liver	  at	   least	  6-­‐cm	  thick	  and	  free	  of	   large	  
vascular/bony	   structures.	   The	   median	   value	   of	   successful	   acquisitions	   (target	   =	   10)	   is	  
deemed	   to	   be	   representative	   of	   the	   liver	   stiffness,	   represented	   as	   LSM.	   If	   no	   value	   was	  
obtained	  following	  10	  acquisitions	  LSM	  failure	  was	  documented.	  LSM	  was	  only	  classified	  as	  
‘valid’	   if	   all	   three	   of	   the	   manufacturer’s	   criteria(Castéra	   et	   al.,	   2010a)	   were	   met:	   1)	   ≥10	  
successful	  acquisitions;	  2)	  success	  rate	  was	  ≥60%;	  and	  3)	  IQR/M	  ratio	  <30%.	  If	  any	  of	  these	  
three	  criteria	  were	  not	  met	  the	  LSM	  was	  classified	  as	  ‘invalid.’	  
	  
2.3.3 Liver	  Biopsy:	  
 
Electronic	  pathology	  records	  were	  reviewed	  to	   identify	  all	  patients	  who	  had	  a	   liver	  biopsy	  
within	  12	  months	  of	  their	  TE.	  Histological	  fibrosis	  staging	  was	  used	  to	  assess	  the	  accuracy	  of	  
TE	   for	   the	   diagnosis	   of	   significant	   and	   advanced	   fibrosis.	   In	   our	   centre,	   liver	   biopsies	   are	  
routinely	  reported	  using	  the	  appropriate	  disease-­‐specific	  liver	  fibrosis	  staging	  (i.e.	  Ishak	  for	  
hepatitis	   C;	   Kleiner	   for	   non-­‐alcoholic	   fatty	   liver	   disease).	   For	   purposes	   of	   this	   study,	  
however,	  each	  biopsy	  was	  re-­‐assessed	  independently	  by	  two	  liver	  pathologists	  (NM	  &	  RB	  or	  
NM	  &	  SH)	  without	  knowledge	  of	  LSM	  results	  or	  other	  clinical	  data.	  In	  cases	  of	  disagreement,	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a	   consensus	  was	   reached	  by	   a	   joint	   review.	   To	   take	   account	   of	   the	  diverse	   aetiologies	   of	  
liver	  disease,	   liver	  fibrosis	  was	  staged	  using	  a	  modified	  version	  of	  the	  Ishak	  scoring	  system	  




Table	  2-­‐1	  Ishak	  fibrosis	  stage.	  *Proportion	  (%)	  of	  area	  of	  illustrated	  section	  showing	  Sirius	  
red	  staining	  for	  collagen	  (10).	  
 
Significant	   fibrosis	   was	   defined	   as	   a	  modified	   Ishak	   score	   >	   2	   and	   advanced	   fibrosis	   as	   a	  
modified	   Ishak	   score	  of	  5	  or	  6.	  The	   length	  of	  biopsy	   specimens	  and	   the	  number	  of	  portal	  
tracts	  sampled	  were	  recorded	  as	  measures	  of	  biopsy	  quality.	  Biopsies	  specimens	  that	  were	  






2.3.4 Data	  collection:	  
 
LSM	   data	  was	   retrospectively	   obtained	   from	   all	   three	   TE	  machines	   in	   our	   unit	   to	   form	   a	  
database	   of	   the	   study	   cohort.	   Recorded	   LSM	   parameters	   included:	   patient	   identification	  
number,	  date	  of	  TE,	  operator,	  TE	  probe,	  number	  of	  successful	  acquisitions,	  success	  rate	  and	  
median	   value	   (IQR)	   of	   successful	   acquisitions.	   Electronic	   histopathology	   reports	   were	  
reviewed	   to	   identify	   those	   patients	  who	   had	   an	   ultrasound-­‐guided	   liver	   biopsy	  within	   12	  
months	   of	   the	   TE	   examination.	   Demographics,	   anthropometric	   measurements	   (weight,	  
height,	  BMI),	   liver	  enzymes	  and	  liver	  disease	  aetiology	  at	  the	  time	  of	  TE	  examination	  were	  
obtained	  for	  these	  cases.	  The	  definitive	  disease	  aetiology	  was	  determined	  by	  a	  combination	  
of	   the	   clinical	   and	   histological	   findings	   and	  was	   categorized	   into	   fatty	   liver	   disease	   [non-­‐
alcoholic	  or	  alcoholic],	   viral	  hepatitis	   [hepatitis	  B,	  C],	  autoimmune	   [autoimmune	  hepatitis,	  
primary	   biliary	   cirrhosis,	   primary	   sclerosing	   cholangitis],	   post-­‐transplant	   and	   other,	   for	  
purposes	  of	  statistical	  analysis.	  
 
2.3.5 Statistical	  Analysis:	  
	  
The	  demographics	  and	  characteristics	  of	  patients	  were	  summarised	  according	  to	  the	  validity	  
criteria	   of	   the	   LSM	   (as	   defined	   above).	   Continuous	   variables	   were	   compared	   with	  
independent	   sample	   t-­‐tests	   and	   Mann-­‐Whitney	   tests	   (as	   applicable),	   and	   categorical	  
variables	  were	  compared	  with	  Fisher’s	  exact	  test.	  
The	   strength	   of	   the	   relationship	   between	   the	   LSM	   and	   the	   modified	   Ishak	   score	   was	  
analysed	   using	   Spearman’s	   rho	   correlation	   coefficients.	   Separate	   coefficients	   were	  
produced	  for	  those	  measurements	  where	  each	  of	  the	  three	  LSM	  validity	  criteria	  were	  met,	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and	   those	  where	   the	   criteria	  were	   contravened.	   The	   coefficients	  were	   then	   compared	   to	  
test	  whether	  non-­‐compliance	  with	  the	  LSM	  validity	  criteria	  is	  detrimental	  to	  the	  ability	  of	  TE	  
to	   predict	   the	   histological	   severity	   of	   liver	   fibrosis.	   The	   modified	   Ishak	   score	   was	   then	  
converted	  into	  two	  binary	  outcomes	  indicating	  the	  presence	  of	  significant	  fibrosis	  (Ishak	  3-­‐
6)	  and	  of	  advanced	  fibrosis/cirrhosis	   (Ishak	  5	  or	  6).	  ROC	  curves	  were	  produced	  to	  test	  the	  
accuracy	  of	  LSM	  in	  the	  prediction	  of	  significant	  and	  advanced	  fibrosis.	  Separate	  ROC	  curves	  
were	  produced	  for	  LSM	  that	  were	  deemed	  ‘valid’	  by	  each	  of	  the	  validity	  criteria,	  and	  those	  
that	  were	  ‘not	  valid’,	  with	  comparisons	  made	  between	  the	  resulting	  AUROC.	  A	  cut-­‐off	  value	  
of	   8	   kPa	  was	   used	   to	   determine	   the	   presence	   of	   significant	   fibrosis,	   above	  which	   further	  
investigation	  is	  deemed	  appropriate(Roulot	  et	  al.,	  2008).	  	  Furthermore,	  the	  use	  of	  different	  
LSM	   cut-­‐offs	   to	   identify	   patients	   with	   significant	   fibrosis	   and	   advanced	   fibrosis	   was	  
examined	  with	  the	  calculation	  of	  sensitivity	  and	  specificity	  statistics,	  as	  well	  as	  the	  PPV	  and	  
NPV.	  Analysis	   of	   different	   LSM	   cut-­‐offs	  was	   only	   performed	  on	   LSM	   that	  met	   the	   validity	  
criteria	  
Binary	  logistic	  regression	  was	  used	  to	  analyse	  the	  effect	  of	  the	  number	  of	  TE	  examinations	  
performed	  on	  the	  likelihood	  of	  a	  valid	  LSM	  reading.	  Prior	  to	  the	  analysis,	  the	  scan	  number	  
was	  log10	  transformed,	  in	  order	  that	  the	  model	  was	  based	  on	  the	  shape	  of	  curve	  generally	  
observed	  in	  a	  learning	  curve	  analysis.	  The	  results	  of	  the	  analysis	  were	  only	  reported	  for	  the	  
first	  100	  TE	  examinations	  as	  some	  operators	  had	  performed	  fewer	  than	  25	  scans.	  This	  was	  
in	   order	   to	   maximise	   their	   usefulness,	   whilst	   minimising	   the	   amount	   of	   extrapolation	  
required.	   However,	   all	   of	   the	   data	   (n=2328)	  was	   used	   in	   the	   production	   of	   the	   statistical	  
model.	  
Analyses	  were	  performed	  using	   IBM	  SPSS	  19	  and	  Microsoft	   Excel,	  with	  p	   values	   less	   than	  





2.4.1 Patient	  characteristics:	  
 
Between	  2008	  and	  2011,	   2311	   LSM	  were	  performed	  as	  part	   of	   the	   clinical	   assessment	  of	  
patients	  attending	  the	  liver	  outpatients	  department.	  Year-­‐on-­‐year	  there	  was	  an	  increase	  in	  
number	  of	  LSM	  performed	  (2008-­‐2009,	  54/month;	  2010-­‐2011,	  78/month).	  Of	  the	  2311	  LSM,	  
127	   (5.5%)	  were	   LSM	   failures	   (zero	   successful	   acquisitions),	   625	   (27.0%)	  were	   invalid	   and	  




Figure	  2-­‐1	  Flow	  diagram	  of	  the	  study.  
	  
153	   patients	   were	   selected	   after	   exclusion	   (black	   shading)	   of	   patients	   in	   which	   the	  
operator	  failed	  to	  get	  a	  single	  LSM	  reading	  (*defined	  as	  LSM	  failure)	  and/or	  when	  biopsy	  





Table	  2-­‐2 Characteristics	  of	  patients	  who	  underwent	  transient	  elastography	  +	  liver	  biopsy 
Continuous	  data	  displayed	  as:	  Geometric	  Mean	  (95%	  Confidence	  Interval(CI))	  Categorical	  








Not	  Valid	  	  
(n=56)	  
Characteristics	   	   	   	  
Age	  (Years)#	   47.4	  (1.4)	   50.1	  (1.5)	   0.232	  
Gender	  -­‐ Male	  	  -­‐ Female	   	  68	  (70.1%)	  29	  (29.9%)	   	  37	  (66.1%)	  19	  (33.9%)	   0.718	  














BMI	  [kg/m2]	   27.9	  (26.7-­‐29.2)	   29.2	  (27.3-­‐31.2)	   0.263	  
AST	  (U/L)	   49.9	  (44.3-­‐56.3)	   48.4	  (40.2-­‐58.1)	   0.762	  
Liver	  Biopsy	   	   	   	  
Time	   difference	   between	   biopsy	   and	   Fibroscan	  
(days)†	  
70.0	  (23.5-­‐122.5)	   69.0	  (12.8-­‐195.0)	   0.953	  
Portal	  Tracts	  (n)	   15.1	  (13.8-­‐16.6)	   14.6	  (12.7-­‐16.7)	   0.630	  
Length	  of	  biopsy	  (mm)	   15.4	  (14.5-­‐16.5)	   16.1	  (14.7-­‐17.6)	   0.477	  


















Transient	  Elastography	  (TE)	   	   	   	  
Operator	  -­‐ Consultant	  -­‐ Specialist	  Registrar	   	  49	  (50.5%)	  48	  (49.5%)	   	  30	  (53.6%)	  26	  (46.4%)	   0.738	  
Probe	  -­‐ M-­‐probe	  -­‐ XL-­‐probe	   	  68	  (70.1%)	  29	  (29.9%)	   	  38	  (67.9%)	  18	  (32.1%)	   0.856	  
LSM	  (kPa)†	   9.4	  (6.6-­‐14.5)	   14.1	  (7.3-­‐26.1)	   	  0.011$*	  


















as:	  Median	   (Quartiles),	   $p-­‐Values	   Bonferroni-­‐Adjusted	   for	   4	   comparisons.	   Significant*	   =	  
p<0.05	  
 
The	  mean	  age	  of	   this	  group	  was	  48.4	   (SE	  1.1)	  years,	  68.6%	  were	  male	  and	   the	  mean	  BMI	  
was	  28.4	  Kg/m2	  (95%	  CI	  27.3-­‐29.5).	  The	  disease	  aetiologies	  (confirmed	  on	  biopsy)	  were	  fatty	  
liver	  disease	   in	  37.9%	   (n=58),	   viral	  hepatitis	   in	  32.0%	   (n=49),	  autoimmune	   in	  8.5%	   (n=13),	  
post-­‐transplant	  in	  9.8%	  (n=15)	  and	  miscellaneous/other	  in	  11.8%	  	  (n=18).	  
 
2.4.2 Liver	  histology	  and	  liver	  stiffness	  measurement	  (LSM):	  
 
The	  median	   time	  difference	  between	   LSM	  and	   liver	   biopsy	  was	   70	  days	   (IQR	  22.0-­‐127.0).	  
The	  mean	  number	  of	  portal	  tracts	  and	  length	  of	  biopsy	  was	  14.9	  (95%	  CI	  13.9-­‐16.1)	  and	  15.7	  
(95%	   CI	   14.9-­‐16.5)	  mm,	   respectively.	   The	   liver	   pathologists	   deemed	   all	   153	   liver	   biopsies	  
adequate	  for	  fibrosis	  staging.	  Seventy	  patients	  (45.7%)	  had	  significant	  fibrosis	  (Ishak	  stage	  3-­‐
6),	   of	  which	  25	  had	   advanced	   fibrosis	   (Ishak	  5-­‐6).	   Seventy-­‐eight	   (51.0%)	  of	   the	   LSM	  were	  
performed	  by	   consultant	  hepatologists,	  with	   remainder	  by	   specialist	   registrars	   in	   training.	  
One	   hundred	   and	   six	   (69.2%)	   of	   the	   LSM	   were	   performed	   using	   the	  M-­‐probe	   versus	   47	  
(30.8%)	  with	  the	  XL-­‐probe.	  Overall,	  the	  median	  LSM	  for	  the	  population	  of	  readings	  was	  10.2	  
kPa	  (IQR	  6.8-­‐17.1).	  	  
 
2.4.3 Importance	  of	  the	  LSM	  validity	  criteria	  for	  predictive	  accuracy:	  
	  
Of	   the	   153	   patients	  with	   paired	   LSM	   and	   liver	   biopsy,	   56	   (36.6%)	   patients	   had	   an	   invalid	  
LSM;	  of	  whom	  21	  patients	   (37.5%)	  had	  <10	  successful	  acquisitions,	  36	   (64.3%)	  had	   IQR/M	  






Figure	  2-­‐2	  Venn	  diagram	  highlighting	  the	  reason(s)	  for	  an	  invalid	  LSM.  
	  
56/153	  patients	  had	  an	  invalid	  LSM.	  Tables	  highlight	  the	  distribution	  of	  spread	  for	  each	  of	  
the	  three	  reasons	  that	  the	  LSM	  was	  classed	  as	  invalid.	  
 
LSM	  were	  significantly	  higher	  in	  patients	  with	  an	  invalid	  scan	  compared	  to	  those	  with	  a	  valid	  
scan	  (14.1	  vs.	  9.4	  kPa;	  p=0.011).	  This	  was	  most	  pronounced	  in	  patients	  without	  fibrosis	  on	  
biopsy	   (12.9	  vs.	  5.6	  kPa;	  p=0.008).	  There	  was	  no	  significant	  difference	   in	  age,	  sex,	  disease	  
type,	   BMI,	  AST	   and	  histological	   parameters	   between	  patients	  with	   a	   valid	   LSM	  and	   those	  
with	  an	  invalid	  LSM	  (Table	  1).	  
The	  correlation	  between	  LSM	  and	  modified	  Ishak	  fibrosis	  stage	  was	  stronger	  in	  patients	  with	  






Figure	  2-­‐3	  Relationship	  between	  the	  LSM	  and	  the	  modified	  Ishak	  stage	  of	  liver	  fibrosis	  for	  
both	  valid	  (black	  circle)	  and	  invalid	  LSM	  (white	  box).  
	  
Median	  LSM	  values	  for	  each	  modified	  Ishak	  stage	  represented	  by	  horizontal	  bar.	  
 
The	  most	   important	   individual	   component	   of	   the	   validity	   criteria	  was	   obtaining	   a	   success	  
rate	  ≥60%.	  The	  correlation	  between	  LSM	  and	  modified	  Ishak	  fibrosis	  stage	  was	  significantly	  
greater	   in	  patients	  with	   success	   rate	  ≥60%	  compared	   to	   those	  with	  <60%	   success	   rate	   (rs	  
0.586	   vs.	   0.018;	   p=0.001).	   This	   correlation	   was	   not	   significant	   for	   IQR/median	   (≥30%	   vs.	  
	  	  
74	  
<30%,	   rs	   0.520	   vs.	   0.264;	   p=0.122)	   and	   number	   of	   successful	   acquisitions	   (≥10	   vs.	   <10,	   rs	  
0.485	  vs.	  0.350;	  p=0.514).	  
 
2.4.4 Average	  stiffness	  values	  for	  patients	  according	  to	  Ishak	  staging	  
Average	  stiffness	  values	  were	  calculated	  for	  patients	  with	  no	  significant	  fibrosis	  (Ishak	  1-­‐2),	  
significant	  fibrosis	  (Ishak	  stage	  ≥3)	  and	  cirrhosis	  (Ishak	  stage	  ≥5).	  The	  results	  were	  then	  split	  
into	   those	   in	   which	   all	   3	   success	   criteria	   had	   been	  met	   and	   those	   where	   they	   were	   not	  
deemed	  “unsuccessful”.	  Prediction	   intervals	  were	  also	  calculated	  to	   illustrate	  the	   levels	  of	  
variability	  in	  the	  data.	  
The	  results	  are	  illustrated	  in	  figure	  2-­‐4	  
 
 
Figure	  2-­‐4	  Effect	  of	  Success	  on	  predictive	  accuracy 
 
Patients	  with	  cirrhosis	  and	  unsuccessful	  scans	  had	  a	  lower	  limit	  of	  confidence	  of	  4.9,	  rising	  
to	  7.6	  in	  patients	  with	  a	  successful	  scan.	  
	  	  
75	  
2.4.4.1 Ishak>3	  	  
Of	   the	   97	   valid	   scans,	   68	   (70%)	   agreed	   with	   the	   biopsy	   (i.e.	   stiffness≤8	   and	   Ishak<3	   or	  
stiffness>8	  and	  Ishak≥3).	  The	  effects	  of	  a	  range	  of	  factors	  on	  the	  difference	  between	  those	  
with	  and	  without	  agreement	  are	  tested	  below:	  
 
  	  	   Agreement	  Between	  Scan	  and	  Biopsy	   	  	  
Factor	   No	   Yes	   p-­‐Value	  
BMI	   27.7	  (25.2-­‐30.3)	   28.1	  (26.6-­‐29.6)	   0.774	  
AST	   47.9	  (38.3-­‐59.7)	   50.9	  (43.9-­‐58.9)	   0.647	  
Portal	  Tracts	  (cm)	   14.5	  (12.5-­‐16.9)	   15.4	  (13.8-­‐17.3)	   0.544	  
Date	  Difference	  (Days)†	   114.7	  (19.9)	   84.2	  (10.7)	   0.183	  
Diagnosis#	   	   	   0.307	  
 Viral	   10	  (35.7%)	   18	  (64.3%)	   	  
 Steatohepatitis	   10	  (25.6%)	   29	  (74.4%)	   	  
 AI/PSC/PBC	   0	  (0.0%)	   7	  (100.0%)	   	  
 Post-­‐Transplant	   4	  (40.0%)	   6	  (60.0%)	   	  
 Other	   5	  (38.5%)	   8	  (61.5%)	   	  
Operator#	   	   	   1.000	  
 Consultant	   15	  (31.3%)	   33	  (68.8%)	   	  
 SPR	   14	  (29.2%)	   34	  (70.8%)	   	  
Probe#	   	   	   0.029*	  
 M	   25	  (36.8%)	   43	  (63.2%)	   	  
 XL	   4	  (13.8%)	   25	  (86.2%)	   	  
Table	  2-­‐3	  Factors	  Predicting	  Agreement	  Between	  Scan	  and	  Biopsy 
	  
Data	   displayed	   as	   geometric	   mean	   (95%	   confidence	   interval)	   and	   p-­‐values	   from	  
independent	  sample	  t-­‐tests,	  unless	  stated	  otherwise	  
#N(%),	  with	  p-­‐value	  from	  Fisher’s	  exact	  test	  
†Median	  (Quartiles),	  with	  p-­‐value	  from	  Mann-­‐Whitney	  test	  
*Significant	  at	  p<0.05	  
	  
Hence,	  it	  can	  be	  concluded	  that	  scans	  performed	  with	  the	  “XL”	  probe	  are	  more	  likely	  to	  be	  







Of	   the	   97	   valid	   scans,	   54	   (56%)	   agreed	   with	   the	   biopsy	   (i.e.	   stiffness≤8	   and	   Ishak<5	   or	  
stiffness>8	  and	  Ishak≥5).	  The	  effects	  of	  a	  range	  of	  factors	  on	  the	  difference	  between	  those	  
with	  and	  without	  agreement	  are	  tested	  below:	  
  	  	   Agreement	  Between	  Scan	  and	  Biopsy	   	  	  
Factor	   No	   Yes	   p-­‐Value	  
BMI	   28.5	  (26.5-­‐30.6)	   27.5	  (25.8-­‐29.3)	   0.447	  
AST	   52.8	  (44.0-­‐63.4)	   47.8	  (40.5-­‐56.3)	   0.410	  
Portal	  Tracts	  (cm)	   15.1	  (13.2-­‐17.3)	   15.2	  (13.4-­‐17.2)	   0.979	  
Date	  Difference	  (Days)†	   70.0	  (24.0-­‐272.0)	   68.5	  (5.0-­‐124.5)	   0.819	  
Diagnosis#	   	   	   0.599	  
 Viral	   12	  (42.9%)	   16	  (57.1%)	   	  
 Steatohepatitis	   19	  (48.7%)	   20	  (51.3%)	   	  
 AI/PSC/PBC	   2	  (28.6%)	   5	  (71.4%)	   	  
 Post-­‐Transplant	   6	  (60.0%)	   4	  (40.0%)	   	  
 Other	   4	  (30.8%)	   9	  (69.2%)	   	  
Operator#	   	   	   0.149	  
 Consultant	   17	  (35.4%)	   31	  (64.6%)	   	  
 SPR	   25	  (52.1%)	   23	  (47.9%)	   	  
Probe#	   	   	   0.824	  
 M	   31	  (45.6%)	   37	  (54.4%)	   	  
 XL	   12	  (41.4%)	   17	  (58.6%)	   	  
Table	  2-­‐4	  Factors	  Predicting	  Agreement	  Between	  Scan	  and	  Biopsy	  
	  
Data	   displayed	   as	   geometric	   mean	   (95%	   confidence	   interval)	   and	   p-­‐values	   from	  
independent	  sample	  t-­‐tests,	  unless	  stated	  otherwise	  
#N(%),	  with	  p-­‐value	  from	  Fisher’s	  exact	  test	  
†Median	  (Quartiles),	  with	  p-­‐value	  from	  Mann-­‐Whitney	  test	  







Table	   2-­‐5	   summarises	   the	   accuracy	   of	   LSM	   in	   predicting	   fibrosis	   (AUROC),	   based	   on	  
obtaining	   each	   of	   the	   individual	   validity	   criteria	   and	   when	   all	   3	   of	   the	   criteria	   are	   met	  
(defined	  as	  a	  valid	  LSM).	  AUROC	  for	  significant	  fibrosis	  (Ishak	  3-­‐6)	  was	  significantly	  greater	  
when	  all	  three	  of	  the	  LSM	  validity	  criteria	  were	  met	  (0.83	  vs.	  0.66;	  p=0.048),	  with	  a	  success	  
rate	  ≥60%	  being	  the	  most	  important	  individual	  component	  to	  achieve	  accuracy	  (Table	  2-­‐5a).	  
In	  contrast,	  none	  of	  the	  individual	  components	  of	  the	  LSM	  validity	  criteria	  had	  a	  significant	  
effect	  on	  the	  prediction	  of	  advanced	  fibrosis	  (Ishak	  5-­‐6)	  (Table	  2-­‐5b).	  	  
 
Components	  of	  the	  	  
LSM	  Validity	  Criteria	  
AUROC	  (SE)	  of	  LSM	  based	  on	  
obtaining	  individual	  components	  
of	  the	  criteria	   p-­‐Value	  
No	   Yes	  
(a)	  Significant	  Fibrosis	  (Ishak	  3-­‐6)	   	   	   	  
IQR/M	  <30%	   0.75	  (0.10)	   0.77	  (0.04)	   0.805	  
Success	  Rate	  ≥60%	   0.56	  (0.12)	   0.84	  (0.04)	   0.032*	  
≥10	  successful	  acquisitions	   0.58	  (0.16)	   0.80	  (0.04)	   0.189	  
All	  3	  criteria	  obtained	   0.66	  (0.08)	   0.83	  (0.04)	   0.048*	  
	   	   	   	  
(b)	  Advanced	  Fibrosis	  (Ishak	  5-­‐6)	   	   	   	  
IQR/M	  <30%	   0.69	  (0.17)	   0.85	  (0.04)	   0.317	  
Success	  Rate	  ≥60%	   0.66	  (0.20)	   0.86	  (0.04)	   0.265	  
≥10	  successful	  acquisitions	   0.76	  (0.15)	   0.82	  (0.04)	   0.749	  
All	  3	  criteria	  obtained	   0.76	  (0.10)	   0.87	  (0.04)	   0.361	  
 
Table	  2-­‐5	   Importance	  of	   the	  validity	  criteria	   for	   LSM	  vs.	   (a)	   significant	  and	   (b)	  advanced	  
fibrosis.	  AUROC	  of	  LSM	  for	  153	  patients.	  
 
Key: Significant* = p<0.05 
	  
The	  published(Roulot	  et	  al.,	  2008,	  McCorry	  et	  al.,	  2012)	  LSM	  cut-­‐off	  of	  8	  kPa	  was	  used	   to	  
determine	  the	  sensitivity,	  specificity,	  NPV	  and	  PPV	  for	  the	  presence	  of	  significant	  (Ishak	  3-­‐6)	  
and	  advanced	  fibrosis	  (Ishak	  5-­‐6)	  (Table	  2-­‐6).	  A	  valid	  LSM	  produced	  a	  sensitivity	  of	  86%	  (95%	  
	  	  
78	  
CI	   71-­‐95)	   and	   specificity	   of	   58%	   [CI	   95%	   44–71],	   whereas	   an	   invalid	   LSM	   resulted	   in	   a	  
sensitivity	   of	   84%	   (CI	   95%	   64-­‐95)	   and	   a	   specificity	   of	   42%	   (CI	   95%	   22-­‐63)	   	   (Table	   6a).	  
Subsequently,	   the	   NPV	   for	   the	   presence	   of	   significant	   fibrosis	   was	   84%	   for	   a	   valid	   LSM	  
compared	   to	   71%	   for	   an	   invalid	   LSM.	   Furthermore,	   the	   NPV	   for	   presence	   of	   advanced	  
fibrosis	  was	  100%	  for	  a	  valid	  LSM	  versus	  93%	  for	  an	  invalid	  LSM	  (Table	  6b).	  
	  
Components of LSM 
validity criteria Sensitivity % Specificity % PPV % NPV % 
a. Significant Fibrosis (Ishak 3-6) 
IQR/M <30%  
No 88 (64 - 99) 42 (15 - 72) 68 (45 - 86) 71 (29 - 96) 
Yes 84 (71 - 93) 55 (43 - 67) 58 (46 - 70) 82 (68 - 92) 
Success Rate 
≥60% 
No 78 (40 - 97) 29 (10 - 56) 37 (16 - 62) 71 (29 - 96) 
Yes 86 (75 - 94) 60 (46 - 72) 67 (55 - 77) 82 (68 - 92) 
≥10 successful 
acquisitions 
No 86 (42 – 100) 29 (4 - 71) 55 (23 - 83) 67 (9 - 99) 
Yes 85 (73 - 93) 56 (43 - 67) 61 (50 - 72) 82 (68 - 91) 
All 3 criteria 
obtained 
No 84 (64 - 95) 42 (22 - 63) 60 (42 - 76) 71 (42 - 92) 
Yes 86 (71 - 95) 58 (44 - 71) 61 (47 - 73) 84 (69 - 94) 
 
b. Advanced Fibrosis (Ishak 5-6) 
IQR/M <30%  
 
No 75 (19 - 99) 24 (9 - 45) 14 (3 - 35) 86 (42 - 100) 
Yes 100 (83 - 100) 46 (36 - 57) 28 (18 - 40) 100 (92 - 100) 
Success Rate 
≥60% 
No 67 (9 - 99) 26 (10 - 48) 11 (1 - 33) 86 (42 - 100) 
Yes 100 (84 - 100) 45 (35 - 56) 28 (18 - 40) 100 (92 - 100) 
≥10 successful 
acquisitions 
No 100 (29 - 100) 27 (6 - 61) 27 (6 - 61) 100 (29 - 100) 
Yes 95 (76 - 100) 43 (34 - 53) 24 (15 - 35) 98 (89 - 100) 
All 3 Criteria 
obtained 
No 88 (47 - 100) 32 (18 - 48) 20 (8 - 37) 93 (66 - 100) 
Yes 100 (79 - 100) 47 (36 - 58) 27 (16 - 40) 100 (91 - 100) 
 
Table	  2-­‐6	  Importance	  of	  the	  validity	  criteria	  for	  LSM	  (cut-­‐off	  >	  8	  kPa)	  vs.	  (a)	  significant	  and	  
(b)	   advanced	   fibrosis.	   Sensitivity,	   Specificity	   and	   Positive/Negative	   Predictive	   values	   of	  






2.4.5 Optimal	  LSM	  cut-­‐offs	  for	  the	  diagnosis	  of	  significant/advanced	  fibrosis	  
 
The	   optimal	   valid	   LSM	   cut-­‐offs	   in	   our	   unit	   for	   the	   diagnosis	   of	   significant	   and	   advanced	  
fibrosis	  are	  outlined	  in	  Table	  2-­‐7.	  In	  general,	  the	  LSM	  cut-­‐off	  of	  10	  kPa	  results	  in	  the	  highest	  
sum	  of	  sensitivity	  and	  specificity	  for	  both	  significant	  and	  advanced	  fibrosis.	  With	  regards	  to	  
predicting	  whether	  a	  patient	  has	  advanced	  fibrosis	  (Ishak	  5-­‐6),	  an	  LSM	  cut-­‐off	  of	  10	  would	  
retain	  the	  100%	  sensitivity	  and	  NPV	  achieved	  with	  a	  cut-­‐off	  of	  8	  kPa,	  but	  in	  addition	  would	  





















(kPa) Sensitivity Specificity PPV NPV 
a. Significant Fibrosis (Ishak 3-6) 
5 100 (92 - 100) 0.15 (0.06 - 0.27) 0.47 (0.37 - 0.58) 1.00  (0.63 - 1.00) 
6 98 (87 - 100) 0.31 (0.19 - 0.45) 0.52 (0.40 - 0.63) 0.94 (0.73 - 1.00) 
7 90 (77 - 97) 0.47 (0.34 - 0.61) 0.57 (0.44 - 0.69) 0.87 (0.69 - 0.96) 
8 0.86 (0.71 - 0.95) 0.58 (0.44 - 0.71) 0.61 (0.47 - 0.73) 0.84 (0.69 - 0.94) 
9 0.83 (0.69 - 0.93) 0.67 (0.53 - 0.79) 0.66 (0.52 - 0.78) 0.84 (0.70 - 0.93) 
10 0.74 (0.58 - 0.86) 0.78 (0.65 - 0.88) 0.72 (0.56 - 0.85) 0.80 (0.66 - 0.89) 
11 0.69 (0.53 - 0.82) 0.82 (0.69 - 0.91) 0.74 (0.58 - 0.87) 0.78 (0.65 - 0.87) 
12 0.57 (0.41 - 0.72) 0.89 (0.78 - 0.96) 0.80 (0.61 - 0.92) 0.73 (0.61 - 0.83) 
13 0.52 (0.36 - 0.68) 0.89 (0.78 - 0.96) 0.79 (0.59 - 0.92) 0.71 (0.59 - 0.81) 
14 0.52 (0.36 - 0.68) 0.93 (0.82 - 0.98) 0.85 (0.65 - 0.96) 0.72 (0.60 - 0.82) 
15 0.43 (0.28 - 0.59) 0.96 (0.87 - 1.00) 0.90 (0.68 - 0.99) 0.69 (0.57 - 0.79) 
20 0.33 (0.20 - 0.50) 0.98 (0.90 - 1.00) 0.93 (0.68 - 1.00) 0.66 (0.55 - 0.76) 
25 0.17 (0.07 - 0.31) 0.98 (0.90 - 1.00) 0.88 (0.47 - 1.00) 0.61 (0.50 - 0.71) 
30 0.10 (0.03 - 0.23) 1.00  (0.94 - 1.00) 1.00  (0.40 - 1.00) 0.59 (0.48 - 0.69) 
b. Advanced Fibrosis (Ishak 5-6) 
5 1.00 (0.79 - 1.00) 0.10 (0.04 - 0.19) 0.18 (0.11 - 0.28) 1.00 (0.63 - 1.00) 
6 1.00 (0.79 - 1.00) 0.22 (0.14 - 0.33) 0.20 (0.12 - 0.31) 1.00 (0.81 - 1.00) 
7 1.00 (0.79 - 1.00) 0.37 (0.27 - 0.48) 0.24 (0.14 - 0.36) 1.00 (0.88 - 1.00) 
8 1.00 (0.79 - 1.00) 0.47 (0.36 - 0.58) 0.27 (0.16 - 0.40) 1.00 (0.91 - 1.00) 
9 1.00 (0.79 - 1.00) 0.54 (0.43 - 0.65) 0.30 (0.18 - 0.44) 1.00 (0.92 - 1.00) 
10 1.00 (0.79 - 1.00) 0.67 (0.55 - 0.77) 0.37 (0.23 - 0.53) 1.00 (0.93 - 1.00) 
11 0.94 (0.70 - 1.00) 0.70 (0.59 - 0.80) 0.38 (0.23 - 0.55) 0.98 (0.91 - 1.00) 
12 0.75 (0.48 - 0.93) 0.78 (0.67 - 0.86) 0.40 (0.23 - 0.59) 0.94 (0.85 - 0.98) 
13 0.69 (0.41 - 0.89) 0.79 (0.69 - 0.87) 0.39 (0.22 - 0.59) 0.93 (0.84 - 0.98) 
14 0.69 (0.41 - 0.89) 0.81 (0.71 - 0.89) 0.42 (0.23 - 0.63) 0.93 (0.84 - 0.98) 
15 0.56 (0.30 - 0.80) 0.86 (0.77 - 0.93) 0.45 (0.23 - 0.68) 0.91 (0.82 - 0.96) 
20 0.44 (0.20 - 0.70) 0.90 (0.81 - 0.96) 0.47 (0.21 - 0.73) 0.89 (0.80 - 0.95) 
25 0.25 (0.07 - 0.52) 0.95 (0.88 - 0.99) 0.50 (0.16 - 0.84) 0.87 (0.78 - 0.93) 
30 0.19 (0.04 - 0.46) 0.99 (0.93 - 1.00) 0.75 (0.19 - 0.99) 0.86 (0.77 - 0.92) 
 
Table	   2-­‐7	   Valid	   LSM	   vs.	   significant/advanced	   fibrosis	   -­‐	   Sensitivity,	   Specificity,	  
Positive/Negative	  Predictive	  values	  of	  variable	  LSM	  cut-­‐offs	  
	  






2.4.6 Effect	  of	  operator	  experience	  on	  obtaining	  a	  valid	  LSM:	  
 
In	  total,	  9	  consultants	  and	  8	  specialist	  training	  registrars	  performed	  over	  25	  LSM	  each	  and	  
29	  operators	  performed	  less	  than	  25	  LSM	  each.	  The	  most	  experienced	  operator	  performed	  
670	   LSM,	  whereas	   the	   least	   experienced	  performed	  1	   in	   clinical	   practice	   (excluding	   the	   3	  
performed	  during	  the	  training	  day).	  Binary	  logistic	  regression	  model	  (Figure	  2-­‐5)	  was	  used	  to	  
consider	   the	   effect	   of	   the	   number	   LSM	   performed	   on	   the	   likelihood	   of	   a	   valid	   LSM,	   as	  
determined	  by	  obtaining	  all	  3	  of	  the	  manufacturers	  validity	  criteria.	  The	  model	  shows	  that	  a	  
10-­‐fold	   increase	   in	   the	   number	   of	   LSM	   that	   an	   operator	   has	   performed	   significantly	  
improves	  their	  odds	  of	  obtaining	  a	  valid	  LSM	  (Odds	  ratio	  1.57,	  95%	  CI	  1.39-­‐1.78;	  p<0.001).	  
Figure	  3	  shows	  that	  only	  46%	  of	  the	  initial	  clinical	  LSM	  performed	  by	  an	  operator	  were	  valid,	  
whereas	   the	   validity	   rate	   rises	   to	   57%	   by	   10	   LSM.	   After	   10	   LSM	   the	   rate	   at	   which	   the	  
operator	  achieves	  a	  valid	  LSM	  slows,	  reaching	  64.7%	  by	  50	  LSM	  and	  67.7%	  by	  100	  LSM.	  In	  
order	  to	  obtain	  a	  valid	  LSM	  80%	  of	  the	  time	  the	  model	  forecasts	  that	  approximately	  2500	  
LSM	  would	  be	  required.	  
The	  black	   line	  represents	   the	  model	  produced	  from	  the	  binary	   logistic	   regression	  analysis.	  
For	   scans	  1-­‐25,	   the	   rates	  of	   validity	   across	   all	   operators	   are	  plotted	  at	   each	   scan	  number	  
(the	  red	  line).	  Since	  the	  number	  of	  operators	  drops	  off	  sharply	  (n=46	  to	  17	  operators)	  after	  
this	   point,	   the	   subsequent	   scans	   are	   summarized	   as	   9	   point	  moving	   average,	   in	   order	   to	  
isolate	  the	  trend	  from	  variability	  in	  the	  data.	  The	  model	  seems	  to	  be	  a	  reasonable	  fit	  to	  the	  




Figure	  2-­‐5	  Statistical	  model	  (learning	  curve)	  to	  highlight	  the	  number	  of	  LSM	  that	  are	  need	  
to	  be	  performed	  by	  an	  operator	  to	  achieve	  a	  consistent	  valid	  LSM.	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There	  was	  an	  unavoidable	  influence	  of	  selection-­‐bias	  that	  accompanies	  ‘real-­‐world’	  clinical	  
decision-­‐making	  that	  means	  that	  some	  patients	  may	  not	  be	  represented	  in	  this	  study.	  The	  
clinician	   may	   have	   chosen	   to	   perform	   a	   liver	   biopsy	   if	   the	   high	   LSM	   reading	   was	   not	   in	  
keeping	  with	  a	  low	  pre-­‐test	  probability	  of	  the	  high	  result,	  which	  may	  have	  introduced	  bias.	  
As	   detailed	   earlier,	   making	   a	   diagnosis	   of	   degree	   of	   fibrosis	   based	   on	   the	   flawed	   gold	  
standard	   of	   liver	   biopsy	   is	   a	   limitation	   of	   any	   study	   like	   this.	   It	   may	   be	   that	   in	   future,	  
Fibroscan	   is	   considered	   an	   alternative	   gold	   standard	   due	   to	   its	   analysis	   of	   a	   greater	  




The	  number	   of	   TE	   being	   performed	   in	   our	   unit	   is	   increasing	   year-­‐on-­‐year,	   to	   over	   75	   per	  
month.	  In	  contrast	  to	  previous	  studies(Lucidarme	  et	  al.,	  2009,	  Myers	  et	  al.,	  2010,	  Wong	  et	  
al.,	  2010)	  our	  ‘real-­‐world’	  data	  highlights	  the	  importance	  of	  adhering	  to	  the	  manufacturer’s	  
recommended	   validity	   criteria	   (≥10	   successful	   acquisitions,	   success	   rate	   was	   ≥60%	   and	  
IQR/M	  <30%).	  Adhering	   to	   the	   criteria	   (and	   in	   particular	   ≥60%	   success	   rate)	   resulted	   in	   a	  
significantly	  greater	  correlation	  with	  liver	  fibrosis	  stage	  and	  greatly	  enhanced	  the	  accuracy	  
of	   a	   negative	   LSM	   in	   ruling	   out	   significant	   (using	   LSM	   cut-­‐off	   >	   8	   kPa,	   NPV	   84%),	   and	  
advanced	   liver	   fibrosis	   (NPV	  100%).	  The	  greatest	   improvement	   in	  ability	  to	  achieve	  a	  valid	  
LSM	   occurs	   in	   the	   operators	   first	   10	   scans,	   and	   thereafter	   the	   validity	   rate	   progressively	  
increases,	  albeit	   very	   slowly.	  This	   study	   should	   inform	  other	  UK	  NHS	  centres	   that	  prior	   to	  
using	  TE	  in	  clinical	  practice,	  novices	  should	  be	  trained	  to	  understand	  the	  clinical	  implications	  
of	  the	  LSM	  validity	  criteria	  and	  should	  undertake	  a	  minimum	  of	  10	  observed	  scans	  prior	  to	  
using	   TE	   independently.	   Our	   data	   suggest	   that	   failure	   to	   meet	   the	   LSM	   validity	   criteria	  
increases	  the	  risk	  of	  over	  interpreting	  an	  LSM	  >	  8	  kPa	  and	  incorrectly	  labelling	  a	  patient	  as	  
having	  significant	  fibrosis,	  in	  those	  without	  fibrosis	  (Figure	  1).	  Furthermore,	  after	  obtaining	  
an	  invalid	  LSM	  <	  8kPa	  the	  clinician	  runs	  the	  risk	  of	  falsely	  reassuring	  7%	  patients	  who	  have	  
underlying	   advanced	   fibrosis	   (Ishak	   5-­‐6).	   In	   contrast,	   when	   a	   valid	   LSM	   is	   performed	  
clinicians	   (consultant	   or	   registrar	   level)	   can	   exclude	   significant	   fibrosis	   and	   to	   a	   greater	  
extent	  advanced	  fibrosis	  with	  a	  high	  degree	  of	  confidence.	  In	  our	  unit,	  using	  the	  cut-­‐off	  of	  8	  
kPa	   with	   a	   valid	   LSM,	   we	   could	   reliably	   exclude	   significant	   and	   advanced	   fibrosis	  
(sensitivities	  Ishak	  >2	  =	  86%;	  Ishak	  5-­‐6	  =	  100%	  and	  NPVs	  Ishak	  >2	  =	  84%;	  Ishak	  5-­‐6	  =	  100%)	  
as	  effectively	  as	  data	  reported	  in	  large	  prospective	  studies(Castera	  et	  al.,	  2005,	  Foucher	  et	  
al.,	  2006,	  Kettaneh	  et	  al.,	  2007),	  nurse-­‐based	  studies(McCorry	  et	  al.,	  2012)	  and	  recent	  meta-­‐
	  	  
85	  
analyses(Tsochatzis	  et	  al.,	  2011,	  Friedrich-­‐Rust	  et	  al.,	  2008b,	  Talwalkar	  et	  al.,	  2007).	  In	  order	  
to	  reduce	  the	  number	  of	  false	  positive	  LSM	  in	  our	  centre,	  whilst	  ultimately	  maintaining	  the	  
ability	  to	  exclude	  advanced	  fibrosis	   (i.e.	  NPV	  100%),	  a	  cut-­‐off	  of	  10	  kPa	  could	  be	  adopted.	  
Even	  by	  increasing	  the	  valid	  LSM	  cut-­‐off	  further	  our	  reported	  number	  of	  false	  positives	  (LSM	  
over	   estimates)	   out-­‐weigh	   those	   recently	   reported	   in	   a	   large	   40	   study	   meta-­‐analysis	   by	  
Tsochatzis	   et	   al(Tsochatzis	   et	   al.,	   2011).	   A	   possible	   explanation	   for	   the	   high	   false	   positive	  
rate	   in	   our	   study	  might	   be	   the	   unavoidable	   influence	   of	   selection-­‐bias	   that	   accompanies	  
‘real-­‐world’	  clinical	  decision-­‐making.	  For	   instance,	   in	  the	  event	  that	  the	  clinician	  has	  a	   low	  
clinical	  suspicion	  of	  advanced	  disease	  (based	  on	  other	  clinical	  findings),	  he/she	  is	  more	  likely	  
to	   proceed	   to	   a	   liver	   biopsy	   in	   the	   event	   of	   an	   unexpected	   high	   LSM	   compared	   to	   an	  
expected	  (confirmatory)	  low	  LSM.	  Furthermore,	  due	  to	  time	  constraints	  it	  is	  routine	  practice	  
in	  our	  centre	  to	  use	  the	  measured	  BMI	  (cut-­‐off	  30	  kg/m2	  (Myers	  et	  al.,	  2012))	  to	  determine	  
the	   correct	   probe	   to	   use,	   rather	   than	   measure	   the	   skin	   to	   capsule	   distance	   (as	   used	   in	  
previous	  studies).	  This	  may	  have	  resulted	  in	  the	  inappropriate	  use	  of	  the	  M-­‐probe	  in	  cases	  
of	  >2.5cm	  subcutaneous	  adipose	  (despite	  a	  BMI	  <	  30	  kg/m2)	  and	  therefore	  overestimates	  of	  
LSM,	  as	  previously	  reported	  with	  the	  M-­‐probe(Myers	  et	  al.,	  2012).	  This	  limitation,	  however,	  
should	  be	  eliminated	  in	  future	  assessment	  in	  our	  centre	  after	  the	  recent	  introduction	  of	  the	  
Fibroscan®	   502	   Touch,	   which	   automatically	   informs	   the	   operator	   of	   which	   size	   probe	   to	  
use.	   As	   in	   all	   studies	   that	   utilise	   liver	   biopsy	   to	   evaluate	   the	   performance	   of	   TE,	   inter-­‐
observer	  agreement	  and	  sampling	  error	  in	  fibrosis	  staging	  must	  be	  considered(Boursier	  and	  
Calès,	  2010).	  In	  order	  to	  minimize	  these	  limitations,	  three	  liver	  pathologists	  (RB,	  SH,	  NM)	  re-­‐
staged	  liver	  fibrosis	  and	  reached	  a	  consensus	  in	  cases	  of	  disagreement	  (<10%	  cases).	  Given	  
that	  the	  median	  time	  delay	  between	  TE	  and	  biopsy	  was	  70	  days	  (IQR	  22-­‐127)	   it	   is	  unlikely	  
that	  progression	  of	  fibrosis	  could	  have	  contributed	  to	  discordance.	  Furthermore,	  time	  delay	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between	  TE	  and	  biopsy	  was	  not	  a	  predictor	  of	  false	  positives/negatives	  in	  our	  study.	  Due	  to	  
the	   sample	   size	   of	   our	   heterogeneous	   cohort,	   the	   employed	   LSM	   cut-­‐offs	   for	  
significant/advanced	   fibrosis	   were	   generic(Talwalkar	   et	   al.,	   2007,	   Roulot	   et	   al.,	   2008,	  
McCorry	   et	   al.,	   2012)	   and	   not	   specific	   to	   individual	   disease	   aetiology	   and/or	   probe	   use.	  
Disease-­‐specific	  and	  probe-­‐specific	  cut-­‐offs	  still	  require	  validation	  in	  UK	  clinical	  practice.	  
	  
It	   is	   important	   to	   understand	   what	   defines	   adequate	   TE	   training	   prior	   to	   widespread	  
incorporation	   into	   UK	   clinical	   practice	   (including	   the	   potential	   for	   community-­‐based	  
assessment(McCorry	   et	   al.,	   2012).	   Previous	   hospital-­‐based	   studies	   have	   reported	  
contrasting	  degrees	  of	  operator	  experience	  that	  are	  required	  to	  achieve	  consistent	  and	  valid	  
LSM	  readings	   (range	  20	   to	  >500	  LSM	  required(Castéra	  et	  al.,	  2010a,	  McCorry	  et	  al.,	  2012,	  
Kettaneh	  et	  al.,	  2007,	  Boursier	  et	  al.,	  2008).	  Our	  statistical	  model	  highlights	  that	  the	  initial	  
training	   period	   should	   incorporate	   a	  minimum	  of	   10	   procedures,	  with	   a	   stable	   degree	   of	  
consistency	  in	  valid	  LSM	  rates	  by	  50	  examinations.	  Furthermore,	  LSM	  validity	  rates	  were	  not	  
affected	  by	   the	   grade	  of	   the	  doctor	   (consultant	   vs	   specialist	   registrar,	   p=0.738).	   This	   is	   in	  
keeping	  with	  previous	   studies	   that	   recommend	   that	  a	  novice,	  of	  any	  medical	  professional	  
status,	  can	  be	  trained	  to	  use	  TE(McCorry	  et	  al.,	  2012,	  Boursier	  et	  al.,	  2008).	  In	  addition,	  our	  
study	  highlights	  for	  the	  first	  time	  in	  clinical	  practice	  that	  complying	  with	  the	  recommended	  
LSM	  validity	  criteria	  (≥10	  successful	  acquisitions,	  success	  rate	  was	  ≥60%	  and	  IQR/M	  <30%)	  
provides	  better	  diagnostic	  accuracy	  than	  those	  not	  fulfilling	  these	  3	  criteria.	  For	  this	  reason,	  
we	  would	  strongly	  advocate	  providing	  guidance	  on	  the	  current	  LSM	  validity	  criteria	   in	   the	  
initial	   training	  program.	  Prospective	   study,	  however,	   is	   required	   to	   fully	  optimize	   the	  LSM	  
validity	  criteria	  and	  understand	  which	  of	  the	  3	  components	  are	  key	  in	  clinical	  practice.	  Due	  
to	  the	  well-­‐document	  methodological	  challenges	  of	  comparing	  TE	  to	  histological	  fibrosis	  in	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clinical	  practice(Boursier	  and	  Calès,	  2010),	   future	  studies	   should	   focus	  on	   the	   influence	  of	  
the	  LSM	  validity	  criteria	  (and	  modified	  versions(Boursier	  et	  al.,	  2012b))	  on	  the	  value	  of	  TE	  in	  
predicting	  clinical	  events	  (i.e.	  liver	  failure,	  HCC,	  death	  etc.).  
	  
In	  summary,	  our	  study	  highlights	  that	  TE	  requires	  minimal	  training	  (≥10	  observed	  LSM)	  and	  
when	   valid	   is	   a	   useful	   tool	   for	   excluding	   advanced	   liver	   fibrosis	   in	   day-­‐to-­‐day	   UK	   clinical	  
practice.	   To	   ensure	   the	   diagnostic	   accuracy	   of	   LSM	   the	   manufacturer’s	   validity	   criteria	  
should	   be	   adhered	   to	   at	   all	   times	   and	   incorporated	   into	   the	   training	   program.	   Until	  
prospective	   data	   are	   available	   in	   UK	   clinical	   practice,	   a	   positive	   LSM	   (≥8	   kPa)	   should	   be	  
interpreted	  with	  care	   in	   the	  absence	  of	  stigmata	  of	  CLD	  and	  the	  decision	  to	  proceed	  with	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3.1 Abstract	  	  
Background:	   Non-­‐invasive	   biomarkers	   have	   been	   shown	   to	   accurately	   predict	   significant	  
liver	  fibrosis	  but	  few	  have	  been	  adopted	  into	  routine	  clinical	  practice	  
Aim:	   To	   investigate	   whether	   non-­‐invasive	   biomarkers	   are	   prognostic	   factors	   for	   clinical	  
outcomes	  (e.g.	  mortality,	  cancer)	  in	  patients	  with	  chronic	  liver	  disease.	  
Methods:	   A	   systematic	   review	   of	   studies	   identified	   in	   EMBASE,	   MEDLINE	   and	   Pubmed	  
Central	   in	   October	   2012	   was	   undertaken	   by	   combining	   terms	   for	   clinical	   outcomes	   with	  
those	  of	  biomarker	  assessments.	  Primary	  studies	  were	  included	  if	  the	  prognostic	  ability	  of	  a	  
biomarker	  had	  been	  examined	  in	  relation	  to	  a	  clinical	  outcome	  in	  an	  adult	  population	  with	  
liver	  disease.	  Where	  possible,	  hazard	  ratios	  (HRs)	  for	  each	  biomarker	  were	  extracted	  (either	  
directly	   or	   from	   log-­‐rank	   information)	   and,	   if	   appropriate,	   pooled	   across	   studies	   using	   a	  
random	  effects	  meta-­‐analysis	  model.	  	  
Results:	  	  
The	   search	   yielded	   1158	   articles.	   31	   screened	   studies	   were	   included	   in	   the	   systematic	  
review.	  There	  was	  substantial	   clinical	  and	  statistical	  heterogeneity	  between	   these	  studies.	  
Markers	   assessed	  were:	   APRI	   (13	   studies,	   7842	   patients),	   Fib-­‐4	   (6	   studies,	   4385	   patients)	  
and	   AST:ALT	   ratio	   (6	   studies,	   1716	   patients).	   Three	   studies	   from	  which	   hazard	   ratio	   (HR)	  
information	  for	  overall	  survival	  could	  be	  extracted	  were	  analysed.	   In	  patients	  with	  HCV	  an	  
APRI	  of	  >1.5-­‐2.0	  revealed	  a	  summary	  unadjusted	  HR	  of	  2.51	  (95%	  CI:	  1.37-­‐4.60)	  for	  overall	  
mortality	   and	   4.43	   (1.64-­‐11.96)	   for	   liver-­‐related	   mortality.	   Three	   studies	   applying	   Fib-­‐4	  
(>3.25)	   to	   viral	   hepatitis	   patients	   gave	   a	   summary	   unadjusted	   HR	   of	   3.70	   (1.98-­‐6.91)	   for	  
overall	  mortality	  and	  6.23	  (2.68-­‐14.47)	  for	  liver	  related	  death.	  	  
Conclusion:	  Use	  of	  APRI	  with	  a	  cut	  off	  of	  >1.5-­‐2	  and	  Fib-­‐4	  >3.25	  provided	  prognostic	  value	  
for	   overall	   and	   liver-­‐related	  mortality	   in	   patients	  with	   viral	   hepatitis.	   Study	   heterogeneity	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restricted	   further	   analyses,	   and	   further	   large,	   prospective,	   studies	   are	   needed	   to	   better	  






Liver	  biopsy	  is	  the	  accepted	  gold	  standard	  for	  the	  assessment	  of	  liver	  fibrosis,	  but	  its	  power	  
is	  reduced	  by	  sampling	  errors	  and	  its	  invasive	  nature	  and	  associated	  complications	  preclude	  
its	  use	   for	   frequent	  monitoring	  of	  disease	  progression	   (Bravo	  et	  al.,	  2001).	  This	  has	   led	  to	  
the	  development	  of	  a	  range	  of	  non-­‐invasive	  biomarkers	  to	  identify	  liver	  fibrosis	  and	  cirrhosis	  
including	  serum	  and	  imaging	  assessments.	  Serum	  markers	  for	  the	  prediction	  of	  fibrosis	  fall	  
into	   two	  categories;	   i)	   Indirect	  markers	   that	   combine	  biochemical	   tests	  with	  demographic	  
information	   (BARD,	   NAFLD	   fibrosis	   score,	   Fib-­‐4,	   APRI,	   AST:ALT	   ratio)	   and	   ii)	   Candidate	  
fibrosis	  markers	   that	  measure	   release	   of	   peptides	   into	   the	   circulation	   during	   fibrogenesis	  
(Martínez	   et	   al.,	   2011).	   Such	   markers	   include	   ELF	   (Rosenberg	   et	   al.,	   2004),	   Fibrotest	  
(Poynard	   et	   al.,	   2004),	   Forns	   (Forns	   et	   al.,	   2002)	   and	   Hepascore	   (Adams	   et	   al.,	   2005).	   In	  
addition,	   imaging	   techniques	   have	   been	   developed	   that	   measure	   liver	   stiffness	   (i.e.	  
transient	  elastography),	  which	  has	  been	  shown	  to	  correlate	  with	  the	  extent	  of	  liver	  fibrosis	  
(Shaheen	  et	  al.,	  2007).	  
	  
The	   ability	   of	   these	  non-­‐invasive	   tests	   to	  predict	   liver	   fibrosis	   stages	   varies	   from	   study	   to	  
study	  and	  ranges	  from	  poor	  (~0.6)	  to	  excellent	  	  (>0.95)	  (Poynard	  et	  al.,	  2007,	  Friedrich-­‐Rust	  
et	   al.,	   2008a,	  Musso	  et	   al.,	   2011).	  A	  major	   clinical	   challenge	   is	   not	  only	   to	   record	   fibrosis	  
stage	   but	   also	   to	   identify	   those	   patients	   at	   risk	   of	   premature	   death	   or	   developing	   the	  
complications	  of	  chronic	  liver	  disease.	  Hyaluronic	  acid,	  a	  key	  component	  of	  the	  extracellular	  
matrix	   and	   P3NP	   were	   the	   first	   biomarkers	   used	   to	   show	   a	   link	   with	   the	   subsequent	  
development	   of	   complications	   of	   liver	   disease	   (Korner	   et	   al.,	   1996,	   Babbs	   et	   al.,	   1988),	  
Histological	  staging	  of	  fibrosis	  is	  a	  significant	  predictor	  of	  liver-­‐related	  mortality	  in	  patients	  
with	   HCV	   (Everhart	   et	   al.,	   2010),	   and	   subsequently	   Poynard	   et	   al	   used	   liver	   biopsy	   as	   a	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comparator	  in	  a	  meta-­‐analysis	  of	  the	  5-­‐year	  prognostic	  value	  of	  APRI,	  Fib-­‐4	  and	  Fibrotest	  in	  
patients	  with	  chronic	  liver	  disease	  (Poynard	  et	  al.,	  2011).	  They	  concluded	  that	  only	  Fibrotest	  
(AUROC	   0.88)	   performed	   similarly	   to	   liver	   biopsy	   (AUROC	   0.86)	   in	   predicting	   survival.	  
However,	   this	   study	   excluded	   several	   key	   biomarkers	   such	   as	   AST:ALT,	   ELF,	   Forns,	  
Hepascore	  and	  Fibrometer,	  did	  not	  assess	  liver-­‐related	  morbidity	  or	  mortality,	  and	  nor	  did	  it	  
assess	  Hazard	  Ratios	  (HR),	  which	  quantifies	  the	  prognostic	  effect	  of	  a	  biomarker	  
	  
The	  aims	  of	  this	  systematic	  review	  were	  twofold.	  Firstly	  to	  summarise	  studies	  that	  assessed	  
the	  prognostic	   ability	  of	   non-­‐invasive	  biomarkers	   in	   relation	   to	  mortality	   and	   liver-­‐related	  
morbidity.	   Secondly	   to	   assess	   the	   heterogeneity	   between	   studies	   for	   each	   biomarker	   in	  
relation	  to	  clinical	  and	  statistical	  criteria,	  and	  to	  perform	  a	  meta-­‐analysis	  to	  summarise	  the	  




This	   systematic	   review	  was	   directed	   by	   a	   protocol	   registered	   on	   the	   PROSPERO	  database	  
(http://www.crd.york.ac.uk/PROSPERO)	   with	   reference	   number	   CRD42012003244.	  
Studies	  published	  as	  full	  papers	  were	  identified	  on	  MEDLINE,	  PubMed	  Central	  and	  EMBASE	  
using	   text	   terms.	   Studies	   with	   only	   an	   abstract	   were	   excluded.	   Terms	   relating	   to	   clinical	  
outcomes	  (e.g.	  ‘encephalopathy’	  OR	  ‘death’	  OR	  ‘liver	  transplant’	  OR	  ‘mortality’	  ‘ascites’	  OR	  
‘cancer’	   OR	   ‘variceal’	   OR	   ‘‘varices’)	   were	   combined	   with	   an	   AND	   operator	   with	   terms	  
relating	  to	  biomarker	  assessment	  (e.g.	  ‘Aspartate	  Platelet	  Ratio	  Index’	  (APRI),	  OR	  ‘Fib-­‐4,’	  OR	  
‘aspartate-­‐to-­‐alanine	   transaminase	   ratio’	   (AST:ALT),	  OR	   ‘BARD,’	  OR	   ‘NAFLD	  Fibrosis	  Score,’	  
OR	   ‘Enhanced	   Liver	   Fibrosis’	   (ELF)	   OR	   ‘Hepascore,’	   OR	   ‘Fibrotest,’	   OR	   ‘Fibrometer,’	   OR	  
‘Forns’	  OR	  ‘Fibroscan,’	  OR	  ‘transient	  elastography’).	  The	  biomarkers	  chosen	  were	  those	  that	  
were	   acknowledged	   as	   being	   validated	   for	   the	   prediction	   of	   onset	   and	   diagnosis	   of	   liver	  
fibrosis.	   Searches	   were	   conducted	   in	   October	   2012,	   and	   given	   the	   paucity	   of	   biomarker	  
studies	  in	  the	  previous	  ten	  years	  searches	  were	  restricted	  to	  those	  published	  after	  1	  January	  
2002.	   Titles	   and	  abstracts	  of	   the	   search	   results	  were	   screened	   for	   relevance.	   Full	   texts	  of	  
relevant	   articles	   were	   obtained	   and	   assessed	   for	   inclusion	   in	   the	   review	   against	   the	  
following	  criteria:	  Patients	  >18	  years	  old	  and	  that	   the	  biomarker	   in	  question	  was	  used	   for	  
the	  prognosis	  of	  a	  clinical	  endpoint	  rather	  than	  the	  diagnosis	  of	  its	  presence.	  Both	  stages	  of	  
the	  selection	  process	  were	  undertaken	   independently	  by	  two	  reviewers	  (CC	  and	  MJA)	  and	  
disagreements	   were	   resolved	   by	   discussion.	   This	   systematic	   review	   was	   reported	   in	  





3.3.1 Data	  collection:	  
Data	   were	   extracted	   from	   study	   reports	   independently	   by	   two	   authors	   (C.C.	   and	   M.J.A)	  
using	   a	   prepared	   checklist.	   Discrepancies	   were	   resolved	   by	   discussion	   involving	   a	   third	  
reviewer	   (P.N.)	   if	   necessary.	   The	   following	   data	  were	   extracted	   from	   each	   study:	   year	   of	  
study,	   disease	   type,	   clinical	   outcome	  measures,	   non-­‐invasive	   biomarkers	   used,	   biomarker	  
cut-­‐off(s),	  number	  of	  patients,	  and	  the	  reported	  measure	  of	  prognostic	  effect,	  for	  example	  
Area	   under	   the	   ROC	   curve	   (c-­‐statistic),	   HR,	   or	   relative	   risk	   (RR)	   for	   each	   clinical	   outcome	  
(listed	  in	  the	  search	  criteria).	  Where	  prognostic	  effects	  were	  poorly	  reported	  we	  sought	  to	  
derive	   the	   HR	   estimate	   and	   its	   confidence	   interval	   (CI)	   indirectly	   using	   the	   methods	   of	  
Parmar	   et	   al(Parmar	   et	   al.,	   1998)	   by	   examining	  other	   available	  data	   such	   as	   log	   rank	   test	  
statistics,	   their	   p	   values,	   and	   total	   number	   of	   patients	   and	   events	   in	   each	   group.	   Both	  
unadjusted	   and	   adjusted	   HR	   estimates	   were	   sought	   for	   each	   study,	   and	   the	   choice	   of	  
adjustment	   factors	   recorded	   for	   each	   study.	   Quality	   assessment	   of	   studies	   included	   was	  
performed	   in	   accordance	   with	   QUADAS-­‐2	   guidelines	   for	   diagnostic	   test	   studies	  
(supplementary	   table	   1)	  modified	  with	   prognostic	   rather	   than	   diagnostic	   components,	   as	  
the	   aim	   was	   to	   assess	   the	   prognostic	   ability	   of	   each	   marker.	   When	   assessing	   patient	  
selection,	  risk	  of	  bias	  was	  assessed	  by	  looking	  at	  patient	  enrolment	  and	  study	  design.	  Here	  
we	  also	  made	  sure	  that	  the	  included	  patients	  matched	  the	  review	  question.	  When	  assessing	  
the	   index	   test,	   we	   assed	   if	   the	   test	  was	   interpreted	  without	   knowledge	   of	   the	   reference	  
standard,	  and	  also	   if	  a	   threshold	  was	  used.	  The	   reference	  standard	   in	  our	  question	  was	  a	  
clinical	  outcome,	  but	  we	  also	  assessed	  if	  the	  standard	  was	  assessed	  without	  knowledge	  of	  
the	   index	  test	  result.	  Finally,	   flow	  and	  timing	  of	  the	  studies	  were	  assessed	  by	  determining	  




3.3.2 Statistical	  analysis:	  
Meta-­‐analyses	   of	   prognostic	   results	   were	   considered	   for	   each	   test	   in	   relation	   to	   each	  
outcome	  separately,	   if	  HR	  estimates	  and	  their	  95%	  confidence	  intervals	  could	  be	  obtained	  
for	  at	  least	  two	  studies.	  Studies	  were	  not	  qualitatively	  summarised	  if	  the	  cut-­‐offs	  varied	  too	  
much.	  Cut-­‐offs	  were	  also	  not	  summarised	  if	  they	  were	  analysed	  as	  a	  continuous	  variable	  or	  
if	  data	  were	  mixed	  between	  univariable	  (unadjusted)	  and	  multivariable	  (adjusted)	  reporting.	  
Studies	  were	  also	  excluded	  if	  they	  compared	  different	  cut	  offs	  within	  the	  same	  study	  (e.g.	  
comparing	  an	  AST:ALT	  of	  1-­‐2	   vs.	   2).	  Where	  meta-­‐analysis	  was	  appropriate,	   interest	  effect	  
estimates	   for	   each	   test	   were	   pooled	   across	   trials	   using	   a	   random	   effects	   meta-­‐analysis	  
model	  within	  STATA	  (version	  12).	  This	  model	  accounts	  for	  between-­‐study	  heterogeneity	  in	  
the	   log	   HR	   effect	   estimates,	   which	   is	   likely	   to	   occur.	   Heterogeneity	   across	   studies	   was	  
examined	  using	  the	  I-­‐squared	  statistic,	  which	  gives	  the	  percentage	  of	  the	  total	  variability	  in	  
the	   data	   due	   to	   between-­‐study	   heterogeneity.	   Each	   random-­‐effects	   analysis	   was	  
summarised	   by	   reporting	   the	   summary	   (average)	   prognostic	   effect	   estimate	   and	   its	  
confidence	   interval.	   Also	   a	   95%	   prediction	   interval	   was	   calculated,	   to	   reveal	   how	   the	  
prognostic	  effect	  of	  the	  marker	  may	  vary	  in	  different	  contexts	  and	  populations,	  due	  to	  the	  
unexplained	  heterogeneity.	  Due	  to	  the	  small	  number	  of	  studies	  suitable	  for	  inclusion	  in	  the	  
meta-­‐analyses	   (<10	   studies),	   examinations	   of	   subgroups,	  meta-­‐regression	   and	   funnel	   plot	  
asymmetry	   (potential	   publication	   bias)	   were	   not	   considered	   sensible	   as	   per	   current	  




The	   literature	   search	   identified	   1456	   studies	   and	   after	   removal	   of	   duplicates	   1158	   were	  
screened	   for	   relevance	   to	   the	   review.	   100	   full	   articles	   were	   subsequently	   obtained	   and	  
assessed	   against	   the	   full	   selection	   criteria	   resulting	   in	   31	   studies	   (reported	   in	   31	   papers)	  
being	   included.	   The	   majority	   of	   studies	   (n=59)	   were	   excluded	   on	   the	   basis	   that	   the	  
biomarker	   was	   used	   for	   diagnosis	   of	   the	   disease	   rather	   than	   examining	   the	   prognostic	  

































Records	  identified	  through	  database	  searching	  
(n	  =	  1456	  	  )	  
Records	  screened	  after	  duplicates	  removed	  
(n	  =	  1158	  )	  
Records	  excluded	  
(n	  =	  	  1058	  )	  
Example	  reasons	  include:	  No	  
Full-­‐text	  articles	  assessed	  for	  eligibility	  
(n	  =	  	  100	  )	  
Full-­‐text	  articles	  excluded,	  with	  
reasons	  
(n	  =	  	  69	  )	  
Paediatric	  (n=7)	  
Studies	  included	  in	  qualitative	  synthesis	  
(n	  =	  	  31	  )	  
Studies	  included	  in	  quantitative	  synthesis	  
(meta-­‐analysis)	  
Duplicates	  excluded	  




3.4.1 Methodological	  differences:	  
When	   grouping	   studies	   for	   potential	   meta-­‐analysis	   of	   each	   biomarker,	   there	   was	  
considerable	   between-­‐study	   heterogeneity	   in	   the	   analysis	   method	   (continuous	   vs.	  
categorical	  modelling	  of	  the	  candidate	  prognostic	  factor),	  chosen	  cut-­‐off	  levels,	  the	  groups	  
of	  outcomes	  recorded,	  follow	  up	  duration	  and	  population	  of	  patients	  at	  baseline.	  The	  most	  
commonly	  analysed	  biomarkers	  were	  the	  indirect	  markers	  and	  they	  were	  mainly	  examined	  
in	   patients	   with	   viral	   hepatitis.	   Characteristics	   of	   the	   included	   studies	   are	   summarised	   in	  
table	  3-­‐1.	  
 
3.4.2 Quality	  assessment	  
All	  studies	  were	  well	  designed	  in	  terms	  of	  patient	  selection,	  but	  it	  was	  not	  possible	  in	  some	  
cases	  to	  assess	  if	  the	  biomarker	  was	  measured	  without	  knowledge	  of	  the	  outcome	  measure.	  
This	  would	  have	  been	  the	  case	  where	  stored	  blood	  samples	  were	  analysed	  after	  the	  event	  in	  
retrospective	  studies.	  	  
	  	  
99	  
Author	   Cohort	   Type	   Size	   Median	  
follow	   up	  
(months)	  
Biomarker	  +	   cut-­‐off.	  
Continuous	   if	   not	  
defined	  
Clinical	  outcome	  measures	   Hazard	  Ratio	  *=multivariate	   AUROC	  	  




Bambha	  	  2012	  	   HIV/HCV	   P	   450	   6.6	  years	   APRI>1.5	   All	   cause	   mortality	   compared	  
to	  <0.5	  
2.78	  (1.87-­‐	  4.12)	  *	   	   	   	   	   	  
Fib4>3.25	   All	   cause	   mortality	   compared	  
to	  <1.5	  
2.58	  (1.68-­‐3.95)	  *	   	   	   	   	   	  
Chon	  201	   HBV	   P	   1126	  
	  
NK	   APRI	   HCC	   or	   Hepatic	  
decompensation	  and	  or	  HCC	  
	   	   	   	   	   0.73	  
Fib4	   	   	   	   	   	   0.74	  
LSM	   	   	   	   	   	   0.79	  
Fung	  2011	   HBV	   P	   528	   35	   LSM	  >10	  kPa	   HCC,	  liver	  related	  mortality	   	   4%	  v	  0%	  p<0.001	   9%	  v	  0%	  p<0.001	   	   	   	  
Ghany	  2011	   HCV	   P	   470	   6.3	  years	   AST:ALT	   ≤0.8	   vs.	  
>0.8	  
Liver	  deaths	  or	  transplant	   	   0.558	  (0.342-­‐0.91)	   	   	   	   	  
Jain	  201	   HIV±	  
HBV/HCV	  
P	   151	   75.3	   APRI>1.5	   Overall	  survival	   2.79	  (1.32-­‐5.91)	   	   	   	   	   	  
FIB-­‐4>3.25	   3.83	  (1.68-­‐8.77)	   	   	   	   	   	  
Kim	  2012	   HBV	   P	   128	   27.8	   LSM	   Liver	   related	   outcomes	  
(decompensation	  and	  HCC)	  
	   	   1.038	  (1.002-­‐1.081)*	   	   	   	  
LSM	  ≥19kPa	   7.176	  (2.257-­‐22.812)	  
Merchante	  2012	   HIV+HCV	   P	   239	  
	  
	  
20.7	   APRI>1.5	   Hepatic	  decompensation	  ±HCC,	  
liver	   related	   mortality	   or	  
transplant,	   death	   of	   any	   cause	  
or	  transplant	  
1.07	  (0.4-­‐2.86)	   0.92	  (0.27-­‐3.2)	   	   	   	   	  
Fib-­‐4>3.25	   1.68	  (0.63-­‐4.48)	   	   	   	   	   	  






0.60	   0.73	   0.72	  
Ngo	  2008	   HBV±HIV	   P	   978	   7.7	   years	  
(av)	  
Fibrotest	  	   Overall	   survival,	   survival	  
without	   HCV	   complications,	  
survival	  without	  HCV	  death	  
	   	   	   0.94	   0.95	   0.89	  
APRI	   	   	   	   0.57	   0.58	   0.55	  
Ngo	  2006	   HCV	   P	   260	   NK	   APRI	   Survival	   without	   HCV	  
complications	  or	  death.	  
Overall	  survival	  
	   	   	   0.67	   0.76	   0.82	  
537	   Fibrotest	   	   	   	   0.76	   0.96	   0.96	  
170	   Forns	   	   	   	   0.73	   0.87	   0.86	  
Nunes	  2010	  	   HCV±HIV	   P	   303	  
	  
61.8	   APRI>1.5	   Liver	   related	   death	   then	   split	  
into	  1,3	  and	  5	  year	  liver	  related	  
mortality	  (5yr	  shown)	  
	   10.18	  (4.86-­‐21.32)	   	   	   0.85	   	  
AST:ALT>1	   	   4.82	  (2.35-­‐9.90)	   	   	   0.72	   	  
Fib-­‐4>3.25	   	   9.45	  (4.51-­‐21.32)	   	   	   0.85	   	  
Sanvisens	  2011	  	   HCV	  ±HIV	  IVDUs	   P	   497	   92.4	   Fib-­‐4>3.25	   Death:	  advanced	  liver	  fibrosis	  v	  
no	  liver	  fibrosis	  
3.89	  (2.28-­‐6.64)	  RR	   	   	   	   	   	  
Forns>6.9	   2.96	  (1.7-­‐5.15)	  RR	   	   	   	   	   	  
Sinn	  2008	  	   HCV	   with	  
treatment	  
P	   1137	   55.2	   APRI>1	   Disease	  progression	   	   	   10.5	  (2.4-­‐46.6)	   	   	   	  
HCV	   without	  
treament	  
5.4	  (3.5-­‐8.3)	  
Vergniol	  2011	   HCV	   P	   1397	   47.3	   APRI>2	   Overall	   survival	   and	   survival	  
without	  liver	  related	  death	  
3.5	  (2.6-­‐4.8)	   5.9	  (3.9-­‐9)	   	   0.66	   0.69	   	  
1401	   Fib-­‐4>3.25	   5.3	  (3.9-­‐7.2)	   9.6	  (6-­‐15)	   	   0.75	   0.76	   	  
1414	   Fibrotest>0.74	   209	  (70-­‐626)	   1598	  (246-­‐1000)	   	   0.8	   0.81	   	  
1457	   LSM>9.5kPa	   48	  930-­‐810	   143	  (66-­‐309)	   	   0.82	   0.87	   	  
Yu	  2006	  	   HCV	   treated	   at	  
6	  months	  
P	   776	   	   APRI>1.5	   All	  cause	  mortality,	  HCC	  and	  all	  
liver	  related	  outcomes	  
	   	   	   0.87	   	   0.88	  
HCV	   untreated	  
at	  baseline	  
562	   	   	   	   	   0.53	   	   0.72	  
Bhala	  2011	  	   NAFLD	   P	   247	   85.6	  (av)	   AST:ALT	  >1	   Overall	  mortality	   3.74	  (1.1-­‐12.68)	   	   	   	   	   	  
Changchien	  2008	  	   HCC	   R	   6381	   NK	   AST:ALT	  1-­‐2	   Survival	   1.260	  (1.166-­‐1.361)*	   	   	   	   	   	  
AST:ALT	  >2	   1.556	  (1.419-­‐1.706)*	  
Chen	  2006	  	   HCC	   R	   11312	   NK	   AST:ALT	  1-­‐2	  v<1	   Overall	  survival	   1.614	  (1.53-­‐1.702)	   	   	   	   	   	  
AST:ALT	  >2	  v	  <1	   3.261	  (3.08-­‐3.453)	  
	  	  
100	  




Haukeland	  2008	  	   ALD	   R	   170	   	   AST:ALT	   Increase	   in	  mortality	   for	   every	  
0.1	  rise	  in	  ratio	  
1.03	  (1.01-­‐1.04)	   	   	   	   	   	  
Hino	  2003	  	   AIH	   P	   73	   70.2	  (av)	   AST:ALT	   Overall	  mortality	   11.67	  (1.15-­‐118.66)	   	   	   	   	   	  
Ichikawa	  2009	  	   HCC	   P	   366	   NK	   APRI	  >10	  /	  cont.	   Posoperative	  hepatic	  failure	   	   	   1.125	   (1.045-­‐	   1.211)	  
OR	  
	   	   	  
Kao	  2011	   HCC	   R	   190	   30.7	   APRI>1	   Overall	  survival	   2.36	  (1.24-­‐6.34)	  
2.53	  (1.20-­‐5.32)	  *	  
	   	   	   	   	  
Klibansky	  2012	  	   Mixed	   P	   667	  
	  
861	  days	   APRI>1.5	   compared	  
to	  <0.5	  
Liver	  related	  outcomes	  such	  as	  
death,	  first	  variceal	  bleed,	  HCC,	  
listed	  for	  transplant.	  
	   	   21.97	   (5.17-­‐93.31)	   Rel	  
Hazard	  
	   	   0.87	  
AST:ALT	   	   	   1.61	   (1.21-­‐2.16)	   Rel	  
hazard	  
	   	   	  
LSM	   >12.5	   kPa	  
comp	  to	  <10.5	  
	   	   	   	   	   	  
Koch	  2011	  	   ITU	  patients	   P	   108	   NK	   LSM>18	   on	  
admission	  to	  ITU	  
ITU	   survival	   and	   long	   term	  
survival	  
Log	  rank	  4.96	   	   	   	   	   	  
Log	  rank	  7.06	  
Lindvig	  2012	  	   Medical	  
admissions	  
P	   212	   30	   LSM>8	   	   	   	   	   0.80	   	   	  
Mayo	  2008	  	   PBC	   P	   161	   7.3	  yrs	   ELF	   measured	   prior	  
to	  event	  
Clinical	   progression-­‐	   new	  
varices,	   variceal	   bleed,	   liver	  
related	  death	  or	  transplant.	  
	   	   	   	   	   0.748	  0	  yr,	  
0.784	  8	  yr	  
Naveau	  2009	  	   ALD	   P	   218	  
	  
NK	   APRI	   	   	   	   	   0.56	   0.59	   	  
Fib-­‐4	   	   	   	   	   0.64	   0.65	   	  
Fibrotest	   	   	   	   	   0.69	   0.79	   	  
Forns	   	   	   	   	   0.43	   	   	  
Hepascore	   	   	   	   	   0.69	   0.80	   	  
Nyblom	  2006	  	   PBC	   R	   126	   NK	   AST:ALT	   Overall	  mortality	   Not	  sig	   	   	   	   	   	  
Nyblom	  2007	  	   PSC	   R	   72	   NK	   AST:ALT>1	   Liver	  related	  death	   	   3.82	  (2.2-­‐6.7)	   	   	   	   	  
Parkes	  2010	  	   Mixed	   P	   457	   7	  years	   ELF	  continuous	   Liver	   related	   outcomes	   (death	  
and	  morbidity)	  
	   	   2	  (1.8-­‐2.2)	   	   	   0.86	  
ELF	  8.34-­‐10.425	   6.1	  (1.8-­‐20.6)	  
ELF	  10.426-­‐12.51	   36.4	  (10.9-­‐120.9)	  
ELF	  12.52-­‐16.67	   115.9	  (33.2-­‐405.1)	  
Sporea	  2011	  	   Mixed	   P	   1000	   NK	   LSM>50.7	   Occurrence	  of	  variceal	  bleeding	   	   	   	   	   	   0.73	  





3.4.3 APRI	  systematic	  review	  
Thirteen	   studies	   (total	   patients	   7842)	   used	   APRI	   either	   as	   a	   continuous	   variable	   or	   with	  
varying	  cut	  offs	  from	  >1	  to	  >2.	  Median	  follow	  up	  ranged	  from	  20	  to	  75.3	  months	  
 
3.4.3.1 HCV:	  	  
Using	  APRI	  as	  a	  continuous	  variable	  Ngo	  et	  al	  (Ngo	  et	  al.,	  2006)	  examined	  260	  patients	  and	  
found	   an	   AUROC	   for	   overall	   survival	   of	   0.67,	  whilst	   AUROCs	   for	   overall	   survival	   excluding	  
HCV-­‐related	  death	  and	  complications	  were	  0.76	  and	  0.82	  respectively.	  When	  APRI	  was	  used	  
with	  a	  cut	  off	  (Yu	  et	  al.,	  2006)	  AUROCs	  for	  all-­‐cause	  mortality	  varied	  as	  expected	  on	  the	  cut-­‐
off	  value	  used	  and	  also	  on	  its	  application	  before	  or	  after	  anti-­‐viral	  treatment.	  AUROC	  values	  
using	  an	  APRI	  cut	  off	  of	  >1.5	  were	   lower	  (0.531)	   in	  untreated	  patients	  at	  baseline	  than	  for	  
patients	  6	  months	  after	  anti-­‐viral	  treatment	  (0.875).	  Furthermore,	  measurement	  of	  the	  APRI	  
score	  6	  months	  after	  treatment	  also	  had	  a	  good	  discriminatory	  value	  for	  the	  development	  of	  
HCC	  with	  an	  AUROC	  of	  0.870	  during	  a	  mean	  follow	  up	  of	  4.75	  (1-­‐12.2)	  years.	  This	  compared	  
favourably	  to	  its	  use	  in	  the	  untreated	  cohort	  where	  an	  AUROC	  of	  0.715	  was	  observed.	  When	  
liver-­‐related	  deaths	  were	  examined	  using	  a	  cut	  off	  of	  >0.75,	  the	  relative	  risk	  (RR)	  was	  5.78	  
(2.31-­‐14.45)	   in	   the	   treated	   cohort.	   Use	   of	   an	   APRI	   cut-­‐off	   of	   >1	   in	   treated	   and	   untreated	  
cohorts	  of	  patients	  with	  viral	  hepatitis	  demonstrated	  that	  APRI	  predicted	  the	  development	  
of	   liver	  related	  outcomes,	  although	  AUROC	  statistics	  were	  not	  provided	  (Sinn	  et	  al.,	  2008).	  
However,	  multivariate	  analysis	  for	  liver	  related	  outcomes	  of	  the	  untreated	  cohort	  revealed	  a	  
HR	   of	   5.4	   (3.5-­‐8.3)	   rising	   to	   10.5	   (2.4-­‐46.6)	   in	   the	   treated	   cohort	   (Sinn	   et	   al.,	   2008).	   In	   a	  
separate	  study	  of	  nearly	  1500	  patients	  with	  viral	  hepatitis	  the	  HR	  for	  overall	  prognosis	  was	  





3.4.3.2 HCV	  ±	  HIV:	  	  
Three	   studies	   used	   an	  APRI	   cut-­‐off	   >1.5	   to	   assess	   its	   prognostic	   value	   for	   overall	   or	   liver-­‐
related	  mortality.	  Merchante	  et	  al	   found	  no	  significant	  prognostic	  value	   (Merchante	  et	  al.,	  
2012),	  whereas	  Bambha	  et	  al	  quoted	  an	  HR	  for	  all-­‐cause	  mortality	  of	  2.78	  (1.87-­‐4.12)	  when	  
compared	   to	   patients	   with	   an	   APRI	   cut-­‐off	   of	   <0.5	   (Bambha	   et	   al.,	   2012).	   Nunes	   et	   al	  
provided	   AUROC	   data	   for	   the	   ability	   of	   an	   APRI	   cut-­‐off	   of	   >1.5	   at	   three	   time	   points	   to	  
discriminate	   between	   those	   without	   and	   those	   with	   a	   definite	   or	   probable	   liver-­‐related	  
mortality	   (0.9	   at	   1	   year,	   0.88	   at	   3	   years	   and	   0.85	   at	   5	   years).	   The	   reported	   HR	   for	   liver-­‐
related	  mortality	  of	  individuals	  with	  an	  APRI	  >1.5	  (vs.	  <1.5)	  was	  10.18	  (4.86-­‐21.32)	  (Nunes	  et	  
al.,	  2010a).	  
 
3.4.3.3 HIV±	  HBV	  or	  HCV:	  	  
Only	  one	  study	  (n=151)	  looked	  at	  this	  cohort	  (Jain	  et	  al.,	  2012),	  and	  with	  an	  APRI	  cut-­‐off	  of	  
>1.5	   the	   HR	   for	   overall	   survival	   was	   2.79	   (1.32-­‐5.91)	   and	   the	   HR	   for	   adjusted	   all-­‐cause	  
mortality	  was	  2.64	  (1.22-­‐5.75).	  	  
 
3.4.3.4 HBV:	  	  
One	   study	  of	   1126	  patients	   looked	  at	   the	  use	  of	  APRI	   as	   a	   continuous	   variable	   in	   an	  HBV	  
cohort	  with	  emphasis	  on	  the	  development	  of	  HCC	  (Chon	  et	  al.,	  2012).	  Its	  AUROC	  was	  0.729	  
(0.659-­‐0.799)	  and	  when	  expanded	   to	   include	  patients	  developing	  hepatic	  decompensation	  






3.4.3.5 Hepatocellular	  carcinoma:	  	  
In	  a	  study	  of	  patients	  following	  radio-­‐frequency	  ablation	  (RFA)	  for	  HCC	  (Kao	  et	  al.,	  2011),	  an	  
APRI	   cut-­‐off	  of	  >1	   (vs.	   ≤1)	   gave	  an	  adjusted	  HR	   for	  overall	   survival	  of	  2.528	   (1.201-­‐5.320).	  
HCC	   recurrence	  and	  development	  of	  metastases	  were	  also	  associated	  with	  APRI	  using	   the	  
same	  cut	  off	  with	  an	  adjusted	  HR	  of	  1.877	  (1.25-­‐2.82)	  and	  2.143	  (1.172-­‐3.919)	  respectively.	  
Ichikawa	   et	   al	   used	   two	   different	   cut-­‐offs	   in	   a	   cohort	   of	   patients	   who	   were	   to	   undergo	  
resection	  for	  HCC	  (Ichikawa	  et	  al.,	  2009).	  	  APRI	  as	  a	  continuous	  variable	  was	  an	  independent	  
pre-­‐operative	   risk	   factor	   for	   postoperative	   hepatic	   failure	   (Odds	   Ratio	   (OR)=1.098	   (1.018-­‐
1.184)).	  The	  authors	  compared	  patients	  with	  low	  vs.	  high	  APRI	  (<10	  and	  ≥10)	  and	  found	  that	  
patients	  with	  a	  high	  APRI	  had	  an	  increased	  incidence	  of	  ascites,	  pleural	  effusion	  and	  death	  
from	  hepatic	  failure.	  
 
3.4.3.6 Other	  aetiologies:	  	  
Two	   studies	   looked	   at	   APRI	   in	   patients	   with	   a	   non-­‐viral	   cause	   for	   their	   liver	   disease	   and	  
found	  mixed	  results.	  In	  a	  cohort	  of	  667	  patients	  with	  mixed	  liver	  aetiologies	  (Klibansky	  et	  al.,	  
2012),	  the	  univariate	  relative	  hazard	  for	  liver	  related	  outcomes	  was	  21.97	  (5.17-­‐93.31)	  using	  
an	  APRI	  cut-­‐off	  of	  >1.5.	  In	  contrast,	  for	  patients	  with	  ALD	  the	  prognostic	  strength	  was	  much	  
less	  with	  an	  AUROC	  for	  overall	  death	  of	  0.56	  (0.48-­‐0.64)	   (Naveau	  et	  al.,	  2009).	  When	  non-­‐
liver	  related	  death	  was	  examined,	  the	  AUROC	  rose	  only	  slightly	  to	  0.60	  (0.50-­‐0.69).	  
 
3.4.4 AST:ALT	  ratio	  systematic	  review	  
Six	  studies	  were	  identified	  that	  included	  a	  total	  of	  1716	  patients	  of	  differing	  aetiologies,	  with	  






3.4.4.1 Immune-­‐mediated	  liver	  disease:	  	  
For	   patients	  with	   PBC	   the	  AST:ALT	   ratio	  was	   not	   associated	  with	   the	   development	   of	   any	  
clinical	  outcomes	   (Nyblom	  et	  al.,	   2006).	   Two	  papers	  were	   identified	   in	   cohorts	  of	  patients	  
with	   PSC	   (Treeprasertsuk	   et	   al.,	   2010,	   Nyblom	   et	   al.,	   2007),	   and	   using	   AST:ALT	   ratio	   as	   a	  
continuous	  variable,	  no	  prognostic	  ability	  was	  seen.	  However,	  when	  a	  cut	  off	  of	  >1	  was	  used,	  
a	  HR	  of	  3.82	  (2.2-­‐6.7)	  was	  seen	  for	  liver-­‐related	  death	  (median	  follow	  up	  8	  years;	  range	  1-­‐28	  
years).	   A	   small	   study	   of	   73	   patients	   with	   autoimmune	   hepatitis	   (mean	   follow-­‐up	   70.2	  
months)	   using	   AST:ALT	   ratio	   as	   a	   continuous	   variable,	   found	   a	   univariate	  HR	   for	   death	   of	  
3.25	  (CI	  not	  quoted)	  with	  an	  OR	  of	  11.67	  (1.15-­‐118.66)	  (Hino	  et	  al.,	  2003).	  
 
3.4.4.2 HCV:	  	  
Using	  an	  AST:ALT	   ratio	  of	  <0.8	  vs.	  >0.8	  as	  a	  prognostic	   factor	   for	  hepatic	  decompensation	  
produced	  an	  HR	  of	  0.416	  (0.233-­‐0.743)	  and	  a	  HR	  0.558	  (0.342-­‐0.910)	  for	  liver	  related	  deaths	  
or	  liver	  transplant	  (Ghany	  et	  al.,	  2011).	  When	  an	  AST:ALT	  ratio	  of	  >1	  was	  used	  the	  AUROC	  for	  
liver-­‐related	  death	  at	  5	  years	  in	  another	  study	  was	  0.72	  (0.61-­‐0.80)	  (Nunes	  et	  al.,	  2010a).	  
 
3.4.4.3 Other	  causes	  of	  liver	  disease:	  	  
In	  a	  cohort	  of	  247	  NAFLD	  patients	  with	  a	  mean	  follow	  up	  of	  86.5	  months	  an	  AST:ALT	  ratio	  of	  
>1	  was	  associated	  with	  an	  adjusted	  OR	  for	  overall	  mortality	  of	  3.74	  (1.1-­‐12.68)	  (Bhala	  et	  al.,	  
2011).	  An	  increase	  of	  0.1	  in	  the	  ratio	  resulted	  in	  an	  increased	  mortality	  with	  an	  HR	  of	  1.07	  
(1.04-­‐1.1)	  in	  a	  small	  (n=170)	  Norwegian	  cohort	  of	  ALD	  patients	  (Haukeland	  et	  al.,	  2008).	  In	  a	  





(1.21-­‐2.16)	  was	  described,	  but	  this	  was	  not	  found	  to	  be	  significant	  after	  multivariate	  analysis	  
(Klibansky	  et	  al.,	  2012).	  	  
 
3.4.4.4 Hepatocellular	  carcinoma:	  	  
In	  patients	  with	  HCC,	  only	   two	  papers	  were	   found	   that	  used	   the	  AST:ALT	   ratio.	  Chen	  et	  al	  
(Chen	  et	  al.,	  2006)	  quoted	  two	  cut-­‐offs;	   if	  the	  ratio	  was	  1-­‐2	  then	  the	  OR	  of	  overall	  survival	  
was	   1.623	   (1.535-­‐1.716),	   however	   if	   the	   ratio	   was	   increased	   to	   >2,	   the	   OR	   rose	   to	   2.969	  
(2.792-­‐3.158).	  Similar	  results	  were	  also	  found	  by	  Changchien	  et	  al	  with	  a	  HR	  for	  survival	  of	  
1.260	  (1.166-­‐1.361)	  and	  1.556	  (1.419-­‐1.706)	  using	  AST:ALT	  ratios	  of	  1-­‐2	  and	  >2	  respectively	  
(Changchien	  et	  al.,	  2008).	  
 
3.4.5 Fib-­‐4	  
Six	  studies	  using	  Fib-­‐4	  were	  identified	  that	   included	  a	  total	  of	  4385	  patients	  and	  were	  split	  
between	   those	   using	   it	   as	   a	   continuous	   variable	   and	   those	   that	   chose	   a	   cut-­‐off	   of	   >3.25.	  
Most	  of	  the	  patients	  in	  these	  studies	  had	  viral	  liver	  disease.	  
 
3.4.5.1 Viral	  liver	  disease:	  	  
Using	  a	  cut-­‐off	  of	  >3.25	  in	  a	  cohort	  of	  patients	  with	  HCV	  Vergniol	  et	  al	  (Vergniol	  et	  al.,	  2011)	  
showed	  that	  the	  HR	  for	  overall	  survival	  was	  5.3	  (3.9-­‐7.2)	  and	  9.6	  (6-­‐15)	  for	  survival	  without	  a	  
liver-­‐related	  death.	  In	  cohorts	  including	  patients	  with	  HCV	  who	  were	  co-­‐infected	  with	  HIV	  or	  
HBV,	   the	  AUROC	   for	  prognosis	  was	  0.85	   (0.76-­‐0.90)	  at	  5	  years	  whilst	   the	  HR	   for	  prognosis	  
was	  9.45	  (4.51-­‐19.79)	  (Nunes	  et	  al.,	  2010a).	  Two	  further	  studies	  generated	  HR	  values	  of	  2.58	  





(1.68-­‐8.77)	  using	  >3.25	  compared	  to	  <3.25	  as	  the	  cut-­‐off	  (Jain	  et	  al.,	  2012).	  A	  study	  of	  drug	  
users	  with	  advanced	  liver	  fibrosis	  (Sanvisens	  et	  al.,	  2011)	  found	  that	  a	  Fib-­‐4	  cut-­‐off	  of	  >3.25	  
was	  associated	  with	  a	  RR	  of	  death	  of	  3.89	  (2.28-­‐6.64),	  whilst	  Merchante	  et	  al	  (Merchante	  et	  
al.,	  2012)	  did	  not	  identify	  significance	  for	  a	  Fib-­‐4	  cut-­‐off	  of	  >3.25	  in	  an	  HIV	  /	  HCV	  co-­‐infected	  
cohort.	  Using	  Fib-­‐4	  as	  a	  continuous	  variable	   in	  a	  cohort	  of	  patients	  with	  HBV	  an	  AUROC	  of	  
0.744	   (0.676-­‐0.813)	   was	   found	   which	   increased	   to	   0.784	   (0.683-­‐0.886)	   if	   hepatic	  
decompensation	  was	  included	  as	  an	  outcome	  (Chon	  et	  al.,	  2012).	  
 
3.4.5.2 Alcohol	  induced	  liver	  disease:	  	  
One	   study	   of	   218	   patients	   looked	   at	   Fib-­‐4	   (cut-­‐off	   unclear)	   in	   this	   cohort	   (Naveau	   et	   al.,	  
2009),	  identifying	  an	  AUROC	  for	  overall	  death	  of	  0.64	  (0.55-­‐0.71).	  
 
3.4.6 ELF	  panel	  
In	   2008,	   Mayo	   et	   al	   (Mayo	   et	   al.,	   2008)	   prospectively	   analysed	   161	   PBC	   patients	   and	  
concluded	  that	  ELF	  could	  be	  a	  prognostic	  factor	  for	  clinical	  outcomes	  related	  to	  liver	  disease	  
(e.g.	   development	   of	   new	   varices,	   variceal	   haemorrhage,	   ascites,	   encephalopathy,	   liver	  
related	   death	   or	   liver	   transplant).	   Each	   1-­‐point	   increase	   in	   ELF	   was	   associated	   with	   a	  
threefold	  increase	  in	  future	  complications.	  In	  addition,	  they	  found	  that	  6	  years	  prior	  to	  the	  
first	  complication,	  ELF	  had	  a	  prognostic	  AUROC	  of	  0.684	  (0.528-­‐0.814).	  In	  2010,	  with	  larger	  
numbers	   of	   patients,	   a	   broader	   range	   of	   liver	   aetiologies,	   and	   using	   ELF	   as	   a	   continuous	  
variable	  (Parkes	  et	  al.,	  2010)	  it	  had	  an	  OR	  of	  2.2	  (1.7-­‐2.9)	  for	  prognosis	  of	  liver	  outcomes	  6	  









Ngo	  et	  al	  published	  2	  papers	  studying	  Fibrotest	  as	  a	  continuous	  variable	  in	  groups	  of	  patients	  
with	  differing	  aetiologies.	   In	  a	   study	  of	  1074	  HBV	   (±HIV)	  patients	   there	  was	  an	  AUROC	   for	  
overall	   survival	   of	   0.94	   (0.89-­‐0.96),	  whilst	   for	   survival	  without	   liver	   complication	  or	  death,	  
the	  multivariate	  HR	  was	  5.21	  (3.53-­‐6.88)	  (Ngo	  et	  al.,	  2008).	  In	  a	  cohort	  of	  537	  patients	  with	  
HCV	  there	  was	  an	  AUROC	  for	  the	  prognosis	  of	  overall	  survival	  of	  0.76	  (0.63-­‐0.84)	  and	  0.96	  
(0.93-­‐0.98)	   for	   survival	  without	   death	   from	   liver	   disease	   (Ngo	   et	   al.,	   2006).	   Vergniol	   et	   al	  
(Vergniol	  et	  al.,	  2011)	  also	  looked	  at	  patients	  with	  HCV,	  but	  used	  a	  Fibrotest	  cut	  off	  of	  >0.74	  
and	  showed	  a	  HR	  for	  overall	  survival	  of	  209	  (70-­‐626).	  When	  used	  in	  a	  cohort	  of	  218	  patients	  
with	  ALD,	  the	  AUROC	  for	  overall	  death	  was	  0.69	  (0.61-­‐0.76)	  giving	  a	  risk	  ratio	  (RR)	  for	  overall	  
death	  of	  3.7	  (1.2-­‐11.7)	  and	  23.2	  (3.2-­‐167.3)	  for	  liver-­‐related	  death	  (Naveau	  et	  al.,	  2009).	  
 
3.4.8 Forns	  
Three	   studies	   looked	   at	   the	   prognostic	   value	   of	   Forns.	   In	   patients	   with	   HCV	   (±HIV)	   and	  
advanced	  liver	  fibrosis,	  Sanvisens	  (Sanvisens	  et	  al.,	  2011)	  used	  a	  cut	  off	  of	  0.74	  and	  found	  a	  
RR	   of	   death	   of	   2.96	   (1.7-­‐5.15)	   when	   comparing	   them	   to	   patients	   without	   advanced	   liver	  
failure.	  Another	  study	  in	  patients	  with	  HCV	  demonstrated	  the	  AUROC	  for	  overall	  survival	  was	  
0.73	   (0.46-­‐0.87),	  which	   rose	   to	   0.87	   (0.52-­‐0.97)	   for	   survival	  without	   liver-­‐related	   death	   or	  





cohort	  of	  patients	  with	  ALD	  (Naveau	  et	  al.,	  2009),	  the	  AUROC	  for	  prognosis	  of	  overall	  death	  
was	  0.43	  (0.35-­‐0.51).	  	  
 
3.4.9 Hepascore	  
Only	  one	  paper	   looked	  at	  Hepascore	   for	   its	  prognostic	   value;	  Naveau	  et	  al	   (Naveau	  et	  al.,	  
2009)	   analysed	   data	   in	   a	   cohort	   of	   patients	   with	   ALD	   using	   Hepascore	   as	   a	   continuous	  
variable,	  and	  demonstrated	  an	  AUROC	  for	  prognosis	  of	  0.69	  (0.62-­‐0.76)	  with	  a	  RR	  for	  death	  
of	  0.9	  (0.2-­‐3.1).	  
	  
3.4.10 LSM	  
There	   have	   been	   several	   studies	   looking	   at	   LSM	   and	   its	   prognostic	   value,	   but	   comparison	  
was	  not	  possible	  due	  to	  marked	  heterogeneity	  of	  disease	  types,	   liver	  stiffness	  cut-­‐offs	  and	  
clinical	  outcomes.	  Disease	  types	  included	  HBV	  (n=3),	  HCV	  (n=2),	  mixed	  liver	  aetiology	  studies	  
(n=2)	  and	  acute/intensive	  medical	  illness	  (n=2).	  The	  range	  of	  LSM	  cut-­‐offs	  (kPa)	  ranged	  from	  
>8.0	  up	  to	  50.7	  kPa	  (Fung	  et	  al.,	  2011,	  Chon	  et	  al.,	  2012,	  Kim	  et	  al.,	  2012b,	  Merchante	  et	  al.,	  
2012,	   Vergniol	   et	   al.,	   2011,	   Lindvig	   et	   al.,	   2012,	   Koch	   et	   al.,	   2011,	   Klibansky	   et	   al.,	   2012,	  







3.5.1 Random	  effects	  meta-­‐analysis	  of	  HCV	  and	  APRI	  to	  predict	  overall	  death:	  
Meta-­‐analysis	  of	  three	  studies	  (Vergniol	  et	  al.,	  2011,	  Merchante	  et	  al.,	  2012,	  Jain	  et	  al.,	  2012)	  
from	  which	  unadjusted	  HR	  estimates	   for	  overall	  death	  could	  be	  extracted	  was	  performed.	  
The	  summary	  HR	  for	  an	  APRI	  cut-­‐off	  of	  >2	  (Vergniol	  et	  al.,	  2011)	  was	  3.5	  (95%	  CI:	  2.58-­‐4.76),	  
whereas	   for	  an	  APRI	   cut-­‐off	  of	  >1.5	   (Merchante	  et	  al.,	   2012,	   Jain	  et	  al.,	   2012)	   the	  HR	  was	  
1.82	   (95%	   CI:	   0.71-­‐4.65).	   An	   overall	   summary	   HR	   of	   2.51	   (1.37-­‐4.60)	   for	   APRI	   >1.5-­‐2	   was	  
calculated	   as	   illustrated	   in	   Figure	   3-­‐2,	   with	   a	   high	   proportion	   of	   between	   study	  
heterogeneity	  (I-­‐squared	  81.2%).	  	  
	  




Overall  (I-squared = 81.2%, p = 0.005)
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3.5.2 Random	  effects	  meta-­‐analysis	  of	  HCV	  and	  APRI	  to	  predict	  liver	  death:	  
Analysis	  of	  3	  studies	  (Vergniol	  et	  al.,	  2011,	  Nunes	  et	  al.,	  2010a,	  Merchante	  et	  al.,	  2012)	  was	  
possible	   using	   the	   criteria	   indicated	   earlier.	   The	  HR	   for	   an	   APRI	   cut-­‐off>2	  was	   5.90	   (2.88-­‐
8.96),	   whereas	   for	   an	   APRI	   cut-­‐off	   of	   >1.5	   the	   HR	   was	   3.24	   (0.31-­‐33.93).	   An	   overall	  
unadjusted	  summary	  HR	  of	  4.43	  (1.64-­‐11.96)	  for	  an	  APRI	  >1.5-­‐2	  was	  calculated	  as	  illustrated	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3.5.3 Random	  effects	  meta-­‐analysis	  of	  AST:ALT	   in	  patients	  with	   liver	  disease	   to	  predict	  
overall	  death:	  
Meta-­‐analysis	  of	  two	  (Bhala	  et	  al.,	  2011,	  Changchien	  et	  al.,	  2008)	  studies	  was	  possible	  using	  
adjusted	   HR	   data,	   although	   the	   AST:ALT	   ratio	   cut-­‐offs	   were	   different	   between	   the	   two	  
studies	  (>1	  and	  >2).	  The	  summary	  HR	  was	  not	  statistically	  significant	  at	  1.93	  (0.92-­‐4.07),	  and	  
there	  was	  a	  large	  proportion	  of	  between-­‐study	  heterogeneity	  (I-­‐squared)	  49.1%.	  Results	  are	  
illustrated	  in	  Figure	  3-­‐4.	  
	  
Figure	  3-­‐4	  Meta-­‐analysis	  of	  AST:ALT	  to	  predict	  overall	  death	  in	  patients	  with	  liver	  disease	  
	  
 
































3.5.4 Random	  effects	  meta-­‐analysis	  of	  Fib-­‐4	  in	  patients	  with	  viral	  liver	  disease	  to	  predict	  
overall	  death:	  
Three	  studies	  were	  included	  (Vergniol	  et	  al.,	  2011,	  Jain	  et	  al.,	  2012,	  Merchante	  et	  al.,	  2012)	  
in	  the	  meta-­‐analysis	  and	  all	  used	  the	  same	  cut	  off	  of	  3.25.	  The	  unadjusted	  summary	  HR	  was	  
3.697	  (1.977-­‐6.914)	  (I-­‐squared	  73.5%)	  and	  the	  results	  are	  illustrated	  in	  Figure	  3-­‐5.	  	  
	  










































3.5.5 Random	  effects	  meta-­‐analysis	  of	  Fib-­‐4	  in	  patients	  with	  viral	  liver	  disease	  to	  predict	  
liver-­‐related	  death:	  
Three	   studies	  were	   included	   (Merchante	   et	   al.,	   2012,	  Nunes	   et	   al.,	   2010a,	   Vergniol	   et	   al.,	  
2011)	   in	  the	  meta-­‐analysis	  all	  using	  the	  same	  cut-­‐off	  of	  3.25.	  The	  unadjusted	  summary	  HR	  
was	  6.23	  (2.68-­‐14.47)	  (I-­‐squared	  60.5%),	  and	  the	  results	  are	  illustrated	  in	  Figure	  3-­‐6.	  
	  	  
Figure	  3-­‐6	  Meta-­‐analysis	  of	  Fib-­‐4	  to	  predict	  liver	  related	  death	  in	  viral	  liver	  disease	  patients	  	  
	  
Analysis	  of	  APRI	  (total	  patients,	  n=3726)	  and	  Fib-­‐4	  (n=3734)	  data	  included	  three	  papers	  for	  
each,	  although	  both	  included	  data	  from	  239	  patients	  by	  Merchante	  et	  al	  (Merchante	  et	  al.,	  
2012)	  for	  whom	  the	  overall	  and	  liver-­‐related	  mortality	  figures	  included	  liver	  transplantation	  
as	  part	  of	  their	  end-­‐point.	  To	  specifically	  focus	  on	  mortality	  as	  a	  true	  end-­‐point,	  we	  repeated	  
the	  random-­‐effect	  analysis	  with	  the	  Merchante	  et	  al	  data	  excluded,	  and	  the	  positive	  HRs	  for	  
overall	  and	  liver-­‐related	  death	  remained	  significant.	  	   	  







































Whilst	   there	  has	  been	  extensive	  study	  of	  non-­‐invasive	  biomarkers	  to	   identify	  the	  presence	  
and	  extent	  of	  liver	  fibrosis	  few	  studies	  have	  focussed	  on	  their	  potential	  prognostic	  value	  for	  
subsequent	  non-­‐liver	  and	  liver-­‐related	  clinical	  events.	  Use	  of	  such	  biomarkers	  to	  predict	  an	  
individual's	   risk	   of	   clinical	   outcomes	   would	   enable	   health	   care	   specialists	   to	   prioritise	  
interventions	  for	  those	  at	  greatest	  risk.	  	  
	  
This	  study	  represents	  a	  comprehensive	  analysis	  of	   the	  published	   literature.	  Our	  systematic	  
review	  identified	  31	  studies	  that	  had	  used	  non-­‐invasive	  biomarkers	  to	  predict	  clinical	  events	  
in	  patients	  with	  liver	  disease.	  Although	  the	  studies	  displayed	  a	  large	  degree	  of	  heterogeneity	  
with	   regards	   to	   biomarker	   use,	  methodology	   and	   study	   population	   our	   systematic	   review	  
reinforced	  the	  prognostic	  value	  of	  certain	  biomarkers.	  At	  present	  the	  most	  compelling	  data	  
relate	   to,	   APRI	   and	   Fib-­‐4	   which	   have	   the	   most	   robust	   evidence	   as	   prognostic	   factors	   for	  
death	  in	  patients	  with	  viral	  hepatitis.	  	  
	  
Simple	  scoring	  systems	  (APRI,	  AST:ALT,	  Fib-­‐4)	  and	  specialist	  non-­‐invasive	  tests	  (ELF,	  transient	  
elastography)	   were	   consistently	   associated	   with	   the	   development	   of	   HCC	   and	   hepatic	  
decompensation	   over	   a	   mean	   follow-­‐up	   period	   of	   45.7	   months.	   In	   patients	   with	   viral	  
hepatitis,	  our	  random-­‐effects	  meta-­‐analysis	  models	  demonstrated	  that	  both	  APRI	  (cut	  off	  of	  
>1.5-­‐2.0)	   and	   Fib-­‐4	   (cut-­‐off>3.25)	  were	   associated	  with	   increased	   overall	   and	   liver-­‐related	  
mortality,	  over	  an	  average	  of	  45.3	  and	  43.0	  months	  respectively.	  This	  finding	  has	  potentially	  







In	  the	  case	  of	  AST:ALT	  ratio,	  although	  there	  were	  two	  studies	  with	  significant	  HR	  for	  death,	  
there	   is	   caution	   about	   its	   interpretation	   due	   to	   the	   high	   inter-­‐study	   heterogeneity.	   In	  
particular,	   the	   latter	  made	   the	   resultant	   confidence	   interval	   cross	  1,	   therefore	  making	   the	  
resultant	  HR	  of	  uncertain	  prognostic	  value.	  	  
	  
Akin	   to	   the	   findings	   of	   the	   Poynard	   meta-­‐analysis	   (Poynard	   et	   al.,	   2011),	   we	   show	   that	  
biomarkers	  hold	  potential	  prognostic	  information	  that	  may	  be	  useful	  to	  clinicians	  wishing	  to	  
understand	  how	  the	  prognosis	  of	  clinical	  outcomes	  is	  affected	  by	  an	  abnormal	  result.	  AUROC	  
analysis	   aids	   discrimination	   of	   patients,	   but	   is	   not	   optimal	   in	   predicting	   future	   risk	   or	  
stratifying	   individuals	   into	   risk	   categories.	  Our	   larger	   review	  and	  analysis	  has	   improved	  on	  
previous	   studies	   by	   providing	   HR	   information	   showing	   the	   size	   of	   prognostic	   effect	   that	  
elevations	  in	  Fib-­‐4	  and	  APRI	  have	  on	  clinical	  outcomes.	  	  
 
3.6.1 Limitations	  of	  this	  study:	  
Many	  of	  the	  studies	  reviewed	  primarily	  focused	  on	  the	  diagnosis	  of	  fibrosis	  rather	  than	  the	  
prognosis	  of	  clinical	  outcomes	  and	  hence	  data	  presented	   in	  them	  is	  often	  not	  complete	  or	  
could	  not	  be	  extracted	   for	   this	  purpose.	   The	   search	   strategy	   in	   itself	   is	   a	   limitation	  of	   the	  
study.	   	   Some	   papers	   may	   have	   been	   missed	   by	   the	   incorrect	   spelling	   or	   non-­‐standard	  
method	  of	  describing	  terms	  searched	  for.	  Since	  our	  search	  was	  performed,	  there	  have	  also	  
been	  2	  major	  studies	  that	  have	  been	  released	  by	  Kim	  at	  al(Kim	  et	  al.,	  2013)	  and	  Angulo	  et	  
al(Angulo	  et	  al.,	  2013)	  	  that	  may	  have	  re-­‐enforced	  the	  meta-­‐analysis.	  They	  have	  also	  shown	  





panels,	   is	   a	   significant	   predictor	   of	   mortality,	   mainly	   from	   cardiovascular	   causes,	  
independent	  of	  other	  known	  factors	  
	  
The	  major	  limitation	  of	  this	  study	  is	  the	  relatively	  small	  number	  of	  studies	  and	  the	  marked	  
variation	  in	  their	  design,	  which	  precluded	  their	  inclusion	  in	  some	  of	  the	  meta-­‐analyses.	  With	  
the	  exception	  of	  APRI,	  Fib-­‐4	  and	  AST:ALT,	  many	  of	  the	  other	  biomarkers	  studied	  could	  not	  be	  
meta-­‐analysed	   as	   either	   the	   data	   were	   not	   provided	   to	   obtain	   HRs	   or	   the	  
clinical/methodological	   heterogeneity	   was	   considered	   too	   severe	   to	   justify	   pooling.	   The	  
latter	  was	  due	  to	  several	  discrepancies	  between	  the	  study	  designs	  and	  objectives,	  including:	  
a	   wide	   range	   of	   clinical	   outcome	   measures	   (HCC,	   decompensation,	   mortality,	   varices,	  
encephalopathy),	   disease	   types	   (viral,	   autoimmune,	   cancer),	   study	   design	   (prospective	   vs.	  
retrospective),	  continuous	  values	  vs.	  variable	  biomarker	  cut-­‐offs,	  and	  importantly	  a	  paucity	  
of	  published	  HR.	  Nevertheless,	  this	  study	  does	  provide	  novel	  information	  on	  the	  prognostic	  
value	   of	   pooled	   studies	   providing	   a	   platform	   for	   further	   investigation.	   	  Moreover,	   formal	  
assessment	   of	   publication	   bias	   (e.g.	   funnel	   plot	   asymmetry)	   was	   not	   possible	   due	   to	   the	  
small	   number	  of	   studies	   in	   each	  meta-­‐analysis,	  which	   remains	   a	   concern	   as	   such	  bias	   is	   a	  
recognised	   issue	   in	   prognosis	   studies.	   (Riley	   et	   al.,	   2013).	   	   Finally,	  most	   of	   the	   analysable	  
data	  were	  from	  patients	  with	  viral	  liver	  disease	  and	  as	  such	  generalisation	  to	  other	  causes	  of	  
liver	  disease	  should	  be	  undertaken	  with	  caution.	  
 
3.6.2 Future	  research:	  
Future	  multi-­‐centre	  collaborative	  studies,	  based	  on	  similar	  study	  populations	  using	  validated	  





(http://www.strobe-statement.org)	  to	  improve	  interpretability	  are	  likely	  to	  provide	  clearer	  
insights	   as	   multiple	   small	   unrelated	   studies	   have	   the	   potential	   to	   add	   further	   to	   the	  
uncertainty	  (Riley	  et	  al.,	  2013).	  Prospective	  validation	  of	  the	  thresholds	  for	  each	  biomarker	  
will	  be	  key	  to	  generating	  robust	  conclusions.	  However,	  the	  greatest	  utility,	  and	  challenge,	  of	  
such	  biomarkers	  is	  likely	  to	  be	  in	  primary	  care,	  where	  the	  absence	  of	  liver	  biopsy	  has	  limited	  
the	   validation	   of	   biomarkers	   in	   liver	   fibrosis.	   However,	   assessing	   their	   prognostic	   value	   in	  
this	  setting	  could	  greatly	  aid	  clinicians	  with	  prioritising	  their	  management,	  and	  at	  the	  same	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Cirrhosis	   is	   the	   common	   endpoint	   of	   an	   aberrant	   repair	   process	   that	   results	   from	  
uncontrolled,	   chronic	   inflammation	   and	   liver	   injury	   (Brenner	   et	   al.,	   2010,	   Friedman,	   2000,	  
Iredale	  et	  al.,	  1998,	  Iredale,	  2003)	  The	  aetiology	  of	  chronic	   liver	  disease	  is	  varied	  but	  if	   left	  
untreated	  all	  can	  lead	  to	  scarring	  of	  the	  liver	  (cirrhosis)	  and	  its	  associated	  complications	  such	  
as	  ascites,	  portal	  hypertension	  and	  hepatocellular	  carcinoma.	  
The	  ability	  to	  assess	  the	  severity	  of	  fibrosis	  is	  important	  clinically	  to	  predict	  prognosis,	  and	  to	  
plan	   and	   assess	   response	   to	   therapy.	   For	   example	   patients	  with	   severe	   fibrosis	   should	   be	  
screened	   for	   complications	   of	   cirrhosis	   whereas	   those	   with	   no	   or	   mild	   fibrosis	   need	   less	  
intensive	  follow	  up.	  
Traditionally	   the	  main	  way	  of	  assessing	   liver	   fibrosis	  has	  been	  the	   liver	  biopsy,	  which	   is	  an	  
invasive	  test	  that	  carries	  with	  it	  a	  small	  but	  definite	  complication	  rate.	  Patients	  who	  undergo	  
liver	  biopsy	  are	  put	  at	  risk	  of	  bleeding	  and	  pain	  post	  procedure	  with	  a	  small	  mortality	  rate.	  
Liver	   biopsy	   is	   also	   open	   to	   inter-­‐reviewer	   differences	   in	   scoring	   and	   interpretation	   and	  
sampling	  errors	  because	  such	  a	  small	  piece	  of	  liver	  tissue	  is	  assessed.	  
These	  issues	  have	  prompted	  the	  search	  for	  non-­‐invasive	  methods	  of	  assessing	  liver	  fibrosis	  
including	   simple	   blood	   tests	   that	   reflect	   liver	   damage	   and	   dysfunction	   and	   as	   the	  
pathogenesis	  of	   liver	  injury	  became	  better	  understood	  the	  use	  of	  groups	  of	  molecules	  that	  
directly	   reflect	   fibrinolysis	   and	   fibrinogenesis	   as	   well	   as	   those	   that	   reflect	   underlying	  
inflammation	   and	   immune	   activation.	   Recent	   interest	   has	   also	   focussed	   on	   novel	   imaging	  






The	   purpose	   of	   this	   study	   was	   to	   assess	   the	   accuracy	   of	   a	   panel	   of	   immune	   and	   fibrosis	  
associated	   gene	   products	   in	   the	   diagnosis	   and	   assessment	   of	   liver	   fibrosis	   compared	   to	  




4.1.1.1 Molecular	  mechanisms	  of	  liver	  fibrogenesis	  
There	  are	  many	  different	  causes	  of	  liver	  injury	  including	  infections,	  toxic	  injury,	  autoimmune	  
diseases	   and	   ischemic	   damage.	   	   Many	   of	   these	   will	   resolve	   spontaneously	   allowing	   liver	  
repair	   and	   regeneration	   to	  occur	  without	   scarring	  or	  permanent	  damage.	   	  However	   if	   the	  
injury	   persists	   or	   is	   repetitive	   chronic	   liver	   disease	   results	   characterised	   by	   chronic	  
inflammation	   (hepatitis)	   and	   scarring	   (fibrosis)	   develops	   which	   can	   progress	   over	   time	   to	  
cirrhosis.	  
	  
The	   response	   to	   repetitive	   injury	   in	   the	   liver	   is	   wound	   healing,	   which	   is	   characterised	   by	  
chronic	   inflammation	   and	   fibroblast	   activation	   leading	   to	   the	   increased	   production	   and	  
deposition	  of	  extracellular	  matrix.	  In	  the	  wound	  healing	  response,	  increased	  ECM	  is	  a	  normal	  
and	  appropriate	  response	  to	  injury	  but	  excessive	  accumulation	  of	  ECM	  due	  to	  persistent	  or	  
repetitive	   injury,	  myofibroblast	  activation	  and	  a	  failure	  of	  resolution	  and	  remodelling	   leads	  
to	   disruption	   of	   normal	   tissue	   architecture	   and	   consequent	   loss	   of	   function.	   	   The	  
constituents	   of	   the	   matrix	   laid	   down	   during	   liver	   fibrogensis	   are	   complex	   and	   include	  
basement	  membrane	  and	  interstitial	  collagens,	  proteoglycans,	  and	  matrix	  glycoproteins	  such	  





macrophages,	  which	   secrete	   both	  matrix	   degrading	   enzymes	   (MMPs)	   and	   their	   inhibitors,	  
(TIMPs).	  	  MMPs	  are zinc-­‐dependent	  endopeptidases	  that	  degrade	  a	  range	  of	  matrix	  proteins	  
and	   also	   modulate	   the	   function	   of	   cytokines	   and	   growth	   factors	   that	   are	   critical	   for	  
regeneration,	   repair	   and	   wound	   healing.	   	   Excessive	   or	   aberrant	   wound	   healing	   leads	   to	  
cirrhosis.	  
 
4.1.1.2 Markers	  of	  liver	  fibrosis	  
As	  discussed	  in	  the	  introduction,	  several	  indirect	  markers	  of	  fibrosis	  have	  been	  studied	  over	  
the	  last	  few	  years.	  These	  include	  a	  mixture	  of	  commonly	  measured	  biochemical	  markers	  of	  
liver	  injury	  and	  function	  and	  clinical	  features	  of	  liver	  disease.	  Direct	  markers	  are	  those	  that	  
are	   released	   into	   blood	   as	   a	   direct	   consequence	   of	   fibrogenesis	   and	   include	   ECM	  
components,	   matrix	   modulating	   enzymes	   and	   their	   inhibitors	   and	   markers	   of	   immune	  
activation	  and	  inflammation	  that	  drives	  fibrosis.	  
In	  this	  project	  we	  compared	  different	  types	  of	  biomarkers,	  some	  of	  which	  are	  commercially	  
available,	  others	  of	  which	  are	  experimental	  with	  indirect	  markers	  against	  the	  gold	  standard	  
of	  histological	  assessment	  of	   fibrosis.	  Some	  biomarkers	  are	  specifically	  marketed	   to	  assess	  
fibrosis	   (ELF	  and	  Fibrotest),	   but	  we	  also	   chose	  a	  panel	  of	  novel	  markers	   that	   reflect	  other	  
potential	  roles	  during	  chronic	  inflammation	  and	  fibrogenesis.	  
The	  rationale	  behind	  the	  choice	  of	  each	  of	  these	  markers	  is	  explained	  below.	  Where	  studies	  
have	   looked	   at	   levels	   of	   a	   particular	   marker	   in	   the	   past,	   this	   is	   described.	   Once	   all	   the	  
markers	  were	  measured,	   statistical	  analysis	  was	  used	   to	  assess	   the	  ability	  and	  accuracy	  of	  
individual	  or	  combinations	  of	  serum	  markers	  to	  predict	   fibrosis,	  with	  the	  aim	  of	  creating	  a	  






4.1.2 Currently	  Available	  Commercially	  marketed	  markers	  of	  fibrosis	  
 
4.1.2.1 Fibromax	  
Fibromax	   consists	   of	   three	   tests	   combined.	   These	   are	   Fibrotest	  measuring	  hepatic	   fibrosis	  
stage,	   SteatoTest	   measuring	   steatosis	   and	   NashTest	   assessing	   necroinflammation	   along	   a	  
Kleiner	  NAS	  score.	  	  
The	  panel	  consists	  of:	  
Alpha	  2	  macroglobulin	  
• Haptoglobin	  
• Apolipoprotein	  A1	  
• Total	  Bilirubin	  
• AST	  
• ALT	  
• Gamma	  GT	  
• Fasting	  glucose	  
• Total	  Cholesterol	  
• Triglyceride	  (TG)	  
Fibrotest	  has	  been	  validated	   in	  patients	  with	  HCV,	  HBV,	  ALD	  and	  NAFLD	  in	  a	  meta-­‐analysis	  
with	  the	  AUROC	  for	  the	  diagnosis	  of	  bridging	  fibrosis	  (F2/F3/F4	  vs.	  F0/F1)	  with	  AUROC	  data	  







Condition	   AUROC	  for	  F0-­‐1	  vs.	  F2-­‐4	  
HCV	   0.84	  (0.82-­‐0.87)	  
HBV	   0.81	  (0.78-­‐0.83)	  
ALD	   0.87	  (0.82-­‐0.92)	  
NAFLD	   0.84	  (0.76-­‐0.92)	  
Table	  4-­‐1	  Published	  AUROCs	  for	  Fibrotest	  
 
 
4.1.2.2 ELF	  	  
ELF	  consists	  of	  	  
• Hyaluronic	  acid	  
• Procollagen	  3	  
• Tissue	  Inhibitor	  of	  Metalloproteinase	  1	  
It	  has	  been	  shown	  to	  accurately	  predict	  moderate	  to	  severe	  fibrosis	  in	  several	  aetiologies	  of	  
chronic	  liver	  disease.	  	  
For	  chronic	  HCV	  the	  pooled	  AUROC	  for	  prediction	  of	  Ishak	  4-­‐6	  fibrosis	  was	  0.85	  (0.81-­‐0.89)	  
(Parkes	  et	  al.,	  2011).	  	  
In	  PBC,	  ELF	  to	  predict	  cirrhosis	  has	  an	  AUROC	  of	  0.76	  (0.63-­‐0.89)	  or	  significant	  fibrosis	  with	  
an	  AUROC	  of	  0.75	  (0.67-­‐0.82).(Mayo	  et	  al.,	  2008)	  
In	  NAFLD,	  ELF	  can	  predict	  severe	  fibrosis,	  moderate	  fibrosis	  and	  no	  fibrosis	  with	  AUROC’s	  of	  










Ultrasound	  allows	   for	   a	   rapid	   and	  non-­‐invasive	  assessment	  of	   liver	   structure	   including	   the	  
vasculature	  and	  biliary	  tree.	  It	  is	  possible	  for	  operators	  to	  give	  an	  assessment	  of	  liver	  disease	  
based	   on	   the	   appearance	   of	   liver	   parenchyma.	   Excessive	   fat	   accumulation	   in	   hepatocytes	  
results	   in	   an	   “echo-­‐bright”	   signal	   and	   the	   architectural	   changes	   of	   cirrhosis	   give	   rise	   to	   a	  
nodular	   or	   irregular	   liver	   edge.	   Recently	   transient	   elastography	   (Fibroscan	   TM)	   has	   been	  
developed	  by	  EchoSens	  in	  France	  to	  provide	  a	  simple	  and	  non-­‐invasive	  test	  for	  the	  presence	  
of	   liver	   fibrosis.	   It	   transmits	   a	   low	   frequency	   vibration	   into	   the	   tissue	   inducing	   an	   elastic	  
shear	  wave	  through	  the	  liver,	  the	  speed	  of	  which	  correlates	  with	  liver	  stiffness.	  The	  scan	  can	  
be	   adversely	   affected	   by	   ascites,	   necro-­‐inflammation(Kim	   et	   al.,	   2012a)	   or	   extrahepatic	  
cholestasis(Millonig	  et	  al.,	  2008).	  MRI	  elastography	  has	  also	  been	  used,	  although	  mostly	  in	  a	  
research	  setting.	  	  This	  is	  more	  expensive	  and	  requires	  more	  sophisticated	  interpretation	  but	  
it	  has	  the	  advantage	  that	  when	  combined	  with	  spectroscopy	  it	  can	  also	  allow	  assessment	  of	  






4.2 Rationale	  for	  markers	  assessed	  
 
Below	  we	  have	  set	  out	  what	  evidence	  there	   is	   for	  potential	   links	  between	  the	  markers	  we	  
assessed	  and	  liver	  fibrosis.	  
 
4.2.1 Cytokines	  and	  markers	  of	  immune	  activation	  
 
4.2.1.1 CD40	  ligand	  (CD154)	  
CD154	   is	  a	  member	  of	  the	  TNF	  superfamily	  expressed	  on	  and	  secreted	  by	  activated	  T	  cells	  
and	  endothelial	  cells.	  When	  it	  binds	  as	  a	  trivalent	  ligand	  to	  its	  receptor	  CD40	  on	  target	  cells	  
it	  provides	  a	  co-­‐stimulatory	  signal	  for	  activation	  and	  differentiation	  of	  dendritic	  cells	  and	  B	  
cells.	   In	   experimental	   animals,	   blocking	   CD40/CD40L	   co-­‐stimulatory	   pathway	   prevents	   the	  
development	  of	  allograft	  rejection	  in	  several	  models	  of	  organ	  allograft	  rejection.	  In	  humans,	  
CD40	  ligand	  is	  expressed	  by	  intrahepatic	  Kupffer	  cells	  and	  macrophages	  as	  well	  as	  T	  cells	  and	  
it	  has	  been	  implicated	  in	  hepatocyte	  and	  cholangiocyte	  killing	  by	  activating	  CD40	  dependent	  
apoptosis	  in	  these	  cells	  during	  liver	  injury(Afford	  et	  al.,	  1999,	  Afford	  et	  al.,	  2001,	  Gaweco	  et	  
al.,	  1999).	  
One	   study	   has	   found	   no	   increased	   in	   CD154	   levels	   in	   the	   blood	   in	   chronic	   liver	   disease	  
compared	  to	  normal	  controls	  (Mayo	  et	  al.,	  2006).	  Although	  CD154	  messenger	  ribose	  nucleic	  







This	   cytokine	   has	   pro-­‐inflammatory	   and	   immunoregulatory	   properties.	   It	   is	   primarily	  
produced	  at	  site	  of	  inflammation	  by	  activated	  monocytes	  and	  macrophages.	  Elevated	  levels	  
of	  TNF	  alpha	  are	  seen	  in	  acute	  and	  chronic	  liver	  disease	  and	  the	  main	  source	  in	  the	  liver	  is	  
felt	  to	  be	  the	  Kupffer	  cells	  and	  infiltrating	  macrophages.	  It	  promotes	  stellate	  cell	  activation	  
and	   increases	   MCP-­‐1	   production.	   It	   has	   mixed	   properties	   as	   mentioned	   above	   in	   that	  
although	   it	   stimulates	   production	   of	   fironectin,	   it	   reduces	   the	   synthesis	   of	   types	   1	   and	   3	  
collagen.	   Its	   main	   role	   in	   hepatic	   fibrogenesis	   is	   probably	   the	   activation	   of	   stellate	  
cells(Reeves	  and	  Friedman,	  2002).	  Levels	   in	  healthy	  controls	  are	  <4pg/ml	  which	  is	  elevated	  
to	   >10pg/ml	   in	   alcoholics(Gonzalez-­‐Quintela	   et	   al.,	   2008)	   or	   patients	   affected	   by	  
HCV(Zylberberg	  et	  al.,	  1999).	   	   In	  patients	  with	  cirrhosis,	  elevated	  levels	  are	  seen	  compared	  




Adiponectin	   is	   a	   hormone	   that	   modulates	   a	   number	   of	   metabolic	   processes,	   including	  
glucose	   regulation	   and	   fatty	   acid	   catabolism	   but	   which	   also	   acts	   as	   a	   potent	   immune	  
modulating	   cytokine.	   It	   has	   antilipogenic	   and	   anti-­‐inflammatory	   effects.	   Low	   levels	   of	  
circulating	   adiponectin	   are	   associated	   with	   several	   manifestations	   of	   the	   metabolic	  
syndrome,	   including	   insulin	   resistance	   and	   type	   2	   diabetes	  mellitus	   as	  well	   as	  NAFLD	   and	  
NASH(Havel,	  2004).	  Hypoadipponectinaemia	  has	  also	  been	  demonstrated	  to	  be	  a	  feature	  of	  





Circulating	  adiponectin	  is	   increased	  in	  liver	  cirrhosis	  independent	  of	  the	  aetiology	  (Kaser	  et	  
al.,	   2005)	   and	   in	   subjects	   with	   more	   advanced	   chronic	   liver	   disease,	   suggesting	   it	   is	   an	  
indicator	   of	   severity	   of	   chronic	   liver	   disease.	   	   Adiponectin	   levels	   correlate	   positively	   with	  
surrogate	  markers	   of	   hepatic	   fibrosis	   (transient	   elastography,	   fasting	   serum	  bile	   acids	   and	  
hyaluronate)	  as	  demonstrated	  by	  Balmer	  et	  al	   in	  2010.	  The	  respective	  R	  values	  were	  0.45,	  
0.51	  and	  0.52.	  (Balmer	  et	  al.,	  2010)	  
 
4.2.1.4 Insulin	  	  
Homeostatic	  Model	  Assessment	  of	   Insulin	  Resistance	   (HOMA-­‐IR)	   is	  a	  method	   for	  assessing	  
beta-­‐cell	   function	   and	   insulin	   resistance	   (IR)	   from	   basal	   (fasting)	   glucose	   and	   insulin.	   The	  
relationship	   between	   glucose	   and	   insulin	   in	   the	   basal	   state	   reflects	   the	   balance	   between	  
hepatic	   glucose	   output	   and	   insulin	   secretion.	   Type	   2	   diabetes	   is	   more	   prevalent	   among	  
patients	  with	   chronic	  HCV	   compared	  with	   those	  with	  other	   liver	   diseases	   and	   the	   general	  
population.	   IR	  plays	  a	  primary	  role	   in	  the	  development	  of	  type	  2	  diabetes	  mellitus.	  A	  2003	  
study	  by	  Hui	  et	  al(Hui	  et	  al.,	  2003)	  showed	  that	  Hepatitis	  C	  virus–infected	  subjects	  with	  stage	  
0	  or	  1	  hepatic	  fibrosis	  had	  higher	  levels	  of	  insulin	  and	  HOMA-­‐IR,	  and	  that	  increased	  HOMA-­‐IR	  
is	  a	  predictor	  of	   the	  stage	  of	   fibrosis	  and	   the	   rate	  of	   fibrosis	  progression.	   	  A	   study	  of	  HCV	  
patients	   from	   Egypt	   illustrates	   the	   correlation	   between	   HOMA-­‐IR	   and	   fibrosis	  
stage(Mohamed	  et	  al.,	  2011).	  Another	  study	  found	  that	  HOMA-­‐IR	  remained	  an	  independent	  
predictor	  of	  fibrosis	  stage	  even	  after	  the	  exclusion	  of	  subjects	  with	  cirrhosis,	  which	  is	  known	  






In	   cirrhotics,	   the	   more	   severe	   the	   disease,	   the	   lower	   the	   HOMA-­‐IR	   that	   is	   detected	   (see	  
below)(Yagmur	  et	  al.,	  2006)	  and	  this	  is	  lower	  than	  seen	  in	  healthy	  controls.	  
 
4.2.1.5 Leptin	  
Adipose	   tissue	   secretes	   substances	   called	   adipocytokines	   such	   as	   adiponectin,	   leptin,	  
resistin,	   plasminogen	   activator	   inhibitor	   1	   (PAI-­‐1),	   and	   TNF-­‐α.	   Activated	   stellate	   cells	   have	  
also	   been	   shown	   to	   express	   leptin,	   which	   acts	   as	   a	   paracrine	   modulator	   of	  
fibrinogenesis(Potter	  et	  al.,	  1998).	  Recently	  it	  has	  been	  proposed	  that	  obesity	  is	  a	  low	  grade	  
inflammatory	   state	   contributing	   to	   insulin	   resistance	   and	   type	   2	   diabetes.(Greenberg	   and	  
Obin,	  2006)	  Hypertrophied	  adipocytes	  in	  obesity	  release	  chemokines	  such	  as	  TNF-­‐A,	  Il6	  and	  
nitric	  oxide,	  which	  recruit	  macrophages.	  This	  in	  turn	  leads	  to	  adipocytokine	  dysregulation.	  
High	   serum	   leptin	   levels	   are	   seen	   in	   cirrhotic	   patients(Testa	   et	   al.,	   2000)	   	   and	   hepatic	  
cirrhosis	   is	   six	   times	   more	   prevalent	   in	   obese	   individuals	   than	   in	   the	   general	  
population(Ratziu	  et	   al.,	   2000).	   The	   relationship	  between	   serum	   leptin	   concentrations	  and	  
the	  severity	  of	  liver	  fibrosis	  is	  unclear.	  Some	  studies	  suggest	  that	  despite	  high	  serum	  leptin	  
concentrations	  in	  NAFLD	  patients,	  there	  is	  no	  relationship	  between	  leptin	  and	  the	  severity	  of	  
hepatic	  fibrosis(Angulo	  et	  al.,	  2004),	  however	  	  Lemoine	  et	  al.	  measured	  serum	  leptin	  levels	  
in	   74	   patients	   with	   biopsy-­‐proven	   disease	   (57	   NASH,	   17	   simple	   steatosis)	   and	   found	  
significantly	  higher	  levels	  in	  the	  NAFLD	  group	  (14.3	  ±11.1	  ng/ml)	  compared	  with	  the	  control	  
(5.8	  ±6.6	  ng/ml)	  .(Lemoine	  M,	  2009)	  In	  another	  study,	  serum	  leptin	  levels	   in	  the	  liver	  were	  
not	   significantly	   different	   between	   patients	   with	   NASH	   and	   those	   with	   simple	  





In	  HCV	  patients,	  a	  positive	  correlation	  is	  seen	  not	  only	  with	  fibrosis	  stage	  but	  also	  body	  mass	  
index	  (BMI).(Piche	  et	  al.,	  2004)	  Levels	   in	  control	  samples	  (6.4	  ±4.1	  ng/ml)	  were	   lower	  than	  
patients.	  Males	  had	  lower	  levels	  compared	  to	  females	  (4.1	  ±3.2	  vs.	  8.7	  ±3.6	  ng/ml).	  
These	   studies	   suggest	   that	   leptin	   plays	   important	   roles	   in	   liver	   diseases	   by	   attenuating	  
hepatic	  steatosis,	  exacerbating	  liver	  fibrosis,	  and	  possibly	  promoting	  HCC	  growth.	  
 
4.2.1.6 Resistin	  
Resistin	   is	   a	   polypeptide	   of	   12.5kDa.	   It	   reduces	   insulin	   sensitivity	   in	   adipocytes,	   skeletal	  
muscle	  and	  hepatocytes	  by	  supressing	  insulin	  stimulated	  glucose	  uptake.	  It	  therefore	  aids	  in	  
maintaining	   blood	   glucose	   levels	   during	   fasting	   by	   activating	   hepatic	   gluconeogenesis.	  
Higher	   serum	   resistin	   levels	   are	   found	   in	  obese	   individuals	   and	  diabetic	  patients.	   It	   is	   also	  
expressed	  in	  leukocytes	  and	  tissue	  macrophages.	  Observing	  increased	  levels	  of	  resistin	  in	  the	  
presence	  of	  Il-­‐1,	  Il-­‐6	  ad	  TNF-­‐a,	  supports	  this.	  	  
In	  viral	  hepatitis	  patients,	  significantly	  higher	   levels	  of	  resistin	  are	  seen	  comparing	  patients	  
with	  F4-­‐6	  vs.	  F0-­‐3.(Tsochatzis	  et	  al.,	  2008).	   Levels	  of	   resistin	  varied	  according	   to	  aetiology.	  
Hepatitis	  C	  and	  B	  patients	  had	  values	  of	  7.1	  ng/ml	  ±	  2.5,	  whereas	  NASH	  levels	  were	  lower	  at	  
5.7	  ±2.8.	  No	  controls	  were	  used.	  
In	  another	  study	  from	  a	  few	  years	  earlier,	  the	  same	  link	  was	  seen	  (Yagmur	  et	  al.,	  2006).	  Here	  
a	  control	  population	  of	  healthy	  donors	  yielded	  a	  value	  of	  4ug/l.	  In	  addition,	  a	  link	  was	  seen	  







IFN-­‐γ	  inhibits	  the	  in	  vitro	  activation	  of	  stellate	  cells	  (Baroni	  et	  al.,	  1996)	  and	  their	  synthesis	  of	  
extra	   cellular	   matrix(Reeves	   and	   Friedman,	   2002).	   In	   murine	   models	   IFN-­‐γ	   deficient	   mice	  
have	   a	   more	   pronounced	   fibrotic	   response	   to	   carbon	   tetrachloride	   damage,	   which	   was	  
reduced	  by	  administration	  of	   IFN-­‐γ(Shi	  et	  al.,	  1997).	  Things	  may	  not	  be	  as	   straightforward	  
however,	  as	  a	  study	  performed	  on	  liver	  biopsy	  specimens	  from	  patients	  with	  HCV	  infection,	  
showed	   that	   increased	   IFN-­‐γ	   expression	   was	   associated	   with	   portal	   inflammation	   and	  
fibrosis	  stage(Napoli	  et	  al.,	  1996).	  	  This	  reflects	  the	  dichotomous	  effects	  of	  IFNg	  on	  immune	  
activation	  and	  hepatitis	  and	  fibrosis	  per	  se.	  
Serum	  levels	  are	  elevated	  in	  patients	  with	  primary	  biliary	  cirrhosis	  were	  44pg/ml	  compared	  
to	  19pg/ml	  when	  measured	  in	  non-­‐cirrhotics	  (Fracchia	  et	  al.,	  2000).	   Interestingly	   levels	  are	  
not	   elevated	   in	   chronic	   carriers	   of	   HBV,	   which	   may	   reflect	   the	   lack	   of	   inflammation	  





4.2.2.1 RANTES	  (Regulated	  upon	  Activation,	  Normal	  T	  cell	  Expressed	  and	  Secreted)	  	  
RANTES	   (or	  CCL5)	   is	   a	   cytokine	   that	   attracts	   several	   subsets	  of	   activated	   lymphocytes	   and	  
monocytes	  that	  express	   its	  G-­‐protein	  coupled	  receptors	  C-­‐C	  motif	   receptor	  1	   (CCR1),	  CCR3	  
and	  CCR5.	  CCR5	  is	  expressed	  by	  hepatic	  stellate	  cells	  suggesting	  that	  the	  cells	  are	  a	  target	  as	  
well	   as	   a	   source	   for	   CCL5	   in	   the	   liver	   (Schwabe	   et	   al.,	   2003).	   In	   a	  murine	   CCL5	   knockout	  





immune	   cell	   infiltration	   in	   2	   models	   of	   liver	   injury:	   CCl4	   toxicity	   and	   MCD	   (methionine	  
choline-­‐deficient)	  diet	  induced	  steatohepatitis.	  (Berres	  et	  al.,	  2010)	  This	  study	  also	  showed	  a	  
link	   with	   fibrosis	   stage	   in	   HCV/NASH	   and	   fibrosis	   indicating	   that	   CCL5	   expression	   is	  
associated	  with	  fibrotic	  liver	  disease.	  
 
4.2.2.2 Serum	  Interferon-­‐gamma-­‐inducible	  protein	  10	  (IP-­‐10)	  	  	  
Serum	   interferon-­‐gamma-­‐inducible	  protein	  10	   (IP-­‐10)	   is	   also	   called	  C-­‐X-­‐C	  motif	   chemokine	  
(CXCL)10.	   	   It	   is	   a	   chemokine	   that	   plays	   a	   central	   role	   in	   liver	   inflammation	   by	   recruiting	  
effector	  lymphocytes	  to	  the	  liver(Shields	  et	  al.,	  1999,	  Curbishley	  et	  al.,	  2005,	  Oo	  and	  Adams,	  
2010)	  and	  is	  elevated	  in	  flares	  of	  Hepatitis	  B	  and	  C	  as	  well	  as	  in	  PBC.	  	  	  CXCL10	  binds	  to	  the	  
chemokine	   receptor	   CXCR3	   as	   do	   two	   related	   chemokines	   CXCL9,	   and	   CXCL11.	   	   These	  
chemokines	  were	  measured	   in	  healthy	  controls,	  patients	  with	   liver	   fibrosis	  and	  cirrhosis	  of	  
various	   disease	   aetiologies	   to	   investigate	   their	   role	   in	   disease	   progression.(Tacke	   F,	  
2010)CXCL9	  and	  CXCL10	  but	  not	  CXCL11	  levels	  were	  positively	  associated	  with	  the	  severity	  
of	   liver	   fibrosis	   and	  CXCL10	  was	   elevated	   across	   all	   stages	   of	   cirrhosis.	   In	   addition,	   CXCR3	  
chemokines	  were	  associated	  with	  hepatic	  synthetic	  capacity	  and	  the	  development	  of	  clinical	  
complications	  of	  cirrhosis.	   IP-­‐10	  has	  been	  found	  to	  predict	   response	  to	  current	  Hepatitis	  C	  
treatment	   (Ribavirin	   and	   Pegylated	   Interferon).(Reiberger	   T,	   2008).	   CXCL10	   levels	   also	  
correlate	   with	   the	   presence	   of	   necroinflammation	   which	   is	   characterised	   by	   CXCR3+	  
lymphocyte	   infiltrates(Zeremski	   et	   al.,	   2008)	   .In	  mice	   CXCL10	  deficiency	   is	   associated	  with	  
attenuated	  fibrosis	  in	  the	  CCl4	  model.	  It	  was	  also	  noted	  that	  HSCs	  express	  CXCR3,	  respond	  to	  





In	  a	   study	   looking	  at	   fibrosis	  development	  1	   year	  after	   liver	   transplant	   for	  HCV,	  a	  positive	  
correlation	   between	   CXCL10	   levels	   and	   fibrosis	   stage	   was	   observed	   Levels	   ≤140pg/ml	  
significantly	  predicted	  the	  absence	  of	  F2	  fibrosis	  and	  a	  level	  of	  ≤220pg/ml	  did	  the	  same	  for	  
F3(Berres	   et	   al.,	   2011).	   	   Elevated	   levels	   of	   CXCL10	   correlated	  with	   ALT	   levels	   as	  might	   be	  
expected	   given	   the	   above	   findings	   in	   several	   inflammatory	   liver	   diseases(Nagayama	  et	   al.,	  
2001).	  
CXCL10	  in	  murine	  models	  
In	  the	  murine	  model	  of	  CCl4	  fibrosis	  CXCL10	  deficiency	  was	  associated	  with	  reduced	  fibrosis	  
compared	  with	  wild	  type	  mice.	  It	  was	  also	  noted	  that	  NK	  cells	  numbers	  were	  raised	  and	  that	  
HSCs	   express	   CXCR3,	   respond	   to	   CXCL10	   and	   secrete	   CXCL10	  when	   stimulated	  with	   IFN-­‐γ	  
(Hintermann	  et	  al.,	  2010).	  
 
4.2.2.3 CXCL11/	  Interferon-­‐inducible	  T	  cell	  alpha	  chemoattractant	  (I-­‐TAC)	   	  
This	  cytokine,	  also	  known	  by	  the	  name	  I-­‐TAC	  is	  expressed	  by	  leukocytes	  and	  detected	  in	  the	  
liver.	  It	  interacts	  with	  CXCR3	  and	  is	  chemotactic	  for	  activated	  T	  cells(Cole	  et	  al.,	  1998).	  
In	   patients	   with	   mixed	   cryoglobulinaemia	   and	   chronic	   HCV,	   significantly	   higher	   levels	   of	  
CXCL11	  were	  seen	  in	  the	  blood	  (Antonelli	  et	  al.,	  2011)	  and	  even	  higher	  levels	  were	  seen	  in	  
those	  patients	  with	  an	  active	  vasculitis.	  	  In	  the	  Berres	  study	  looking	  at	  fibrosis	  development	  
1	  year	  after	  liver	  transplant	  for	  HCV,	  a	  positive	  correlation	  between	  CXCL10	  and	  to	  a	  lesser	  







4.2.2.4 	  MCP-­‐1	  
 
MCP-­‐1	  (also	  known	  as	  CCL2)	  is	  a	  potent	  chemotactic	  factor	  for	  monocytes	  and	  macrophages.	  
Its	  sources	  include	  both	  intrahepatic	  and	  peripheral	  mononuclear	  cells.	  CCL2	  secretion	  is	  up-­‐
regulated	   during	   chronic	   hepatitis	   and	   correlates	  with	   the	   number	   of	   cells	   infiltrating	   the	  
portal	   tract(Marra	   F	   and	   M,	   1998).	   It	   is	   elevated	   in	   alcoholic	   liver	   disease	   and	   reflects	  
severity	   of	   hepatic	   inflammation	   (Fisher	   et	   al.,	   1999).	   One	   study	   looked	   at	   MCP-­‐1	  
polymorphisms	   and	   noted	   that	   HCV	   patients	  who	   are	   genetically	   predisposed	   to	   produce	  
greater	   amounts	   of	   MCP-­‐1	   protein	   are	   more	   prone	   to	   hepatic	   inflammation	   and	  
fibrogenesis.(Mühlbauer	   et	   al.,	   2003).	   Measurement	   of	   this	   may	   direct	   more	   aggressive	  
therapy	   toward	   those	   patients	   with	   an	   increased	   risk	   of	   disease	   progression.	   	   In	   patients	  
with	  acute	  liver	  failure,	  elevated	  levels	  of	  MCP-­‐1	  are	  observed	  (see	  below)	  over	  controls	  and	  
patients	  with	  chronic	  liver	  failure(Roth	  et	  al.,	  2009).	  
	  
Levels	  of	  MCP-­‐1	  vary	  between	  studies,	  probably	  reflecting	  different	  assays	  used.	  In	  a	  study	  
of	   HCV	   patients,	   controls	   had	   levels	   of	   MCP-­‐1	   of	   209.56-­‐±26.33	   pg/ml	   and	   patients	   with	  
cirrhosis	  had	  levels	  of	  192.75-­‐±59.52	  pg/ml	  whereas	  those	  with	  HCC	  had	  elevated	  levels	  of	  
302.67	   ±44.52	   pg/ml.	   These	   differences	   were	   not	   however	   significant(Tachibana	   et	   al.,	  
2007).	  
 
4.2.2.5 Interleukin	  1B	  	  
Il-­‐1B	   is	   a	   pro-­‐inflammatory	   cytokine	   generated	   in	   response	   to	   inflammatory	   activation.	   	   It	  





molecules,	   cytokines	   and	   chemokines	   by	   a	   broad	   range	   of	   cell	   types.	   	   In	   one	   study,	   IL-­‐1B	  
levels	  were	  not	  significantly	  increased	  in	  cirrhotic	  patients	  compared	  with	  controls.(Napoli	  J,	  
1994)	  and	  other	  studies	  have	  reported	  	  lower	  Il-­‐1B	  levels	  compared	  to	  controls.	  Spanakis	  et	  
al	  describe	  mean	  levels	  of	  Il-­‐1B	  of	  22pg/ml	  in	  controls,	  which	  was	  reduced	  in	  patients	  with	  
HCV(Spanakis	  et	  al.,	  2002).	  
 
4.2.2.6 	  Il-­‐6	  
Il-­‐6	   plays	   an	   important	   role	   in	   regulating	   cell	   growth	   and	   differentiation	   as	   well	   as	   the	  
immune	  response.	  It	  binds	  to	  the	  Il-­‐6	  receptor	  which	  is	  a	  protein	  complex	  consisting	  of	  IL-­‐6	  
receptor	   (Glycoprotein	   80)	   subunit	   binding	   to	   Gylcoprotein	   130	   (GP	   130).	   GP	   130	   is	   a	  
transmembrane	  protein	  and	  is	   important	  in	  signal	  transduction	  after	  the	  cytokine	  engages.	  
Once	  this	  occurs,	  it	  interacts	  with	  Janus	  kinases	  to	  create	  an	  intracellular	  signal.	  This	  initiated	  
intracellular	  signalling	   is	   strictly	  dependent	  on	  the	   function	  of	  GP130	   (Ishihara	  and	  Hirano,	  
2002).	  
Il-­‐6	   has	   been	   shown	   to	   induce	   fibroblast	   proliferation	   and	   collagen	   production	   as	  well	   as	  
synthesis	  of	  TIMP.	  Elevated	  Il-­‐6	  levels	  are	  seen	  after	  partial	  hepatectomy	  suggesting	  a	  role	  in	  
hepatocyte	   proliferation	   and	   liver	   regeneration(Matsunami	   et	   al.,	   1992).	   In	   Il-­‐6	   deficient	  
mice	  treated	  with	  CCl4,	  fibrotic	  changes	  were	  less	  evident	  than	  amongst	  controls	  and	  TGFB	  
expression	  was	  also	  reduced(Natsume	  et	  al.,	  1999,	  Kovalovich	  et	  al.,	  2000).	  	  
Levels	   in	   human	   subjects	   are	   significantly	   elevated	   in	   patients	  with	   cirrhosis	   compared	   to	  
controls(Migita	  et	  al.,	  2006)	  .	  HCC	  was	  associated	  with	  more	  frequently	  elevated	  levels	  of	  Il-­‐6	  







Il-­‐10	   is	   an	   anti-­‐inflammatory	   cytokine	   primarily	   produced	   by	   monocytes,	   which	   plays	   an	  
important	   role	   in	   regulating	   and	   terminating	   inflammatory	   and	   immune	   responses.	   	   	   Il-­‐10	  
deficient	   mice	   are	   more	   prone	   to	   hepatic	   fibrosis	   in	   the	   presence	   of	   helminthic	  
infection(Mentink-­‐Kane	   et	   al.,	   2011)	   and	   CCL4	   (Louis	   et	   al.,	   1998).	   Il-­‐10	   has	   also	   been	  
implicated	  in	  the	  mechanism	  of	  action	  of	  stem	  cell	  therapy	  in	  mice	  (Suh	  et	  al.,	  2012).	  	  	  
A	   study	   from	   2000	   in	   Gastroenterology	   showed	   that	   in	   humans,	   administration	   of	   Il-­‐10	  
reduces	  hepatic	  inflammation	  and	  liver	  fibrosis	  in	  the	  presence	  of	  HCV(Nelson	  et	  al.,	  2000).	  
When	   the	   final	   study	  was	   reported,	   elevated	   levels	   of	   HCV	  were	   seen	   in	   patients	   despite	  
lower	  levels	  of	  fibrosis.	  This	  was	  due	  to	  changes	  in	  immunologic	  viral	  surveillance(Nelson	  et	  
al.,	  2003).	  	  In	  a	  study	  of	  patients	  with	  cirrhosis(Lin	  et	  al.,	  2007),	  elevated	  levels	  of	  Il-­‐10	  were	  
observed	  over	  controls.	  
 
4.2.2.8 	  Il-­‐12	  p70	  
Il-­‐12	  is	  produced	  by	  stimulated	  macrophages	  and	  B	  cells	  and	  promotes	  the	  development	  of	  
Th1	   polarised	   immune	   responses	   characterised	   by	   interferon	   gamma	   production	   and	   cell-­‐
mediated	   immunity.	   IFN	   feeds	   back	   on	   T	   and	   NK	   calls	   to	   stimulate	   more	   Il-­‐12	   thereby	  
amplifying	  the	   inflammatory	  response	  to	   infections.	   	   It	   is	  a	  heterodimer	  of	   two	  chains	  p35	  
(light	   chain)	  and	  p40	   (heavy	   chain)	   resulting	   in	   the	  active	  70kDa	   (p70)	   form	  of	   Il-­‐12.	   	   Il-­‐12	  
deficient	   mice	   infected	   with	   trypanosomes	   show	   reduced	   transaminases	   and	   liver	  
inflammation(Barkhuizen	  et	  al.,	  2008).	  Mice	  deficient	   in	   Il-­‐10	  show	  increased	  expression	  of	  
IFNg	  and	  Il-­‐12	  in	  response	  to	  Toxoplasma	  infection	  (Gazzinelli	  et	  al.,	  1996).	  And	  Il-­‐12	  is	  down	  





documented	  (see	  below)	  in	  patients	  with	  alcoholic	  hepatitis	  and	  cirrhosis(Tung	  et	  al.,	  2010).	  	  
Controls	  had	  mean	   levels	  of	   39.3	  pg/ml	   	   ±8.3,	  with	   cirrhotics	  having	  mean	   levels	  of	   110.5	  
pg/ml	  ±41.6.	  Il-­‐12	  has	  also	  been	  implicated	  in	  the	  pathophysiology	  of	  PBC(Hirschfield	  et	  al.,	  
2009).	  The	  binding	  of	   Il-­‐12	  to	   its	  receptor	   is	  proposed	  to	  modulate	  autoimmune	  responses	  
by	  stimulating	  interferon	  gamma	  production.	  	  
 
4.2.2.9 Il-­‐13	  
Il-­‐13	  is	  a	  TH2	  cytokine	  known	  to	  induce	  fibrosis	  through	  the	  regulation	  of	  TGFβ	  production	  
and	   activation(Fichtner-­‐Feigl	   et	   al.,	   2007,	   Lee	   et	   al.,	   2001).	   Lee	   et	   al	   showed	   using	   a	  
transgenic	  (Tg)	  mouse	  that	  over-­‐expresses	  IL-­‐13	  in	  the	  lung,	  that	  IL-­‐13	  is	  a	  potent	  inducer	  of	  
MMP-­‐9	   and	   TGF-­‐β1	   expression.	   The	   activation	   of	   TGF-­‐β1	   is	   mediated	   by	   a	   MMP-­‐9-­‐
dependent	  mechanism.	  They	  also	  showed	  that	  when	  TGF-­‐β	  activity	   is	  neutralized,	  collagen	  
deposition	   in	   the	   lungs	   of	   the	   IL-­‐13	   Tg	   mice	   is	   substantially	   decreased.	   Thus	   indicating	   a	  
direct	   functional	   link	   between	   IL-­‐13	   and	   TGF-­‐β.	   	   In	   murine	   schistosomiasis	   howeverIl-­‐13	  
exert	  its	  profibrogenic	  role	  independently	  of	  TGFβ.(Kaviratne	  et	  al.,	  2004)	  A	  study	  by	  Weng	  
et	  al	   in	  2009	  showed	   that	  both	  TGFβ	  and	   Il-­‐13	  are	  associated	  with	   fibrosing	  CLD,	  but	   that	  
their	  impact	  differs	  depending	  on	  the	  aetiology	  of	  the	  damage(Weng	  et	  al.,	  2009).	  They	  also	  
showed	  that	  elevated	  levels	  of	  Il-­‐13	  are	  observed	  in	  patients	  with	  HCV	  compared	  to	  controls	  
(72.87pg/ml	  ±26.83	  vs.	  45.41pg/ml	  ±3.73)	  
 
4.2.2.10 Il-­‐17	  
IL-­‐17	   is	   the	   signature	   cytokine	   of	   a	   family	   of	   proinflammatory	   cytokines	   that	   play	   an	  





autoimmune	  and	  destructive	  inflammatory	  diseases.	  	  In	  murine	  models,	  increased	  levels	  of	  
Il-­‐17	  and	  its	  receptor	  are	  seen	  in	  response	  to	  liver	  injury.	  Il-­‐17	  then	  activates	  inflammatory	  
and	   liver	   resident	   cells	   and	   facilitates	   production	   of	   Il-­‐6,	   Il-­‐1	   and	   TNF	   alpha.	   It	   has	   been	  
observed	  to	  directly	  induce	  production	  of	  collagen	  in	  HSC	  by	  activating	  the	  Stat	  3	  signalling	  
pathway(Meng	  et	  al.,	  2012).	  
In	   humans,	   Il-­‐17	   is	  mainly	   produced	   by	   CD4+	   TH17	   cells,	   but	   can	   be	   produced	   by	   CD8+	   T	  
cells,	  monocytes,	  neutrophils	  and	  eosinophils.	  Its	  receptor	  is	  widely	  found	  on	  epithelial	  and	  
stromal	   cells(Oo	   and	   Sakaguchi,	   2013).	   Il-­‐17	   increases	   expression	   and	   secretion	   of	   certain	  
chemokines	  (CXCL1,	  6	  and	  8)	  as	  well	  as	  growth	  factors	  granulocyte	  colony-­‐stimulating	  factor	  
(GCSF)	  and	  granulocyte	  macrophage	  colony-­‐stimulating	  factor	  (GMCSF),	  and	  Il-­‐6	  to	  mobilise,	  
recruit	   and	   activate	   neutrophils.	   In	   a	   study	   looking	   at	   patients	  with	   alcoholic	   related	   liver	  
disease,	  elevated	  levels	  of	  plasma	  Il-­‐17	  have	  been	  observed	  compared	  to	  patients	  with	  ALD	  
(median	  55.9pg/ml)	  and	  healthy	  subjects	  (0	  pg/ml)	  (Lemmers	  et	  al.,	  2009).	  	  	  	  
 
 
4.2.3 Markers	  of	  tissue	  injury	  
 
4.2.3.1 Cytokeratin-­‐18	  (CK-­‐18)	  
In	  vitro	  experiments	  have	  shown	  increased	  cellular	  release	  of	  cytokeratin	  18	  fragments	  into	  
the	  extracellular	  space	  as	  a	  consequence	  of	  caspase	  activation	  during	  the	  intermediate	  stage	  
of	   apoptosis.	   CK18	   is	   the	  major	   intermediate	   filament	   protein	   in	   the	   liver	   and	   one	   of	   the	  
most	  prominent	  substrates	  of	  caspase	  during	  hepatocyte	  apoptosis(Linder	  et	  al.,	  2004)	  	  CK-­‐





studies	   show	   that	   CK-­‐18	   fragments	   independently	   predict	   the	   presence	   of	   NASH	   and	  
correlate	  with	  the	  magnitude	  of	  hepatocyte	  apoptosis	  and	  disease	  severity.(Feldstein	  et	  al.,	  
2009,	  Wieckowska	  et	   al.,	   2006)	  CK-­‐18	  has	   also	  been	   found	   to	   elevated	   in	   cholestatic	   liver	  
disease,	  viral	  hepatitis,	  hepatocellular	  carcinoma	  and	  alcoholic	  hepatitis.(Yilmaz,	  2009)	  
	  
M65	   is	   associated	   with	   overall	   cell	   death	   and	   M30	   is	   associated	   with	   apoptotic	   cell	  
death(Kramer	   et	   al.,	   2004).	   The	   ratio	   between	   them	   is	   an	   indication	   of	   the	   proportion	   of	  
apoptosis	  compared	  to	  total	  cell	  death.	  Interpreting	  the	  ratio	  can	  be	  difficult,	  but	  a	  low	  level	  
(ratio	  of	  <5%)	  of	  cleaved	  CK18	  (M30)	  in	  the	  presence	  of	  high	  levels	  of	  CK18	  indicates	  a	  high	  
component	  of	  necrotic	  cell	  death	  whereas	  a	  ratio	  of	  >20%	  may	  indicate	  apoptosis.	  It	  is	  this	  
that	  may	  aid	  in	  the	  diagnosis	  of	  NASH	  vs.	  NAFLD.	  Studies	  are	  on	  going	  into	  its	  clinical	  efficacy	  
though.	  
Recently	   it	  has	  been	  shown	  by	  Joka	  at	  al	   that	  the	  M65	  assay	  had	  a	  better	  correlation	  with	  
fibrosis	  and	  steatosis(Joka	  et	  al.,	  2012).	  	  
	  
CK18	   has	   been	   used	   to	   predict	   recovery	   from	   acute	   liver	   failure(Volkmann	   et	   al.,	   2008).	  
Elevated	  levels	  of	  M30	  were	  associated	  with	  spontaneous	  recovery	  whereas	  elevated	  levels	  
of	   M65	   were	   associated	   with	   a	   worse	   outcome	   suggesting	   that	   caspase	   activation	   and	  
apoptosis	  is	  associated	  with	  survival	  and	  thus	  Implicating	  a	  caspase	  independent	  cell	  death	  







4.2.4 Endothelial	  adhesion	  receptors 
4.2.4.1 Vascular	  Adhesion	  Protein	  1	  (VAP-­‐1)	  
VAP-­‐1	   is	   a	   homodimeric	   transmembrane	   sialoglycoprotein	   and	   amine-­‐oxidase	   enzyme,	  
which	  is	  constitutively	  expressed	  by	  hepatic	  sinusoidal	  endothelial	  cells	  and	  high	  endothelial	  
venules.	  It	  is	  also	  expressed	  as	  a	  soluble	  protein	  in	  the	  serum.	  It	  is	  released	  from	  cytoplasmic	  
stores	  where	  it	  is	  important	  in	  mediating	  the	  interaction	  and	  binding	  of	  lymphocytes	  to	  the	  
endothelium.	  VAP-­‐1	  expression	  increased	  with	  chronic	  inflammation	  in	  the	  vessels	  of	  tonsils,	  
gut,	  skin	  and	  synovium.	  	  
Soluble	  VAP-­‐1	  is	  generated	  by	  the	  cleavage	  of	  membrane	  bound	  protein	  from	  the	  surface	  of	  
endothelial	  cells	  and	  adipocytes.	  Circulating	  VAP-­‐1	  accounts	  for	  most	  of	  the	  amine	  oxidase	  
activity	  in	  both	  humans	  and	  mice.	  Its	  role	  is	  uncertain,	  but	  it	  has	  been	  shown	  to	  be	  elevated	  
in	   certain	   liver	   diseases,	   particularly	   in	   patients	   with	   alcoholic	   liver	   disease	   (Jeff’s	  
16/17).(Weston	  and	  Adams,	  2011)	  
The	   concentrations	   of	   VAP-­‐1	  measured	  by	   Enzyme-­‐linked	   immunosorbent	   assay	   (ELISA)	   in	  
healthy	   individuals	   were	   found	   to	   be	   between	   49-­‐138	   ng/mL(Kurkijärvi	   et	   al.,	   1998).	   The	  
difference	   of	   sVAP-­‐1	   concentrations	   between	   the	   liver	   patient	   group	   and	   normal	   controls	  
was	   statistically	   highly	   significant	   (p,	   0.0001).	   Moreover,	   when	   comparisons	   were	   made	  
according	   to	   the	   nature	   of	   the	   liver	   disease,	   differences	   within	   the	   liver	   disease	   group	  
became	  apparent.	  The	  highest	  values	  of	  circulating	  soluble	  VAP-­‐1	  was	  found	  in	  patients	  with	  
active	   cirrhosis	   due	   to	   ALD	   but	   not	   in	   those	   with	   acute	   liver	   damage	   from	   paracetamol	  
poisoning.	   Thus,	   increased	   circulating	   levels	   of	   soluble	   VAP-­‐1	   are	   associated	   with	   chronic	  





VAP-­‐1	  activity	  rather	  than	  total	  VAP-­‐1	  level	  is	  also	  elevated	  in	  certain	  disease	  conditions	  such	  
as	   diabetic	   atheroscelrosis(Magyar	   and	   Meszaros,	   2003).	   However,	   when	   the	   vessels	   are	  
homogenised	  and	  tissue	  activity	  is	  assessed,	  there	  was	  an	  inverse	  correlation	  with	  elevated	  
serum	  levels	  and	  decreased	  tissue	  levels	  (Nunes	  et	  al.,	  2010b).	  In	  liver	  tissue	  work	  in	  our	  lab	  
has	   shown	   that	   serum	  VAP-­‐1	  activity	   correlates	  well	  with	   total	   serum	  VAP-­‐1(Trivedi	  et	  al.,	  
2013).	  PSC	  was	  also	  noted	  to	  have	  higher	  levels	  of	  tissue	  VAP-­‐1	  activity	  compared	  to	  other	  
diseases	  such	  as	  PBC	  or	  AIH.	  
 
4.2.5 Profibrotic	  growth	  factors	  
4.2.5.1 Fibroblast	  growth	  factor	  basic	  (FGFb)	  	  
FGFb	  is	  present	  in	  basement	  membranes	  and	  sub-­‐endothelial	  matrix	  of	  blood	  vessels.	  During	  
wound	  healing	  and	  tumour	   formation,	  heparan	  sulphate	  degrading	  enzymes	  activate	  FGFb	  
leading	  to	  angiogenesis(Rusnati	  and	  Presta,	  1996).	  Elevated	   levels	  of	  basic	  FGF	  are	  seen	   in	  
chronic	   liver	   disuse(Jin-­‐no	   et	   al.,	   1997).	   Very	   high	   levels	   were	   seen	   in	   hepatocellular	  
carcinoma	  (HCC)	  patients	  (see	  below),	  however	  its	  use	  as	  a	  marker	  for	  HCC	  is	  limited	  due	  to	  
lack	   of	   specificity	   and	   also	   that	   in	   healthy	   patients,	   co-­‐existent	   acute	   illness	   significantly	  
raises	  FGF(Hsu	  et	  al.,	  1997).	  
 
4.2.5.2 Vascular	  endothelial	  growth	  factor	  (VEGF)	  
This	   growth	   factor	   promotes	   angiogenesis	   and	   is	   produced	  by	   hepatocytes	   in	   response	   to	  
tissue	  injury	  when	  it	  is	  associated	  with	  proliferation	  of	  endothelial	  cells	  and	  elevated	  levels	  





In	  humans,	  elevated	  levels	  of	  VEGF	  are	  observed	  in	  acute	  hepatitis	  and	  levels	  correlate	  with	  
rises	  in	  transaminases	  (Akiyoshi	  et	  al.,	  1998),	  but	  VEGF	  levels	  are	  reduced	  in	  cirrhotics	  with	  
mean	   levels	   (see	   below)	   of	   63	   ng/l	   in	   cirrhotics,	   360	   in	   controls	   and	   1123	   in	   acute	  
hepatitis(Assy	  et	  al.,	  1999).	  Within	  cirrhotics	  however,	  there	  was	  no	  difference	  in	  levels	  seen	  
depending	  on	  Childs	  score.	  
 
4.2.5.3 Serpin	  E1	  
Serpin	  E1,	  also	  known	  as	  PAI-­‐1	  is	  a	  serine	  protease	  inhibitor	  that	  inhibits	  tissue	  plasminogen	  
activator	  (tPA)	  and	  urokinase.	  These	  are	  the	  principal	  activators	  of	  plasminognen	  and	  hence	  
fibrinolysis.	  It	  is	  an	  acute	  phase	  protein	  that	  can	  be	  induced	  during	  inflammation(Bergheim	  
et	   al.,	   2006).	   PAI-­‐1	   is	   known	   to	   be	   induced	   in	   models	   of	   hepatic	   fibrosis	   and	   is	   directly	  
produced	  by	  stellate	  calls	  when	  activated	   in	  vitro(Leyland	  et	  al.,	  1996).	   	   In	  a	  model	  of	  bile	  
duct	  ligation	  in	  PAI-­‐1	  knockout	  mice,	  significant	  protection	  against	  accumulation	  of	  ECM	  was	  
seen.	   Alongside	   the	   increased	   expression	   of	   activated	   stellate	   cells	   and	   collagen	   synthesis	  
seen	  with	   the	   injury,	   there	  was	   increased	   activity	   of	   tPA.	   This	   suggests	   that	   PAI-­‐1	   plays	   a	  
causal	  role	  in	  fibrosis	  during	  cholestasis.	  This	  is	  largely	  due	  to	  activation	  of	  tPA-­‐induced	  HGF,	  
which	  is	  a	  known	  antifibrotic	  agent.	  Elevated	  matrix	  metallopeptidase	  9	  (MMP9)	  were	  seen,	  
along	  with	  increased	  collagen	  degradation(Bergheim	  et	  al.,	  2006,	  Wang	  et	  al.,	  2007).	  
Different	  models	   of	   damage	   have	   however	   shown	   contradictory	   results.	   In	   a	   CCL4	  model,	  
fibrosis	  was	  enhanced	  in	  PAI-­‐1−/−	  mice	  after	  chronic	  CCl4	  administration.	  Indeed,	  all	   indices	  
of	  liver	  damage	  were	  elevated	  in	  PAI-­‐1−/−	  mice	  compared	  with	  wild-­‐type	  mice.	  This	  enhanced	  
liver	  damage	  correlated	  with	  impaired	  hepatocyte	  proliferation.	  These	  data	  suggest	  that	  PAI-­‐





mediated	   by	   its	   influence	   on	   inflammation	   and	   fibrosis	   or	   helping	   maintain	   hepatocyte	  
division	  after	  an	  injury.	  (von	  Montfort	  et	  al.,	  2010)	  
Levels	   of	   PAI-­‐1	   in	   humans	   are	   noted	   to	   be	   lower	   in	   patients	   with	   obesity	   (10.63	   ±4.82)	  
compared	  to	  controls	  (14.26	  ±11.4)(Espino	  et	  al.,	  2011)in	  a	  small	  group	  of	  Hispanic	  patients	  
and	  that	  there	  was	  no	  difference	  in	  plasma	  levels	  amongst	  obese	  patients	  with	  liver	  fibrosis	  
compared	  to	  those	  without	  fibrosis.	  
 
4.2.5.4 Hepatocyte	  growth	  factor	  (HGF)	  
HGF	   plays	   an	   important	   role	   in	   hepatic	   regeneration	   and	   is	   increased	   in	   liver	   injury.	   It	   is	  
expressed	  in	  non-­‐parenchymal	   liver	  cells	  such	  as	  endothelial	  and	  Kupffer	  cells	  and	  in	  other	  
organs	   including	   the	   lungs	   and	   kidneys(Maher,	   1993).	   It	   is	  mainly	   eliminated	   via	   the	   liver.	  
Serum	   HGF	   is	   elevated	   in	   most	   types	   of	   liver	   disease	   and	   correlates	   with	   inflammatory	  
activity	  in	  chronic	  hepatitis.in	  cirrhotic	  patients	  those	  with	  Childs	  C	  disease	  have	  significantly	  
higher	  levels	  than	  patients	  who	  are	  Childs	  A	  or	  (Shiota	  et	  al.,	  1995).	  	  	  	  
HGF	  has	  also	  been	   shown	   in	   two	  HCV	  cohorts	   to	  be	   correlated	  with	   fibrosis	   stage.(Marin-­‐
Serrano	  et	  al.,	  2010,	   Imbert-­‐Bismut	  et	  al.,	  2001).	  These	  findings	  contrast	  with	  TGFB1	  lower	  
levels	  of	  which	  are	  seen	  as	  fibrosis	  stage	  increases.	  
 
4.2.6 Other	  markers	  of	  immune	  activation	  
4.2.6.1 Monoclonal	  immunoglobulin	  serum	  free	  light	  chains	  (FLC)	  	  
Serum	  FLCs	  are	  comprised	  of	  kappa	  (κ)	  and	  lambda	  (λ)	  light	  chains	  are	  elevated	  in	  many	  B-­‐
cell	   dyscrasias,	   including	  multiple	  myeloma,	   AL	   amyloidosis	   and	   patients	  with	  monoclonal	  





Abnormal	   FLC	   ratios	   have	   also	   been	   described	   in	   patients	   with	   chronic	   lymphocytic	  
leukaemia	  and	  non-­‐Hodgkin’s	  lymphoma(Martin	  et	  al.,	  2007).	  Increased	  concentrations	  of	  κ	  
and	   λ	   FLCs	   can	   result	   from	   reduced	   clearance	   by	   the	   kidneys	   or	   increased	   polyclonal	  
production	  by	  plasma	  B	  cells.	  Polyclonal	  elevations	  of	  FLCs	  have	  been	  reported	  in	  a	  number	  
of	   autoimmune	   diseases	   including	   systemic	   lupus	   erythematosus	   (Aggarwal	   et	   al.,	   2011),	  
Sjögren’s	  syndrome(Gottenberg	  et	  al.,	  2007)	  as	  well	  as	  in	  HIV	  and	  lymphoma(Landgren	  et	  al.,	  
2010).	  Abnormal	  B-­‐cell	  activation	   is	  also	  observed	   in	  autoimmune	   liver	  diseases,	  shown	  by	  
the	   emergence	   of	   autoantibodies	   and	   high	   levels	   of	   immunoglobulins	   detected	   in	   many	  
chronic	  liver	  diseases(Zeman	  and	  Hirschfield,	  2010).	  
In	  addition,	  aberrant	  B	  cell	  function	  is	  observed	  in	  chronic	  HCV	  infection	  where	  persistence	  
of	   the	   virus	   leads	   to	   chronic	   stimulation	   of	   B	   cells	   resulting	   in	   the	   production	   of	  
autoantibodies.	   In	   some	   patients,	   this	   can	   lead	   to	   malignant	   transformation	   of	   B	   cells	  
resulting	   in	   lymphoma	   development.	  Monitoring	   FLC	   levels	   in	   such	   individuals	  may	   prove	  
clinically	   useful	   if	   abnormalities	   in	   FLC	   expression	   define	   individuals	   pre-­‐disposed	   to	  
lymphoma	  formation.	  
FLCs	  are	  normally	  metabolised	  and	  filtered	  by	  the	  kidneys,	  however,	   immunoglobulins	  and	  
FLCs	   are	   excessively	   produced	   in	   patients	  with	  B	   cell	   dyscrasias,	   and	  many	  patients	   suffer	  
kidney	  dysfunction,	   leading	   to	   significant	   impairment	   in	   the	   removal	  of	   these	  FLCs.	  Kidney	  
dysfunction	   is	   also	   associated	  with	   liver	   disease.	   For	   example,	   the	   key	   pathophysiological	  
hallmark	   of	   hepatorenal	   syndrome,	   which	   occurs	   in	   patients	   with	   advanced	   chronic	   liver	  






Furthermore,	   acute	   renal	   failure	   is	   a	   common	   complicating	   factor	   in	   patients	   with	   liver	  
cirrhosis.	  These	  abnormalities	   in	  kidney	  function	  are	  likely	  to	  impact	  on	  the	  concentrations	  
of	   FLCs	   in	   liver	   disease.	   A	   preliminary	   study	   has	   shown	   that	   FLCs	   are	   elevated	   in	   patients	  
with	  chronic	  liver	  disease(Assi	  et	  al.,	  2010)	  hence	  the	  need	  to	  collect	  samples	  from	  a	  larger	  
population	  to	  determine	  the	  potential	  diagnostic	  and	  prognostic	  utility	  of	  FLC	  measurements	  
















4.3.1 Study	  Population	  
All	   patients	   referred	   for	   an	   outpatient	   liver	   biopsy	   between	   September	   20111	   and	   2012	  
were	   identified	   using	   the	   NHS	   pre-­‐admission	   clinics	   booking	   list.	   Patients	   were	   sent	   an	  
information	   sheet	   through	   the	   post	   and	   then	   consented	   at	   the	   clinic	   appointment.	   This	  
appointment	   was	   usually	   2-­‐3	   days	   prior	   to	   the	   biopsy	   having	   taken	   place	   and	   allowed	   a	  
nursing	  checklist	  to	  be	  taken	  along	  with	  blood	  tests	  and	  observations.	  If	  patients	  consented	  
to	  take	  part	  in	  the	  study,	  they	  underwent	  a	  physical	  examination	  and	  Fibroscan.	  
Local	  ethical	  approval	  was	  obtained	  	  
Appendix	   1	   contains	   copies	   of	   all	   of	   the	   relevant	   study	  materials	   such	   as	   consent	   forms,	  
patient	  information	  sheets,	  General	  Practitioner	  letters	  and	  ethical	  approval	  letters.	  
 
4.3.2 Data	  collection	  
Demographics,	  anthropometric	  measurements	  and	  observations	  were	  recorded	  at	  the	  clinic	  
visit	  along	  with	  TE	  measurements.	  For	  TE,	  the	  probe	  type,	  number	  of	  successful	  acquisitions,	  
success	   rate	   and	   interquartile	   range	   (IQR)	   were	   recorded.	   If	   the	   patient	   had	   had	   a	   valid	  




In	  our	  unit,	   all	  operators	  underwent	  a	   certified	   training	   session	   (4	  hour)	  with	  an	  Echosens	  





certification,	   the	  operators	  performed	  3	  TE	  examinations	  on	  volunteers	  with	   the	  Echosens	  
consultant	  in	  attendance	  to	  determine	  if	  the	  application	  of	  the	  TE	  probe	  and	  interpretation	  
of	  the	  LSM	  were	  correct.	  
TE	   was	   performed	   using	   either	   the	   M-­‐probe	   (3.5	   Hz	   frequency)	   or	   XL-­‐probe	   (2.5	   Hz	  
frequency)	   with	   the	   Fibroscan®	   502	   machine	   (Echosens,	   France).	   The	   manufacturer	  
recommends	  that	  the	  XL	  probe	  should	  be	  used	  in	  patients	  with	  a	  skin-­‐capsular	  distance	  >2.5	  
cm	  (measured	  by	  sonographic	  imaging).	  Due	  to	  the	  time	  constraints	  in	  liver	  clinic,	  operators	  
were	  advised	  to	  use	  the	  XL-­‐probe	  in	  patients	  with	  a	  measured	  BMI	  >	  30	  Kg/m2	  (Myers	  et	  al.,	  
2012)	   the	   Fibroscan®	   502	   Touch	   (Echosens,	   France),	   which	   has	   a	   built-­‐in	   automated	  
indicator	   that	   recommends	   the	   probe	   best	   suited	   to	   the	   patient’s	   morphology.	   In	  
accordance	  with	  manufacturer’s	  guidance,	  all	  TE	  examinations	  are	  performed	  in	  our	  clinics	  
with	  the	  patient	  lying	  in	  the	  dorsal	  decubitus	  position	  with	  the	  right	  arm	  extended.	  The	  tip	  of	  
the	  transducer	  probe	  (covered	  with	  coupling	  gel)	  is	  placed	  on	  the	  skin	  in	  an	  intercostal	  space	  
overlying	  the	  right	  lobe	  of	  the	  liver.	  A	  time-­‐motion	  ultrasound	  image	  allows	  the	  operator	  to	  
locate	  a	  portion	  of	   liver	  at	   least	  6-­‐cm	  thick	  and	  free	  of	   large	  vascular/bony	  structures.	  The	  
median	  value	  of	  successful	  acquisitions	  (target	  =	  10)	  is	  deemed	  to	  be	  representative	  of	  the	  
liver	  stiffness,	   represented	  as	  LSM.	   If	  no	  value	  was	  obtained	  following	  10	  acquisitions	  LSM	  
failure	  was	  documented.	  LSM	  was	  only	  classified	  as	  ‘valid’	  if	  all	  three	  of	  the	  manufacturer’s	  
criteria(Castéra	  et	  al.,	  2010a)	  were	  met:	  1)	  ≥10	  successful	  acquisitions;	  2)	  success	  rate	  was	  
≥60%;	  and	  3)	   IQR/M	   ratio	  <30%.	   If	   any	  of	   these	   three	   criteria	  were	  not	  met	   the	   LSM	  was	  






4.3.4 Liver	  Biopsy	  Assessment	  
In	   our	   centre,	   liver	   biopsies	   are	   routinely	   reported	   using	   the	   appropriate	   disease-­‐specific	  
liver	   fibrosis	  staging	   (i.e.	   Ishak	   for	  hepatitis	  C;	  Kleiner	   for	  non-­‐alcoholic	   fatty	   liver	  disease).	  
For	  purposes	  of	  this	  study,	  however,	  each	  biopsy	  was	  re-­‐assessed	  independently	  by	  two	  liver	  
pathologists	  (NM	  &	  RB	  or	  NM	  &	  SH)	  without	  knowledge	  of	  LSM	  results	  or	  other	  clinical	  data.	  
In	  cases	  of	  disagreement,	  a	  consensus	  was	  reached	  by	  a	  joint	  review.	  To	  take	  account	  of	  the	  
diverse	  aetiologies	  of	  liver	  disease,	  liver	  fibrosis	  was	  staged	  using	  a	  modified	  version	  of	  the	  
Ishak	   scoring	   system(Ishak	   et	   al.,	   1995),	   as	   previously	   described	   (Rosenberg	   et	   al.,	   2004).	  
Significant	   fibrosis	   was	   defined	   as	   a	   modified	   Ishak	   score	   >	   2	   and	   advanced	   fibrosis	   as	   a	  
modified	   Ishak	   score	  of	  5	  or	  6.	   The	   length	  of	  biopsy	   specimens	  and	   the	  number of portal 
tracts sampled were recorded as measures of biopsy quality. 
 
4.3.5 Blood	  tests	  
Routine	   clinically	   indicated	   blood	   tests	   including	   full	   blood	   count,	   clotting	   screen	   and	   a	  
biochemical	   profile	  were	   taken	   once	   consent	   had	   been	   obtained	   and	   sent	   to	   the	   hospital	  
laboratory	  for	  processing	  and	  analysis.	  
Blood	   for	   the	   Fibromax	   testing	   were	   packed	   unprocessed	   in	   a	   biohazard	   labelled	   box	  
provided	  by	  the	  company	  and	  posted	  the	  same	  day.	  
The	  research	  blood	  vials	  were	  taken	  to	  the	  University	  of	  Birmingham	  (institute	  of	  Biomedical	  
Research)	   and	   processed	   in	   the	   good	   clinical	   laboratory	   practice	   (GCLP)	   lab	   by	   lab	  
technicians.	   Serum	  was	   obtained	   after	   a	   10	  min	   2700RCF	   spin	   and	   frozen	   to	   -­‐80	   degrees	  
Celsius	  immediately.	  Plasma	  and	  white	  cells	  were	  obtained	  using	  a	  lymphoprep	  gradient	  to	  





but	  with	  no	  centrifuge	  braking.	  Cells	  were	  pipetted	  off	  and	  stored	   in	  foetal	  calf	  serum	  and	  
dimethyl	  sulphoxide	  (DMSO).	  Suspended	  cells	  were	  then	  transferred	  to	  a	  Mr	  Frosty	  freezing	  
container	   to	   allow	   gradual	   reduction	   to	   -­‐80	   degrees	   Celsius	   over	   a	   24	   hours	   period.	   Cells	  
were	   then	   transferred	   to	   a	   liquid	   nitrogen	   container	   and	   stored	   in	   the	   vapour	   phase	   for	  
future	  use	  as	  required.	  	  
 
4.3.5.1 Enzyme-­‐linked	  immunosorbent	  assay	  (ELISA)	  testing	  done	  in	  laboratory	  at	  University	  
of	  Birmingham	  
Serum	  ELISAs	  were	  performed	  according	   to	  manufacturers	  guidelines	   (R&D,	  Mercodia	  and	  
Peviva).	   Peviva	   produce	   the	   CK18	   (M30	   and	   M65)	   assays.	   Merdodia	   produce	   the	   Insulin	  
assay	  and	  R&D	  manufactured	  the	  multiplex	  kits	  that	  all	  the	  other	  markers	  were	  analysed	  for.	  
Serum	  VAP-­‐1	  was	  sent	  to	  two	  labs	  with	  whom	  we	  have	  long-­‐standing	  collaborations:	  Biotie	  
is	  a	  Finnish	  biotech	  company	  who	  have	  established	  VAP-­‐1	  assays;	  the	  Jalkanen	  lab	  at	  Biocity	  
in	  Turku	  has	  established	  assays	  of	  VAP-­‐1	  and	  its	  SSAO	  enzyme	  activity(Kurkijärvi	  et	  al.,	  1998)	  
 
4.3.6 Collagen	  Proportionate	  Area	  (CPA)	  
Sections	   of	   each	   biopsy	   were	   stained	   with	   Van	   Gieson	   using	   an	   autostainer	   to	   reduce	  
variability.	   The	   slides	   were	   then	   loaded	   into	   a	   Leica	   SCN-­‐400	   whole	   slide	   scanner.	   After	  
whole	  section	  digital	  image	  capture	  (Figure	  4-­‐1),	  CPA	  was	  measured	  with	  Image	  J	  software.	  
CPA	   measurement	   included	   steps	   to	   eliminate	   artefacts	   and	   structural	   collagen	   in	   large	  
portal	   tracts	   and	   blood	   vessel	   walls.	   Unfilled	   spaces	   such	   as	   vascular	   cavities	   were	   not	  
included	  in	  the	  measurements(Calvaruso	  et	  al.,	  2009).	  The	  slides	  had	  been	  scanned	  at	  20x	  so	  





magnification	  giving	  a	  scale	  of	  100um/cm	  Closer	  zooming	  gave	  better	   images	  but	  required	  
much	  more	  time	  input.	  Slides	  at	  lower	  magnifications	  were	  felt	  to	  not	  provide	  enough	  detail.	  
	  
Figure	  4-­‐1	  Van	  Gieson	  stained	  liver	  biopsy	  slide	  
	  
	  
A	   very	  high	  definition	  monitor	   (2560x1440)	  was	  used	   for	   this	  process	   to	  ensure	   the	   slides	  
were	  split	  as	  few	  times	  as	  possible.	  	  Once	  the	  area	  of	  slide	  containing	  biopsy	  was	  highlighted,	  








Figure	  4-­‐2	  Stained	  slide	  after	  exterior	  cleared	  using	  Image	  J	  software	  
	  
	  
After	  clearing	  around	  the	  biopsy	  slide	  (Figure	  4-­‐2),	  the	  image	  was	  adjusted	  using	  the	  Image	  J	  
tool	  (Hue,	  Saturation	  and	  Brightness)	  to	  ensure	  that	  the	  Van	  Gieson	  staining	  was	  highlighted	  
only.	   Settings	   used	   were:	   Hue	   166-­‐255,	   Saturation	   70-­‐255	   and	   Brightness	   0-­‐223.	   These	  
settings	  were	  performed	  on	  a	  selection	  of	  biopsies	  across	  the	  Ishak	  stages	  to	  ensure	  the	  best	  
all	  round	  result	  and	  were	  checked	  by	  two	  authors	  (MJA	  and	  SH).	  This	  process	  highlighted	  the	  
fact	   that	   some	   biopsies	   from	   patients	   with	   advanced	   disease	   had	   lower	   than	   expected	  
results	  and	   some	  normal	  biopsies	  appeared	  more	  diseased	   than	  anticipated,	   so	  each	   slide	  
was	   treated	  using	   the	   same	  cut-­‐offs	  as	  well	   as	  personalized	  ones	   to	  allow	   investigation	  of	  
differing	  methodology.	  The	  eventual	  analysis	  of	  slides	  was	  done	  blinded	  to	  the	  Ishak	  stage	  to	  







Figure	  4-­‐3	  Slide	  after	  pixels	  highlighted	  using	  Image	  J	  software	  
	  
Using	  Image	  J	  in	  the	  selected	  section,	  we	  highlighted	  pixels	  in	  red	  using	  the	  above	  settings.	  
They	  were	  then	  selected	  using	  the	  tool	  and	  measured	  giving	  a	  percentage	  value.	  	  
 
 
Figure	  4-­‐4	  Highlighted	  pixels	  now	  selected	  using	  Image	  J	  software	  
	  
The	   whole	   of	   the	   biopsy	   would	   very	   often	   not	   be	   fitted	   on	   the	   screen	   so	   values	   were	  





Once	  the	  Image	  J	  macro	  had	  been	  run,	  the	  resultant	  number	  of	  pixels	  was	  noted	  and	  divided	  
by	  the	  earlier	  total	  to	  give	  a	  %	  area. 
 
4.3.7 VAP-­‐1	  staining	  
A	  selection	  of	  slides	   from	  across	   the	  spectrum	  of	   Ishak	  stages	  were	  also	  stained	  for	  VAP-­‐1	  
(Figure	  4-­‐5)	  in	  the	  lab	  and	  analysed	  using	  the	  same	  method.	  Samples	  were	  fixed	  in	  formalin	  
and	   processed	   through	   to	   paraffin	   wax.	   Tissues	   were	   deparaffinised	   and	   rehydrated	   to	  
water,	  and	  after	  a	   low	  temperature	  retrieval	   technique	   (ALTER)	  were	   immunostained	  on	  a	  
Dako	   Autostainer	   using	   a	   Prestige	   rabbit-­‐anti-­‐human	   VAP-­‐1	   polyclonal	   antibody	   (Sigma,	  










4.3.8 FLC	  and	  Cystatin	  C	  
Combylite	   is	   a	   new	  kit	   produced	  by	   a	   company	   called	   The	  Binding	   Site	   that	  measures	   the	  
total	  concentrations	  of	  free	  kappa	  and	  free	   lambda	  light	  chains	  (FLC)	   in	  a	  single	  assay,	  and	  
gives	  equivalent	  values	  to	  summated	  results	  from	  the	  Freelite	  kappa	  and	  lambda	  assays.	  The	  
Freelite	  assay	  has	  been	  manufactured	   for	  over	  12	  years	  now	  and	  this	  measures	   the	  kappa	  
and	   lambda	   concentrations	   separately.	   Freelite	  was	   run	   to	   determine	   if	   there	  may	   be	   an	  
underlying	  monoclonal	   gammopathy	   in	   any	   of	   the	   Combylite	   high	   samples.	   Samples	  were	  
analysed	   in	   the	  Binding	  Site	   laboratory	   in	  Birmingham	  where	   they	  were	  compared	  against	  
healthy	  controls	  previously	  assessed	  in	  their	  lab.	  
 
 
4.3.9 Statistical	  analysis	  
Data	   were	   analysed	   using	   IBM	   SPSS	   19,	   Graph	   pad	   Prism	   V5	   and	  Microsoft	   excel	   with	   p	  
values	  less	  than	  0.05	  deemed	  to	  be	  indicative	  of	  significance.	  Data	  were	  expressed	  as	  mean	  
±	   SEM	  or	  median	   ±SD	  unless	   stated	   otherwise.	   AUROC	   analysis	  was	   used	   to	   illustrate	   the	  








127	  patients	  were	  sent	  information	  sheets.	  Of	  these,	  40	  patients	  either	  declined	  to	  take	  part	  
or	  did	  not	  turn	  up	  to	  the	  clinic	  slot.	  87	  patients	  were	  therefore	  consented	  to	  take	  part	  in	  the	  
study.	   2	   patients	   then	   did	   not	   proceed	   to	   biopsy	   –	   one	  was	   taking	   aspirin	   and	   the	   other	  
decided	  against	  biopsy.	  	  Final	  statistics	  were	  therefore	  performed	  on	  85	  patients.	  (43	  male,	  
42	  female)	  with	  a	  median	  age	  of	  54.	  Median	  BMI	  was	  30±7.	  Median	  waist	  to	  hip	  ratio	  was	  
0.989±0.17.	  Median	  time	  from	  being	  seen	  to	  biopsy	  was	  2±4.7	  days.	  
 
4.4.2 Fibroscan	  
The	  median	  time	  from	  Fibroscan	  to	  biopsy	  was	  2±27	  days.	   	  Fibroscan	  was	  performed	  in	  77	  
patients	  with	  a	  median	  stiffness	  of	  11kPa	   (IQR	  13.1).	  8	  patients	  had	  a	   failed	  Fibroscan	   (no	  
successful	  readings).	  There	  was	  a	  mean	  success	  rate	  of	  87%	  ±2.8.	  The	  M	  probe	  was	  used	  in	  
31	   cases	   and	   the	   XL	   in	   the	   other	   46	   cases.	   Median	   stiffness	   was	   11.4	   kPa	   ±12.4	   with	   a	  
median	  IQR	  value	  of	  2.6±5.4.	  Median	  IQR	  as	  percentage	  of	  median	  was	  22%±21.	  
A	  valid	  scan	  was	  generated	  if	  success	  rate	  was	  >60%,	  IQR/median	  <30%	  and	  ≥10	  successful	  
readings.	  45	  of	   the	  77	   (58%)	  were	  valid.	   	  Where	  valid	  only	   readings	  are	  used,	   the	  median	  









4.4.3 Blood	  and	  Histology	  results	  
The	  median	  ±SD	  value	  for	  the	  blood	  results	  are	  displayed	  in	  table	  4-­‐2.	  
Haematology	   Chemistry	   Liver	  
Hb	   13.8±1.3	   Na	   141±2.6	   AST	   38±49	  
WCC	   6.5±2.1	   K	   4.2±0.35	   ALT	   53±82	  
Plt	   201±66	   Ur	   5±1.4	   ALP	  (old)	   199	  ±107	  
INR	   1±0.07	   Cr	   70±16.8	   ALP	  (new)	   99±109	  
	   	   Gluc	   5.5±5	   Alb	   45±3.7	  
	   	   	   	   Bili	   9±43	  
	   	   	   	   AFP	   3±1.9	  
	   	   	   	   GGT	   53±108	  
Table	  4-­‐2	  Blood	  results	  
 
Distribution	  of	  histological	  grade	  is	  displayed	  in	  figure	  4-­‐6.	  
Median	  Ishak	  stage	  was	  2±1.79	  and	  median	  biopsy	  length	  was	  23.5cm±6.6.	  
 







Over	  half	  of	   the	  patients	  who	  underwent	  biopsy	  had	  a	  diagnosis	  of	   fatty	   liver.	  Results	  are	  
presented	  in	  table	  4-­‐3.	  
 
Diagnosis	   N	   Percent	  
Viral	  liver	  disease	   15	   17.7	  
Fatty	  liver	   45	   52.9	  
Autoimmune	   13	   15.3	  
PSC	   1	   1.2	  
Others	   11	   12.9	  
Table	  4-­‐3	  Aetiology	  of	  liver	  disease	  
 
 
Correlations	   between	   Ishak	   stage	   and	   variables	   assessed	   are	   shown	   in	   tables	   4-­‐4	   and	   4-­‐5	  
with	  table	  4-­‐5	  being	  a	  subgroup	  analysis	  for	  the	  largest	  cohort	  with	  was	  fatty	  liver	  disease.	  

















Variable	   Spearman	  Correlation	   Significance	   N	  if	  <85	  
BMI	   0.068	   0.534	   	  
Waist:	  Hip	   0.172	   0.116	   	  
FS	  Stiffness	  valid	   0.375	   0.011	   45	  
FS	  Stiffness	  all	   0.240	   	   0.035	   77	  
Platelets	   -­‐0.355	   0.001	   	  
INR	   0.140	   0.200	   	  
Alb	   -­‐0.221	   0.042	   	  
Bili	   0.059	   0.593	   	  
CK18	  M30	   0.155	   0.158	   	  
VAP-­‐1	  Biotie	   0.388	   <0.0001	   	  
VAP-­‐1	  Turku	   0.350	   0.001	   	  
ELF	   	   0.470	   <0.0001	   	  
Hyalauronic	  Acid	   0.476	   <0.0001	   	  
P3NP	   0.250	   0.021	   	  
TIMP1	   0.204	   0.061	   	  
Combilyte	   0.263	   0.015	   	  
VEGF	   0.086	   0.433	   	  
TNF-­‐A	   0.299	   0.005	   	  
Il-­‐10	   0.150	   0.171	   	  
Il-­‐6	   0.079	   0.472	   	  
IFN-­‐G	   0.005	   0.965	   	  
FGFB	   0.034	   0.760	   	  
MCP1	   0.194	   0.076	   	  
RANTES	   -­‐0.216	   0.047	   	  
Leptin	   0.009	   0.936	   	  
Adiponectin	   0.128	   0.244	   	  
Resistin	   0.127	   0.248	   	  
Serpin	   -­‐0.050	   0.648	   	  
HGF	   0.125	   0.256	   	  
CXCL11	   0.219	   0.044	   	  
CD40L	   0.004	   0.970	   	  
CXCL10	   0.388	   <0.001	   	  
Alpha2	  Macroglobulin	   0.531	   <0.001	   77	  
Haptoglobin	   -­‐0.213	   0.069	   74	  
Apolipoprotein	  A1	   -­‐0.158	   0.170	   77	  
Total	  Chol	   -­‐0.174	   0.124	   79	  
Triglyceride	   -­‐0.024	   0.830	   	  
VAP-­‐1	  &	  CXCL10	  	   	  0.480	   <0.0001	   	  
Table	   4-­‐4	   Correlations	   between	   Ishak	   stage	   and	   variables	   for	   all	   patients-­‐	   VAP-­‐1	   and	  
CXCL10	  predicted	  results	  from	  regression	  analysis	  






Variable	   Spearman	  Correlation	   Significance	   N	  if	  <45	  
BMI	   0.006	   0.967	   	  
Waist:	  Hip	   0.237	   0.116	   	  
FS	  Stiffness	  valid	   0.425	   0.043	   23	  
FS	  Stiffness	  all	   0.173	   0.268	   43	  
Platelets	   -­‐0.520	   <0.0001	   	  
INR	   0.282	   0.061	   	  
Alb	   -­‐0.080	   0.601	   	  
Bili	   0.279	   0.063	   	  
CK18	  M30	   0.297	   0.047	   	  
VAP-­‐1	  Biotie	   0.557	   <0.0001	   	  
VAP-­‐1	  Turku	   0.559	   <0.0001	   	  
ELF	   0.591	   <0.0001	   	  
Hyalauronic	  Acid	   0.591	   <0.0001	   	  
P3NP	   0.265	   0.078	   	  
TIMP1	   0.099	   0.516	   	  
Combilyte	   0.337	   0.024	   	  
VEGF	   -­‐0.080	   0.603	   	  
TNF-­‐A	   0.236	   0.118	   	  
Il-­‐10	   0.196	   0.198	   	  
Il-­‐6	   0.121	   0.427	   	  
IFN-­‐G	   -­‐0.055	   0.719	   	  
FGFB	   0.040	   0.792	   	  
MCP1	   0.050	   0.746	   	  
RANTES	   -­‐0.308	   0.039	   	  
Leptin	   -­‐0.053	   0.729	   	  
Adiponectin	   0.001	   0.994	   	  
Resistin	   0.007	   0.964	   	  
Serpin	   -­‐0.302	   0.044	   	  
HGF	   0.038	   0.806	   	  
CXCL11	   0.150	   0.324	   	  
CD40L	   -­‐0.087	   0.572	   	  
CXCL10	   0.352	   0.018	   	  
Fibrotest	   0.604	   <0.0001	   39	  
Alpha2	  Macroglobulin	   0.568	   <0.0001	   40	  
Haptoglobin	   -­‐0.450	   0.004	   39	  
Apolipoprotein	  A1	   -­‐0.043	   0.794	   40	  
Total	  Chol	   -­‐0.327	   0.034	   42	  
Triglyceride	   -­‐0.173	   0.255	   	  
Table	   4-­‐5	   Sub	   Group	   analysis:	   Correlation	   between	   Ishak	   stage	   and	   test	   for	   Fatty	   liver	  







Variable	   Spearman	  
Correlation	  
Significance	   N	  if	  <85	  
Forns	   0.364	   0.004	   61	  
Fib4	   0.411	   <0.0001	   82	  
APRI	   0.299	   0.006	   82	  
AST:ALT	   0.200	   0.072	   82	  
Hepascore	   0.543	   <0.0001	   59	  
Fibrotest	   0.510	   <0.0001	   75	  
ELF	   0.470	   <0.0001	   	  
MELD	   -­‐0.134	   0.220	   	  
Table	  4-­‐6	  Correlations	  between	  Ishak	  stage	  and	  computed	  scores	  for	  all	  patients	  
 
A	   Jonckeere-­‐Terpstra	  analysis	  was	  performed	  which	   looks	   for	   trends	  across	  stages.	  Results	  





Forns	   0.004	   	  
Fib-­‐4	   <0.0001	   3-­‐6	  p=0.04	  
APRI	   0.007	   	  
AST:ALT	   0.079	   	  
Hepascore	   <0.0001	   	  
Fibrotest	   <0.0001	   0-­‐4	  p=0.044	  
1-­‐6	  p=0.026	  
ELF	   <0.0001	   1-­‐5	  p=0.002	  
Fibroscan	   0.011	   	  
CXCL10	   <0.0001	   1-­‐5	  p=0.040	  
VAP-­‐1	  Biotie	   0.001	   1-­‐5	  p=0.021	  
VAP-­‐1	  Turku	   0.002	   	  
Hyalauronic	  acid	   <0.0001	   1-­‐5	  p=0.004	  
1-­‐6	  p=0.023	  
P3NP	   0.020	   1-­‐4	  p=0.021	  
TIMP1	   0.064	   	  




Haptoglobin	   0.054	   	  
Apolipoprotein	  A1	   0.177	   	  







4.4.4 Histograms	   to	   illustrate	  median	   ±SD	   of	  markers	  with	   pairwise	   significance	   added	  
where	  present	  
	  




















Figure	  4-­‐8	  Fib-­‐4	  vs.	  Ishak	  fibrosis	  stage	  showing	  distribution	  of	  Fib-­‐4	  readings	  according	  to	  
fibrosis	  stage.	  Pairwise	  significance	  seen	  between	  F3	  and	  F6	  
	  
 







































Figure	  4-­‐10	  Hepascore	  vs.	  Ishak	  fibrosis	  stage	  showing	  distribution	  of	  Hepascore	  readings	  
according	  to	  fibrosis	  stage	  
	  
	  


















Figure	   4-­‐11	   Fibrotest	   vs.	   Ishak	   fibrosis	   stage	   showing	   distribution	   of	   Fibrotest	   readings	  

























Figure	   4-­‐12	   ELF	   readings	   vs.	   Ishak	   fibrosis	   stage	   showing	   distribution	   of	   ELF	   readings	  
according	  to	  fibrosis	  stage.	  Pairwise	  significance	  seen	  between	  F1	  and	  F5	  
	  
















Figure	  4-­‐13	  Fibroscan	  readings	  vs.	  Ishak	  fibrosis	  score	  with	  8kPa	  cut	  off	  plotted	  
 
Analysis	   of	   Fibroscan	   data	   after	   having	   excluded	   the	   invalid	   scans	   reveals	   a	   positive	  
correlation	  between	   increasing	  stiffness	  and	   fibrosis	   stage.	  No	  patient	  with	  cirrhosis	  had	  a	  
value	  <8kPa.	  
 


























Figure	  4-­‐14	  CXCL10	   (pg/ml)	  vs.	   Ishak	   fibrosis	   score	  showing	  distribution	  of	  CXCL10	   levels	  
according	  to	  fibrosis	  stage.	  Pairwise	  significance	  seen	  between	  F1	  and	  F5	  
	  



















Figure	   4-­‐15	   Biotie	   VAP-­‐1	   (ng/ml)	   vs.	   Ishak	   fibrosis	   score	   showing	   distribution	   of	   VAP-­‐1	  
levels	  according	  to	  fibrosis	  stage.	  Pairwise	  significance	  seen	  between	  F1	  and	  F5	  
	  






















Figure	   4-­‐16	   Turku	   VAP-­‐1	   (ng/ml)	   vs.	   Ishak	   fibrosis	   score	   showing	   distribution	   of	   VAP-­‐1	  
levels	  according	  to	  fibrosis	  stage.	  	  
	  






















Figure	   4-­‐17	   Hyalauronic	   Acid	   (ng/ml)	   vs.	   Ishak	   fibrosis	   score	   showing	   distribution	   of	  
hyalauronic	   readings	   according	   to	   fibrosis	   stage.	   Pairwise	   significance	   seen	   between	   F1	  
and	  F5	  /	  F6	  
	  
	  




























Figure	   4-­‐18	   P3NP	   (ng/ml)	   vs.	   Ishak	   fibrosis	   score	   showing	   distribution	   of	   P3NP	   readings	  
according	  to	  fibrosis	  stage.	  Pairwsie	  significance	  seen	  between	  F1	  and	  F4	  
	  
	  





















Figure	   4-­‐19	   Alpha	   2	  Macroglobulin	   (g/l)	   vs.	   Ishak	   fibrosis	   stage	   showing	   distribution	   of	  


































4.4.5 AUROC	  analysis	  
Test	   Ishak	   0	  
vs.	  1-­‐6	  
Ishak	  
0&1	   vs.	  
2-­‐6	  
Ishak	   0-­‐2	  
vs.	  3-­‐6	  
Ishak	   0-­‐3	  
vs.	  4-­‐6	  
Ishak	   0-­‐4	  
vs.	  5-­‐6	  
Ishak	   0-­‐5	  
vs.	  6	  
Forns	   0.578	   0.626	   0.622	   0.741	   0.794	   0.846	  
Fib-­‐4	   0.600	   0.666	   0.681	   0.781	   0.819	   0.842	  
APRI	   0.554	   0.651	   0.634	   0.691	   0.696	   0.714	  
AST:ALT	   0.638	   0.577	   0.617	   0.605	   0.625	   0.561	  
Hepascore	   0.650	   0.761	   0.771	   0.791	   0.796	   0.836	  
ELF	   0.605	   0.750	   0.744	   0.776	   0.794	   0.764	  
Fibrotest	   0.675	   0.703	   0.769	   0.788	   0.759	   0.947	  
VAP-­‐1	  Biotie	   0.640	   0.679	   0.679	   0.783	   0.746	   0.673	  
Vap-­‐1	  Turku	   0.554	   0.650	   0.660	   0.771	   0.765	   0.760	  
CXCL10	   0.575	   0.677	   0.712	   0.718	   0.782	   0.738	  
Alpha	   -­‐2	  
Macroglobulin	  
0.704	   0.728	   0.788	   0.786	   0.719	   0.917	  
Fibroscan	   0.513	   0.667	   0.704	   0.808	   0.821	   0.818	  
VAP-­‐1	   Biotie	   and	  
CXCL10	  
	   	   0.739	   	   	   	  
 
Table	   4-­‐8	   AUROC	   analysis	   for	   various	  markers	   used	   in	   order	   to	   predict	   degrees	   of	   liver	  
fibrosis.	  	  
 
4.4.6 Sensitivity	  and	  Specificity	  
AUROC	  values	  for	  each	  test	  for	  the	  prediction	  of	  cirrhosis	  (F5-­‐6)	  or	  significant	  fibrosis	  (F3-­‐6)	  
were	  generated.	  Using	   the	  coordinates	  of	   the	  AUROC	  curve,	   sensitivities,	   specificities,	  PPV	  










Test	   Cut	  off	   Sens	  	   Spec	   PPV	   NPV	  
Hepascore	  F5-­‐6	  
AUROC	  0.796	  
0.50	   90.9	   45.8	   0.28	   0.96	  
0.60	   90	   58.3	   0.33	   0.96	  
0.80	   81.8	   66.6	   0.36	   0.94	  
Hepascore	  F3-­‐6	  
AUROC	  0.771	  
0.50	   82.8	   60.0	   0.67	   0.78	  
0.60	   72.4	   70.0	   0.67	   0.78	  
0.80	   62.1	   76.7	   0.72	   0.68	  
CXCL10	  F5-­‐6	  
AUROC	  0.782	  
60	   92.9	   54.9	   0.29	   0.98	  
100	   64.3	   77.5	   0.36	   0.92	  
140	   50.0	   90.1	   0.50	   0.90	  
CXCL10	  F3-­‐6	  
AUROC	  0.684	  
60	   71.8	   63.0	   0.62	   0.72	  
100	   43.6	   82.6	   0.68	   0.63	  
140	   25.6	   91.3	   0.71	   0.59	  
VAP-­‐1	  Biotie	  F5-­‐6	  
AUROC	  0.746	  
460	   92.9	   43.7	   0.25	   0.97	  
590	   71.4	   74.6	   0.36	   0.93	  
630	   50.0	   77.5	   0.30	   0.89	  
VAP-­‐1	  Biotie	  F3-­‐6	  
AUROC	  0.679	  
460	   74.4	   47.8	   0.55	   0.69	  
590	   48.7	   80.4	   0.68	   0.65	  
630	   41.0	   84.8	   0.68	   0.65	  
ELF	  F5-­‐6	  
AUROC	  0.794	  
7.7	   100	   1.4	   0.17	   1.00	  
9.8	   85.7	   59.2	   0.29	   0.95	  
12	   14.3	   94.4	   0.33	   0.85	  
ELF	  F3-­‐6	  
AUROC	  0.744	  
7.7	   97.4	   2.2	   0.46	   0.50	  
9.8	   69.2	   69.6	   0.66	   0.73	  
12	   10.3	   97.8	   0.80	   0.56	  
Fib-­‐4	  F5-­‐6	  
AUROC	  0.819	  
1.5	   85.7	   58.8	   0.30	   0.95	  
3.25	   42.9	   92.9	   0.55	   0.89	  
Fib-­‐4	  F3-­‐6	  
AUROC	  0.681	  
1.5	   64.9	   64.4	   0.60	   0.69	  
3.25	   18.9	   91.1	   0.64	   0.58	  
Fibrotest	  F5-­‐6	  
AUROC	  0.759	  
0.32	   81.8	   39.1	   0.19	   0.93	  
0.59	   45.5	   82.8	   0.31	   0.90	  
0.73	   45.5	   89.1	   0.42	   0.90	  
Fibrotest	  F3-­‐6	  
AUROC	  0.769	  
0.32	   82.9	   52.5	   0.60	   0.78	  
0.59	   34.3	   90.0	   0.75	   0.61	  
0.73	   25.7	   92.5	   0.75	   0.59	  
Fibroscan	  F5-­‐6	  
AUROC	  0.821	  
8	   100	   39.5	   0.23	   1.00	  
12.5	   57.1	   84.2	   0.36	   0.91	  
Fibroscan	  F3-­‐6	  
AUROC	  0.704	  
8	   88.9	   48.1	   0.53	   0.87	  
12.5	   33.3	   81.5	   0.55	   0.65	  






4.4.7 Logistic	  Regression	  to	  predict	  fibrosis	  
 
In	  order	  to	  predict	  significant	  fibrosis	  for	  Ishak	  3-­‐6,	  logistic	  regression	  was	  used	  in	  a	  stepwise	  
manner.	   The	   only	   variables	   that	  were	   significant	  were	   VAP-­‐1	   (both	   Biotie	   and	   Turku)	   and	  
CXCL10	   or	   VAP-­‐1	   and	   alpha	   2	  macroglobulin.	   Alpha	   2	  macroglobulin	   was	   analysed	   in	   the	  
presence	  of	  incomplete	  data	  (i.e.	  77).	  Data	  is	  shown	  in	  tables	  4-­‐9	  and	  4-­‐10.	  
This	  incomplete	  number	  means	  that	  there	  will	  be	  less	  power	  to	  detect	  an	  effect.	  The	  reasons	  
for	   lack	   of	   data	   were	   absence	   of	   kits	   available	   and	   samples	   being	   lost	   in	   the	   post.	   This	  
equates	   to	   a	   random	   effect	   and	   should	   not	   bias	   the	   results.	   Given	   the	   small	   numbers	   of	  
patients	   with	   F5-­‐6	   disease,	   attempting	   logistic	   regression	   would	   be	   statistically	   un-­‐
sound(Peduzzi	   et	   al.,	   1996).	  When	   entering	  VAP-­‐1	   (biotie)	   and	   alpha-­‐2	  macroglobulin	   into	  
stepwise	  logistic	  regression,	  the	  alpha-­‐2	  macroglobulin	  is	  significant	  as	  is	  the	  VAP-­‐1	  hence	  it	  
is	  entered	   into	   the	  model,	  but	  upon	  analysis,	  due	   to	   the	  coefficient	   changing,	  VAP-­‐1	   loses	  
significance.	  This	  is	  hard	  to	  interpret.	  
	  
The	   Odds	   ratio	   (OR)	   here	   used	   with	   a	   continuous	   variable	   represents	   the	   effect	   of	   an	  
increase	  in	  1	  of	  the	  variable.	  Therefore	  Alpha	  2	  Macroglobulin	  which	  has	  very	  low	  values	  is	  
likely	   to	   have	   a	   greater	   odds	   ratio	   than	  VAP	  which	   has	   values	   often	   in	   the	   thousands.	   To	  
adjust	  for	  this,	  standardised	  values	  were	  created	  by	  dividing	  by	  the	  standard	  deviation	  (SD)	  
and	  the	  OR	  were	  recomputed	  as	  below	  (marked	  “std”):	  These	  OR	  represent	  an	   increase	   in	  









Marker	   Sig	   Odds	  Ratio	   95%	  CI	  
CXCL10	   0.011	   1.010	   1.002-­‐1.019	  
Vap-­‐1	  Biotie	   0.028	   1.003	  	   1.000-­‐1.005	  
	   	   	   	  
CXCL10	   0.013	   1.010	   1.002-­‐1.018	  
Vap-­‐1	  Turku	   0.084	   1.001	   0.999	  -­‐1.003	  
	   	   	   	  
Alpha	   2	  
Macroglobulin	  
0.001	   3.053	   1.571-­‐5.931	  
Vap-­‐1	  Biotie	   0.068	   1.002	   0.999-­‐1.005	  
	   	   	   	  
Alpha	   2	  
Macroglobulin	  
0.001	   3.249	   1.673-­‐6.309	  
Vap-­‐1	  Turku	   0.114	   1.001	   0.999-­‐1.002	  
Table	  4-­‐10	  Analysis	  for	  F0-­‐2	  vs.	  3-­‐6	  using	  non	  standardized	  values	  
 
 
Marker	   Sig	   Odds	  Ratio	   95%	  CI	  
CXCL10	  std	   0.011	   2.252	   1.200-­‐4.225	  
Vap-­‐1	  Biotie	  std	   0.028	   2.048	   1.080-­‐3.880	  
	   	   	   	  
CXCL10	  std	   0.013	   2.155	   1.177-­‐3.949	  
Vap-­‐1	  Turku	  std	   0.084	   1.573	   0.942-­‐2.626	  
	   	   	   	  
Alpha	   2	  
Macroglobulin	  std	  
0.001	   2.878	   1.534-­‐5.397	  
Vap-­‐1	  Biotie	  std	   0.068	   1.797	   0.958-­‐3.369	  
	   	   	   	  
Alpha	   2	  
Macroglobulin	  std	  
0.001	   3.052	   1.628-­‐5.722	  
Vap-­‐1	  Turku	  std	   0.114	   1.508	   0.906-­‐2.512	  







4.4.7.1 Logistic	  regression	  to	  predict	  fibrosis	  –	  improving	  on	  commercial	  markers	  
	  
As	  above	  in	  order	  to	  predict	  significant	  fibrosis	  for	  Ishak	  3-­‐6,	  logistic	  regression	  was	  used	  in	  a	  
stepwise	  manner	  but	  using	  commercial	  markers	  where	  all	   variables	  were	  entered	   into	   the	  
model	  whether	   they	  were	  significant	  or	  not.	  3	  models	  were	  used:	  VAP1,	  CXCL10	  and	  then	  
one	  of	  ELF,	  Hepascore	  or	  Fibrotest.	  
Once	   ELF	   has	   been	   included	   in	   the	  model,	   neither	   VAP-­‐1	   (p=0.100)	   nor	   CXCL10	   (p=0.094)	  
adds	  significantly	  to	  the	  model. 
Once	   Hepascore	   has	   been	   included	   in	   the	   model,	   neither	   VAP-­‐1	   (p=0.119)	   nor	   CXCL10	  
(p=0.213)	  adds	  significantly	  to	  the	  model. 
Once	  Fibrotest	  has	  been	  included	  in	  the	  model,	  VAP-­‐1	  (p=0.159)	  does	  not	  add	  significantly	  to	  
the	  model	  but	  CXCL10	  (p=0.032)	  does	  add	  significantly	  to	  the	  model. 
Once	   Fibrotest	   and	   CXCL10	   have	   been	   included	   in	   the	   model,	   VAP-­‐1	   (p=0.279)	   does	   not	  
however	  add	  significantly	  to	  the	  model.	  
 
 
4.4.8 Mann	  Whitney	  U	  analysis	  for	  comparison	  of	  Ishak	  stage	  0-­‐2	  vs.	  3-­‐6	  
 
Mann	   Whitney	   U	   testing	   is	   a	   non-­‐parametric	   test	   to	   test	   a	   null	   hypothesis	   that	   two	  
populations	   are	   the	   same	   against	   an	   alternative	   hypothesis.	   It	   provides	   greater	   efficiency	  
than	  a	  t-­‐test	  on	  non-­‐normal	  distributed	  data	  hence	  its	  application	  here.	  
Significant	  values	  in	  this	  analysis	  (p<0.05)	  show	  that	  the	  value	  of	  the	  variable	  in	  question	  is	  








Ishak	   stage	   0-­‐2	  
median	  ±SD	  
Ishak	   stage	   3-­‐6	  
median	  ±SD	  
Sig	   N	  if	  <85	  
Forns	   351	   7.91±1.6	   8.47±2.0	   0.103	   61	  
Fib-­‐4	   531	   1.19±	  1.02	   1.69	  ±	  1.76	   0.005	   82	  
APRI	   609	   0.43±0.82	   0.58±0.73	   0.037	   82	  
AST:ALT	   638	   0.81±0.33	   0.93±0.73	   0.07	   82	  
Hepascore	   200	   0.35±	  0.32	   0.86±	  0.26	   0.001	   59	  
Fibrotest	   323.5	   0.29±	  0.22	   0.53±0.25	   <0.0001	   75	  
ELF	   459.5	   9.29±1.07	   10.13±	  1.60	   <0.0001	   	  
Fibroscan	   144	   8.40	  ±7.24	   11.65	  ±7.68	   0.022	   45	  
CXCL10	   517	   51.93±	  49.39	   82.88±	  93.43	   0.001	   	  
VAP-­‐1	  Biotie	   575	   468.0±	  172.28	   582.0±	  301.02	   0.005	   	  
VAP-­‐1	  Turku	   610	   1025.0±	  316.75	   1187.0±	  399.75	   0.011	   	  
HA	   463	   51.35±	  196.82	   138.15±	  1099.4	   <0.0001	   	  
P3NP	   619.5	   7.22±	  4.11	   8.59±10.68	   0.014	   	  
TIMP1	   679.5	   246.1±71.82	   296.7±	  177.98	   0.055	   	  
Alpha	   2	  
Macroglobulin	  
313.5	   2.19±	  0.87	   3.06±	  0.81	   <0.0001	   77	  
Haptoglobin	   541.5	   1.60±	  0.60	   1.28±	  0.58	   0.133	   74	  
Apolipoprotein	  
A1	  
635.5	   1.51±	  0.26	   1.47±	  0.42	   0.295	   77	  
 
Table	  4-­‐12	  Mann	  Whitney	  I	  analysis	  for	  comparison	  of	  Ishak	  stage	  0-­‐2	  vs.	  3-­‐6	  
 
 
4.4.9 Comparison	  of	  Biotie	  sVAP	  and	  Turku	  	  sVAP	  
 






Figure	  4-­‐20	  VAP-­‐1	  (Turku	  lab)	  vs.	  VAP-­‐1	  (Biotie	  lab).	  Both	  measured	  in	  ng/ml	  
	  
There	   was	   a	   good	   correlation	   between	   the	   two	   values.	   Pearson	   correlation	   was	   0.784	  
(p<0.0001)	  and	  Spearman	  was	  0.801	  (p<0.0001)	  
	  
	  
The	   plot	   below	   (figure	   4-­‐21)	   shows	   a	   Bland	   –Altman	   plot	   for	   untransformed	   data.	   The	  







Figure	   4-­‐21	   Bland-­‐Altman	   plot	   of	   untransformed	   VAP-­‐1	   (Biotie)	   vs.	   VAP-­‐1	   (Turku).	   Both	  
measured	  in	  ng/ml	  
 
If	   the	  data	   is	   logged	  and	  plotted	  again	  on	  a	  bland-­‐altman	  plot	  (figure	  4-­‐22),	  this	  difference	  
with	  mean	   is	   lost	  suggesting	  a	  proportional	  bias.	  The	  values	   from	  Turku	  are	  approximately	  
twice	  that	  of	  the	  Biotie,	  which	  is	  supported	  by	  the	  third	  plot	  (figure	  4-­‐23),	  which	  illustrates	  



















Figure	   4-­‐22	   Bland-­‐Altman	   plot	   of	   logged	   VAP-­‐1	   (Biotie)	   vs.	   VAP-­‐1	   (Turku)	   showing	   a	  












Figure	   4-­‐23	   Ratio	   between	   VAP-­‐1	   (Biotie)	   and	   VAP-­‐1	   (Turku)	   showing	   a	   constant	   ratio	  





























4.4.10 Image	  J	  analysis	  
4.4.10.1 Standardised	  Image	  J	  analysis	  
78	  slides	  were	  available	   for	  analysis	  as	   some	  blocks	  could	  not	  be	   located	  and	  others	  were	  
not	   available	   due	   to	   use	   in	   other	   research	   projects.	   This	   was	   a	   random	   effect	   again	   and	  
should	  not	  bias	  the	  result.	  
Standardised	  values	  for	  image	  hue,	  saturation	  and	  brightness	  were	  used.	  
Pearson	  correlation	  between	  Image	  J	  values	  and	  Ishak	  stage	  were	  poor	  at	  0.400	  (p<0.0001),	  
but	   when	   personalised	   settings	   were	   used,	   the	   value	   increased	   markedly	   to	   0.810	  
(p<0.0001).	  Spearman	  correlations	  were	  similar	  (0.329	  and	  0.829	  respectively).	  
 






The	   table	   below	   reports	   the	   mean	   and	   median	   collagen	   proportionate	   areas	   when	  
standardized	  settings	  are	  used.	  
Ishak fibrosis stage Mean N Std. Deviation Median 
0 .040879 11 .0222750 .036345 
1 .077798 24 .0756007 .060307 
2 .050245 9 .0267095 .055176 
3 .094889 15 .0837261 .082509 
4 .074674 7 .0702391 .059483 
5 .135242 7 .1080090 .087191 
6 .207490 5 .1359339 .200842 
Total .085888 78 .0839097 .060325 
 







4.4.10.2 Personalized	  Image	  J	  
	  
Figure	  4-­‐25	  Collagen	  proportionate	  area	  using	  Image	  J	  with	  standardised	  settings 
 
The	   table	   below	   shows	   the	  mean	   and	  median	   personalized	   saturation	   settings	  
used	  during	  the	  personalized	  analysis	  
Ishak fibrosis stage Mean N Std. Deviation Median 
0 81.36 11 9.179 80.00 
1 76.92 26 25.580 82.50 
2 75.11 9 8.810 75.00 
3 63.44 16 20.633 67.50 
4 44.67 9 32.334 55.00 
5 40.11 9 31.267 51.00 
6 54.00 5 21.909 60.00 
Total 66.11 85 26.661 70.00 






Table	   4-­‐15	   shows	   the	   collagen	   proportionate	   area	   results	   (mean	   and	   median)	   when	  
personalized	  settings	  are	  used.	  
Ishak fibrosis stage Mean N Std. Deviation Median 
0 .018152 11 .0109808 .013880 
1 .022858 24 .0168104 .019255 
2 .033504 9 .0123297 .032456 
3 .084487 15 .0406477 .069008 
4 .087611 7 .0432270 .101778 
5 .151150 7 .0600619 .165079 
6 .239182 5 .0914836 .236777 
Total .066466 78 .0708790 .040320 
Table	  4-­‐15	  Collagen	  proportionate	  area	  results	  using	  personalised	  settings	  showing	  a	  rise	  
in	  mean	  CPA	  with	  fibrosis	  stage	  
 
The	  R	  squared	  result	  for	  the	  standardized	  results	  was	  0.160	  and	  0.656	  for	  the	  personalized	  
settings.	  	  
When	  the	  difference	   in	  saturation	  settings	  used	  from	  the	  baseline	  of	  70,	  a	  clear	  pattern	   is	  
seen.	  At	   lower	   levels	  of	   Ishak	   fibrosis	   stage,	   Image	   J	  with	   standardized	  settings	  over-­‐reads	  
collagen	  hence	  the	  saturation	  level	  has	  to	  be	  increased	  to	  account	  for	  this.	   Ishak	  stage	  3	  is	  























4.4.11 Using	  the	  personalized	  Image	  J	  settings	  as	  an	  alternative	  gold	  standard	  
	   Spearman	   Significance	   N	  if<78	  
Fib-­‐4	   0.359	   0.002	   75	  
APRI	   0.228	   0.049	   75	  
VAP-­‐1	  Biotie	   0.302	   0.007	   	  
VAP-­‐1	  Turku	   0.276	   0.015	   	  
HA	   0.478	   <0.0001	   	  
P3NP	   0.355	   0.001	   	  
TIMP1	   0.325	   0.004	   	  
CXCL10	   0.455	   <0.0001	   	  
Alpha	   2	  
Macroglobulin	  
0.601	   <0.0001	   73	  
Haptoglobin	   -­‐0.188	   0.119	   70	  
Apolipoprotein	  A1	   -­‐0.042	   0.726	   73	  
Fibrotest	   0.482	   <0.0001	   71	  
Forns	   0.349	   0.008	   56	  
AST:ALT	   0.238	   0.049	   75	  
Fibroscan	   0.451	   0.003	   41	  (45	  valid)	  
ELF	   0.510	   <0.0001	   	  
Hepascore	   0.563	   <0.0001	   55	  
VAP-­‐1	  and	  CXCL10	   0.443	   <0.0001	   	  
Table	  4-­‐16	  Correlation	  of	  variables	  to	  Image	  J	  results	  as	  alternative	  standard	  to	  Ishak	  
 
4.4.11.1 AUROC	  analysis	  of	  Image	  J	  
 
To	   predict	   significant	   fibrosis	   (Ishak	   stages	   3-­‐6),	   the	   personalised	   Image	   J	   settings	   had	   an	  
AUROC	  value	  of	  0.768,	  which	  dropped	  to	  0.551	  when	  the	  standardised	  settings	  were	  used.	  
 
4.4.12 Image	  J	  VAP-­‐1	  analysis	  
 
There	   was	   no	   correlation	   between	   VAP-­‐1	   staining	   and	   Ishak	   fibrosis	   stage	   (figure	   4-­‐27).	  
There	  was	  also	  no	   correlation	  between	   serum	  VAP-­‐1	   levels	   and	  VAP-­‐1	   staining	   (Spearman	  

















4.4.13 SFLC	  and	  Cystatin	  C	  analysis	  
 
Figure	  4-­‐28	  Scatter	  graph	  of	  Freelite	  kappa	  and	  Freelite	  lambda.	  Samples	  from	  liver	  biopsy	  
samples	   (red	   dots)	   showed	   a	   slight	   increase	   in	   light	   chain	   concentrations	   and	   a	   shift	  
towards	   kappa	   ratios	   compared	   with	   healthy	   controls	   (black	   diamonds).	   One	   sample	  
showed	  Combylite	  and	  Freelite	  concentrations	  below	  the	  assay	  detection	  limits	  
 
This	   is	  a	   scatter	  graph	  of	  Freelite	  kappa	  and	  Freelite	   lambda.	  Samples	   from	  the	  study	   (red	  
dots)	  showed	  a	  slight	  increase	  in	  light	  chain	  concentrations	  and	  a	  shift	  towards	  kappa	  ratios	  
compared	   with	   healthy	   controls	   (black	   diamonds).	   One	   sample	   showed	   Combylite	   and	  
Freelite	  concentrations	  below	  the	  assay	  detection	  limits.	  Any	  monoclonal	  FLC	  expansions	  are	  
shown	  by	  kappa/lambda	  ratios	  that	   fall	  outside	  a	  normal	  range	  of	  0.26-­‐1.65.	  Patients	  with	  





the	   reduced	   FLC	   clearance,	   and	   there	   is	   a	   defined	   reference	   range	   for	   patient	  with	   renal	  
failure	  (0.37-­‐3.1,	  blue	  lines)	  
The	   median	   Combylite	   concentration	   in	   samples	   was	   25.2mg/L,	   which	   is	   higher	   than	   in	  
healthy	   controls	   (20mg/L).	   Seven	   patients	   showed	   Combylite	   levels	   >50mg/L,	   which	  
approximates	   to	   the	   summation	  of	   the	   individual	   reference	   ranges	   for	   FLC	   kappa	   and	   FLC	  
lambda	   assays.	   Combylite	   levels	   are	   modestly	   increased	   in	   the	   liver	   biopsy	   samples	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Establishing	   a	   reproducible,	   accurate	   and	   cheap	   non-­‐invasive	  marker	   for	   liver	   fibrosis	   has	  
been	  the	  aim	  of	  researchers	  for	  years.	  Research	  into	  the	  field	  has	  been	  progressing	  recently	  
with	   many	   studies	   adding	   weight	   to	   earlier	   findings	   and	   validating	   them.	   However	  
commercially	  available	  panels	  have	  not	  been	  widely	  adopted	  into	  clinical	  practice	  for	  several	  
reasons.	  Any	  new	  research	  that	   introduces	  new	  clinical	   tests	  must	  be	  repeatedly	  validated	  
before	  it	  will	  be	  accepted	  into	  practice.	  This	  is	  especially	  so	  when	  decisions	  made	  upon	  the	  
information	   provided	   could	   have	   consequences	   to	   patient	   care.	   In	   order	   to	   validate	   new	  
findings,	   samples	   have	   to	   be	   prospectively	   collected	   an	   in	   large	   numbers	   with	   multiple	  
centres.	   This	   all	   takes	   time	   but	   is	   necessary	   to	   quash	   criticisms.	   Such	   studies	   are	   also	  
expensive	  to	  run.	  
Small	   studies	   like	   ours	   are	   valuable	   because	   they	   provide	   further	   validation	   for	   existing	  
biomarkers	  but	  also	  s	  help	  to	  identify	  potential	  new	  markers	  based	  upon	  on	  going	  research	  
that	  may	  be	  added	  to	  the	  panels	  in	  the	  future.	  This	  study	  does	  have	  several	  limitations.	  It	  is	  a	  
single	  centre	  study	  and	  has	  no	  validation	  cohort.	  Numbers	  included	  are	  therefore	  relatively	  
small.	   	   However	   the	   fact	   that	   our	   study	   shows	   ROC	   values	   for	   ELF	   and	   Fibrotest	   that	   are	  
comparable	  to	  previous	  studies	  suggests	  the	  findings	  are	  valid.	  
	  	  
The	   study	   is	   prospectively	   collected	   cohort	   with	   no	   selection	   basis	   other	   than	   that	  
introduced	   by	   the	   requesting	   clinician.	   It	   is	   perhaps	   not	   surprising	   that	   there	   is	   a	   high	  
proportion	  of	   low	  to	  middle	  grade	   Ishak	  stage	  samples,	  as	  clinicians	  are	  unlikely	   to	  biopsy	  





Patients	  were	  not	  selected	  for	  biopsy	  on	  the	  basis	  of	  a	  research	  question	  as	  is	  done	  in	  many	  
other	   studies	   but	   represent	   a	   valid	   representation	   of	   every-­‐day	   patients	   put	   forward	   for	  
biopsy.	  
There	  was	  a	  high	  rate	  of	  Fibroscan	   invalidity	   (42%).	  This	   is	  much	  greater	  than	   in	  published	  
studies	  of	  Fibroscan.	  The	  high	  proportion	  of	  fatty	  liver	  patients	  can	  explain	  this	  high	  rate.	  In	  
normal	  practice,	  the	  clinician	  may	  decide	  against	  a	  scan	  due	  to	  BMI	  but	  in	  the	  study,	  these	  
patients	  were	  scanned	  regardless.	  Many	  clinical	  trials	  using	  Fibroscan	  are	  performed	  in	  viral	  
hepatitis	  patients	  who	  often	  have	  a	  lower	  BMI	  than	  the	  fatty	  liver	  patients.	  	  	  It	  is	  reassuring	  
that	  no	  patient	  with	  a	  Fibroscan	  result	  <8kPa	  had	  a	  histological	  diagnosis	  of	  Ishak	  stage	  ≥4.	  It	  
also	  validates	  the	  findings	  of	  our	  earlier	  study	  that	  the	  Fibroscan	  should	  be	  used	  to	  rule	  out	  
disease	  rather	  than	  to	  rule	  it	   in	  (Corbett	  et	  al.,	  2013).	  In	  neither	  study	  did	  any	  patient	  with	  
F5-­‐6	  disease	  have	  a	  scan	  measurement	  of	  <8kPa.	  Correlations	  are	  also	  far	  more	  significant	  
when	  invalid	  scans	  are	  excluded,	  re-­‐affirming	  the	  importance	  of	  validity.	  It	  is	  reassuring	  that	  
similar	  findings	  are	  seen	  when	  both	  retrospective	  and	  prospective	  data	  collection	  methods	  
are	  used.	  
 
4.5.1 CXCL10	  and	  VAP-­‐1	  
We	  have	  focussed	  particularly	  on	  two	  potential	  biomarkers,	  which	  our	  laboratory	  has	  shown	  
in	   the	   past	   to	   be	   essential	   in	   the	   development	   of	   chronic	   hepatitis	   in	   clinical	   studies	   and	  
animal	  models	   of	   liver	   disease	  CXCL10	   and	  VAP-­‐1.	   	   Based	  on	   their	   biological	   function	   and	  
strong	  mechanistic	  association	  with	  the	  development	  of	  chronic	  hepatitis	  and	  liver	  injury	  we	  
predicted	   they	  would	   be	   good	  biomarkers	   of	   liver	   fibrosis.	   	   This	  was	   indeed	   the	   case	   and	  





regression	   to	   improve	   the	   predictive	   ability	   of	   each	  marker	   to	   predict	   significant	   fibrosis.	  
Given	  the	  small	  numbers	   (<20	   in	  F5-­‐6)	   it	  would	  have	  been	  statistically	  un-­‐sound	  to	  try	   the	  
same	   for	   F5-­‐6.	   The	   ROC	   value	   created	   (0.739)	   by	   combining	   VAP-­‐1	   and	   CXCL10	   through	  
logistic	  regression	  to	  make	  a	  predicted	  probability	  for	  Ishak	  0-­‐2	  vs.	  3-­‐6	  is	  similar	  to	  that	  seen	  
with	  commercially	  available	  tests.	  	  
Our	   study	   confirms	   the	   link	   between	   VAP-­‐1	   and	   fibrosis	   and	   this	   is	   consistent	   with	   work	  
currently	  submitted	  for	  publication	  form	  our	  group	  reporting	  that	  VAP-­‐1	  plays	  an	  important	  
role	  in	  the	  development	  of	  hepatitis	  and	  fibrosis	  in	  several	  animal	  models	  of	  liver	  disease.	  In	  
order	  to	  assess	  its	  clinical	  use,	  larger	  prospective	  studies	  are	  required	  where	  we	  can	  assess	  
serial	   measurements	   and	   see	   how	   well	   it	   predicts	   clinical	   events	   and	   outcome.	   	   We	  
measured	   sVAP-­‐1	   in	   two	  different	   collaborating	   laboratories	   and	   although	   the	  patterns	   of	  
expression	  were	   the	   same	   the	   absolute	   values	   showed	   some	   differences	   emphasising	   the	  
importance	   of	   establishing	   reliable	   clinically	   validated	   assays	   before	   this	   test	   can	   be	   used	  
clinically.	  
 
4.5.2 VAP-­‐1	  and	  alpha-­‐2	  macroglobulin	  
Logistic	   regression	   analysis	   of	   these	   two	   markers	   yielded	   an	   un-­‐interpretable	   result.	  
Stepwise	  analysis	  revealed	  that	  both	  markers	  could	  be	  entered	  into	  the	  model,	  but	  that	  once	  
the	  model	  was	  run,	  due	  to	  the	  change	  in	  co-­‐efficient,	  the	  significance	  of	  adding	  VAP-­‐1	  was	  







4.5.3 Collagen	  proportionate	  analysis	  (CPA)	  
 
The	   accuracy	   of	   CPA	   to	  measure	   fibrosis	   depends	   on	   biopsy	   length	   according	   to	   a	   recent	  
paper(Hall	  et	  al.,	  2013)	  with	  best	  accuracy	  seen	  in	  biopsies	  of	  22-­‐28mm.	  The	  median	  length	  
of	   the	   biopsies	   in	   the	   study	   was	   23.5mm.	   Only	   5	   biopsies	   were	   ≤15mm	   and	   only	   1	   was	  
≤10mm.	   	   What	   became	   clear	   from	   morphometric	   analysis	   was	   that	   a	   “one	   size	   fits	   all”	  
approach	   with	   the	   same	   setting	   applied	   to	   each	   slide	   with	   CPA	   is	   not	   accurate.	   The	  
correlations	   between	   the	   standardised	   settings	   applied	   to	   each	   individual	   slide	  with	   Ishak	  
staging	   were	   far	   worse	   than	   when	   personalised	   settings	   were	   applied	   to	   slides.	   The	  
weakness	  in	  comparing	  a	  histological	  score	  and	  a	  morphometric	  analysis	  is	  the	  fact	  that	  the	  
morphometric	   analysis	   gives	   a	   linear	   scale	   with	   presumed	   equal	   rise	   in	   fibrosis	   between	  
Ishak	  stages	  whereas	  Ishak	  is	  not	  however	  a	  linear	  scale	  and	  encompasses	  much	  more	  than	  
just	   collagen	   load.	   The	   scale	  was	   invented	   to	  not	  only	  describe	   fibrosis	  but	   also	   structural	  
changes	  present	  to	  the	  trained	  eye	  of	  the	  histopathologist.	  
 
4.5.3.1 Comparing	  standardised	  to	  personalised	  Image	  J	  settings	  
As	  explained	  above,	  each	  slide	  was	  analysed	  suing	  standardised	  Image	  J	  settings.	  It	  was	  then	  
re-­‐examined,	  using	  a	  saturation	  setting	  that	  was	  determined	  by	  the	  analyst.	  Sometimes	  this	  
was	  the	  same	  as	  the	  standard	  setting,	  but	  usually	  differed	  especially	  towards	  either	  end	  of	  
the	   Ishak	   spectrum	   (see	  Figure	  4-­‐26	  Scatter	  plot	   to	   illustrate	   change	   in	   saturation	   settings	  
according	  to	  Ishak	  stage).	  The	  proportions	  of	  collagen	  within	  a	  biopsy	  have	  been	  analysed	  in	  
previous	  papers	  (Standish	  et	  al.,	  2006)	  showing	  the	  non-­‐linear	  nature	  of	  the	  rise	  in	  collagen.	  	  





vs.	  the	  personalised	  settings.	  Clearly	  the	  personalised	  settings	  increase	  throughout	  the	  Ishak	  
stages	  rather	  than	  having	  no	  pattern	  other	  than	  a	  marked	  increase	  in	  fibrosis	  at	  Ishak	  stage	  6	  
(established	   cirrhosis)	   when	   standardised	   results	   are	   used.	   The	   personalised	   results	   also	  
compare	   favourably	   to	   the	   Standish	   paper.	   Spearman	   correlation	   of	   the	   personalised	  
settings	  to	  the	  Standish	  results	   is	  0.984	  compared	  to	  0.795	  with	  standardised	  settings.	  The	  
two	  settings	  do	  correlate	  with	  each	  other	  (0.880).	  
 
Ishak	  Stage	   Standardised	   Image	   J	  
result	  (%	  collagen)	  
Personalised	   Image	   J	  
result	  (%	  collagen)	  
Standish	   paper	  
mean	  result	  
0	   3.6%	   1.3%	   1.9%	  
1	   6.0%	   1.9%	   3.0%	  
2	   5.5%	   3.2%	   3.6%	  
3	   8.2%	   6.9%	   6.5%	  
4	   5.9%	   10.1%	   13.7%	  
5	   8.7%	   16.5%	   24.3%	  
6	   20.0%	   23.6%	   27.8%	  
Table	   4-­‐17	   Values	   of	   CPA	   compared	   to	   Ishak	   stage	   having	   used	   standardised	   and	  
personalised	  settings.	  Comparison	  to	  Standish	  results	  included	  
	  
The	  weakness	  of	  using	  personalised	  settings	   in	  the	  analysis	  of	  the	  slides	   is	  the	  potential	  to	  
introduce	  bias.	  A	  truly	  automated	  system	  without	  human	  interference	  can	  be	  relied	  upon	  to	  
make	  decisions	  based	  upon	  a	  protocol.	  Until	   such	  a	  system	   is	  developed,	   the	  potential	   for	  
bias	  exists.	  In	  this	  case	  the	  results	  are	  far	  more	  representative	  of	  previous	  published	  data.	  	  
 
4.5.3.2 Slide	  Staining	  
There	   also	   remains	   the	  unanswered	  question	  over	   the	  optimal	   stain	   to	  be	  used.	  We	  used	  
Van	   Giessen	   as	   this	   is	   the	   standard	   stain	   used	   for	   clinical	   analysis	   in	   our	   histopathology	  
laboratory	   but	   others	   have	   used	   a	   Sirius	   Red	   stain.	   In	   order	   to	   allow	   Image	   J	   to	   pick	   out	  





that	  the	  slide	  could	  only	  be	  used	  for	  the	  purpose	  of	  morphometric	  analysis	  and	  not	  for	  other	  
diagnostic	  reasons.	  This	  may	  have	  implications	  when	  a	  small	  block	  is	  present	  such	  as	  might	  
be	   the	   case	   with	   trans-­‐jugular	   liver	   biopsies.	   Morphometric	   analysis	   is	   also	   very	   time	  
demanding	  and	  until	  some	  of	  the	  process	  can	  be	  automated,	  it	  will	  remain	  largely	  a	  research	  
tool.	  The	  problem	  with	  automating	  the	  process	  is	  that	  as	  I	  have	  demonstrated,	  standardised	  
values	  are	  inappropriate	  for	  analysis	  as	  error	  is	  introduced	  at	  the	  extremes	  of	  Ishak	  staging.	  
Until	   a	   reliable	   automated	  process	   can	  be	  developed	   that	   accounts	   for	   this	   its	  use	  will	   be	  
limited.	  
 
4.5.3.3 VAP	  Morphometric	  analysis	  
As	   can	   be	   seen	   from	   the	   morphometric	   analysis	   of	   the	   VAP-­‐1	   staining,	   there	   was	   no	  
correlation	  between	  serum	  levels	  of	  VAP-­‐1	  and	  the	  degree	  of	  staining	  for	  VAP-­‐1	  on	  the	  liver	  
tissue.	   From	   work	   done	   by	   our	   lab	   we	   do	   know	   that	   total	   serum	   VAP-­‐1	   concentration	  
correlates	   well	   with	   serum	   VAP	   enzyme	   activity	   (Kurkijärvi	   et	   al.,	   1998)	   and	   recent	  
unpublished	  work	  (Trivedi	  et	  al.,	  2013).	  The	  analysis	  was	  done	  using	  explanted	  liver,	  but	  as	  
far	  as	  the	  authors	  are	  aware,	  there	  are	  no	  published	  data	  comparing	  tissue	  and	  serum	  levels	  
of	   VAP-­‐1.	  Most	   of	   the	   staining	   was	   sinusoidal	   and	   on	   the	   vessels	   as	   has	   been	   previously	  
described	  and	  it	   is	  possible	  that	  this	  distribution	  does	  not	  give	  a	  large	  enough	  stained	  area	  
for	   the	  morphometric	   analysis	   to	  be	   sensitive	  enough.	   	   Perhaps	  a	  better	  way	  of	   analysing	  
VAP-­‐1	   levels	   in	   tissue	  would	  be	  a	  western	  blot	  which	  would	  also	  allow	  analysis	  of	  enzyme	  






4.5.3.4 Use	  of	  CXCL-­‐10	  ±	  VAP-­‐1	  to	  composite	  panels	  for	  fibrosis	  testing	  
	  
There	  is	  the	  potential	   in	  the	  future	  to	  add	  CXCL-­‐10	  and	  VAP-­‐1	  to	  composite	  panels	  such	  as	  
ELF	  and	  Fibrotest	  to	  increase	  their	  accuracy	  in	  predicting	  liver	  fibrosis.	  Our	  data	  has	  shown	  
that	   CXCL10	   can	   be	   added	   to	   Fibrotest	   to	   improve	   its	   performance.	   No	   other	   result	   was	  
significant	  although	  adding	  CXCL10	  to	  ELF	  approached	  significance.	  Clearly	  this	  is	  promising,	  







The	  small	  number	  of	  samples	  included	  limits	  a	  study	  like	  this.	  Given	  the	  amount	  of	  tests	  that	  
were	  done	  it	   is	  possible	  that	  one	  of	  them	  may	  have	  been	  positive	  by	  chance.	  However,	  no	  
test	   was	   done	  without	   justification,	   which	   is	   detailed	   earlier.	   In	   order	   to	   improve	   on	   the	  
statistical	   power	  of	   this	   study,	   it	   needs	  more	  numbers,	   and	  hopefully	   colleagues	  upon	  my	  






This	   study	   has	   confirmed	   that	   commercially	   available	   non-­‐invasive	   biomarkers	   (ELF	   and	  
Fibrotest)	  and	  most	  of	  their	  constituents	  correlated	  with	  fibrosis	  stage	  on	  liver	  biopsy.	  	  
Our	  study	  is	  novel	  because	  it	  analysed	  such	  a	  large	  panel	  of	  immune	  and	  fibrosis	  markers	  in	  
patients	  undergoing	  liver	  biopsy	  and	  Fibroscan	  and	  because	  it	  reports	  correlations	  between	  
VAP-­‐1	  and	  CXCL-­‐10,	  new	  biomarkers	  with	  histological	  fibrosis.	  	  	  
The	  novel	  finding	  that	  CXCL10	  when	  paired	  with	  VAP-­‐1	  improves	  the	  ability	  of	  each	  factor	  to	  
diagnose	  significant	  fibrosis	  suggests	  that	  these	  two	  biomarkers	  might	  be	  incorporated	  into	  
new	   clinically	   testable	   panels.	   Greater	   numbers	   would	   also	   probably	   show	   that	   the	  
combination	  of	  VAP-­‐1	  and	  alpha-­‐2	  macroglobulin	  can	  do	  the	  same.	  Further	  work	  should	  be	  
performed	  to	  confirm	  the	  mechanism	  and	  the	  link.	  
	  
Morphometric	   analysis	   by	   CPA	   of	   liver	   fibrosis	   has	   shown	   that	   the	   same	  markers	   can	   be	  
linked	  to	  quantitatively	  measured	  fibrosis.	  CPA	  is	  an	  emerging	  technique	  with	  the	  potential	  
to	  remove	  inter	  and	  intra	  operator	  variance	  although	  given	  the	  need	  for	  additional	  steps	  in	  












Liver	  disease	   is	  on	   the	  rise	  and	  there	   is	  an	   increasing	  need	  to	  be	  able	   to	  accurately	  assess	  
patients	  with	  regard	  to	  their	  fibrosis	  stage	  and	  prognosis	  so	  that	  intervention	  can	  be	  planned	  
in	   those	   most	   likely	   to	   respond	   and	   with	   the	   greatest	   need.	   Traditionally	   liver	   disease	   is	  
assessed	   clinically	   with	   the	   aid	   of	   investigations	   such	   as	   liver	   function	   blood	   tests	   and	  
ultrasound.	  Accurate	  assessment	  of	   liver	   fibrosis	  however	  has	  been	  more	  difficult	  and	  has	  
relied	   on	   liver	   biopsy.	   Liver	   biopsy	   is	   a	   flawed	   technique	   due	   to	   intra	   and	   inter-­‐operator	  
variability	   but	   it	   remains	   the	   gold	   standard	   for	   assessing	   fibrosis.	   It	   is	   not	   without	  
complications	   and	  patients	  will	   experience	  pain,	   as	  well	   as	   being	   subjected	   to	   a	   small	   but	  
definite	   morbidity	   and	   mortality	   risk.	   This	   has	   prompted	   the	   search	   for	   alternative	   and	  
potentially	  better	  markers	  of	  liver	  fibrosis	  that	  are	  non-­‐invasive.	  
In	  this	  thesis	  I	  have	  summarised	  the	  current	  state	  of	  play	  using	  non-­‐invasive	  tests	  to	  assess	  
liver	   fibrosis	   and	   suggested	   new	   markers	   that	   may	   improve	   the	   diagnostic	   accuracy	   and	  
clinical	  utility	  of	  current	  tests.	  
	  
In	  chapter	  2	  we	  detailed	  how	  Fibroscan	  can	  be	  used	  in	  a	  busy	  liver	  unit	  to	  exclude	  significant	  
fibrosis.	  Whilst	   this	   is	  not	  a	  new	  finding,	   the	  fact	  that	  our	  study	  was	  done	   in	  a	  real	  clinical	  
setting	   rather	   than	   as	   part	   of	   a	   research	   protocol	  makes	   it	   directly	   applicable	   to	   the	   real	  
world	  clinic.	  	  Our	  study	  emphasised	  the	  importance	  of	  adhering	  to	  set	  criteria	  that	  validate	  
the	   reading	   and	   of	   excluding	   readings	   that	   fall	   outside	   these	   criteria.	  We	   showed	   that	   if	  
these	  criteria	  are	  not	  adhered	  to	  then	  the	  test	  becomes	  unreliable	  and	  un-­‐interpretable.	  We	  
have	   shown	   that	   it	   might	   be	   possible	   in	   the	   future	   to	   introduce	   local	   cut-­‐offs	   for	   the	  





diagnosis	   of	   significant	   fibrosis,	   although	   this	   will	   complicate	   comparisons	   with	   other	  
departments.	  In	  a	  busy	  liver	  unit	  we	  have	  also	  shown	  that	  Fibroscan	  is	  an	  easy	  skill	  to	  learn	  
and	  one	  we	  suggest	  should	  be	  part	  of	  a	  trainees	  Hepatology	  training	  as	  well	  as	  being	  offered	  
to	  specialist	  nurses.	  This	  will	  aid	  in	  the	  efficiency	  of	  liver	  clinics	  in	  the	  future.	  
	  
In	   chapter	  3	  we	  used	   systematic	   review	  and	  meta-­‐analysis	   to	   show	  how	  well	  non-­‐invasive	  
markers	  of	  liver	  fibrosis	  predict	  clinical	  outcomes	  and	  prognosis	  of	  chronic	  liver	  disease.	  It	  is	  
important	   to	   note	   the	   difference	   between	   prediction	   and	   prognosis	   here.	   Predictive	  
biomarkers	   identify	   subpopulations	   of	   patients	  who	   are	  most	   likely	   to	   respond	   to	   a	   given	  
therapy.	  With	   predictive	   biomarkers	   it	   should	   be	   possible	   to	   select	   the	   therapy	   with	   the	  
highest	   likelihood	   of	   efficacy	   to	   the	   individual	   patient.	   	   A	   prognostic	   biomarker,	   provides	  
information	  on	  the	  likely	  course	  of	  the	  disease	  in	  an	  individual.	  The	  main	  finding	  of	  the	  work	  
is	  that	  APRI	  and	  Fib-­‐4	  can	  be	  used	  to	  predict	  death	  in	  patients	  with	  viral	   liver	  disease.	  This	  
work	  was	  however	   limited	  by	  significant	   study	  heterogeneity	  and	   the	  use	  of	  different	  cut-­‐
offs	   of	   the	   markers	   involved.	   This	   is	   a	   field	   that	   could	   be	   improved	   by	   more,	   large	  
collaborative	  studies	  with	  the	  implementation	  of	  internationalised	  standards.	  
	  
In	   Chapter	   4,	   I	   report	   the	   results	   of	   a	   prospective	   observational	   study	   to	   analyse	   a	   large	  
panel	   of	   established	   and	   new	   serum	   biomarkers	   to	   predict	   fibrosis	   on	   simultaneously	  
collected	   liver	   biopsy.	   We	   showed	   that	   commercially	   available	   tests	   such	   as	   ELF	   and	  
Fibrotest	   accurately	   predict	   liver	   fibrosis	   as	   measured	   by	   histology.	   However	   as	   detailed	  
above,	  the	  gold	  standard	  of	  liver	  biopsy	  is	  flawed	  because	  the	  various	  stages	  are	  not	  linear	  in	  





morphometric	   analysis.	  Non-­‐invasive	   serum	  markers	   rely	   on	   the	   fibrotic	   process	   to	   create	  
markers	  that	  are	  shed	  into	  circulation	  that	  can	  be	  detected.	  A	  pathologist’s	  staging	  via	  Ishak	  
(or	   other	   disease	   specific	   scores)	   is	   not	   just	   based	   on	   the	   degree	   of	   fibrosis	   but	   also	   the	  
architectural	  changes.	  We	  have	  shown	  that	  VAP-­‐1	  and	  CXCL10	  can	  be	  used	  as	  non-­‐invasive	  
markers	   of	   liver	   fibrosis	   with	   AUROC	   values	   that	   approach	   that	   of	   commercially	   available	  
tests.	  The	  study	  follow	  up	  time	  is	  too	  short	  to	  make	  any	  analysis	  of	  the	  tests	  ability	  to	  predict	  
clinical	  outcomes	  but	  these	  data	  will	  be	  available	  as	  part	  of	  the	  long-­‐term	  follow	  up	  of	  the	  
NOBLES	  cohort	  study.	  
	  	  
Also	  presented	   in	  this	  chapter	   is	   the	  morphometric	  analysis	  of	   liver	  biopsy	  samples.	   I	  have	  
shown	  that	  the	  technique	  using	  standardised	  settings	  for	  each	  slide	  yields	  inaccurate	  results	  
when	  compared	  to	  Ishak	  staging	  and	  other	  non-­‐invasive	  markers.	  This	  is	  improved	  upon	  by	  
altering	  the	  settings	  for	  each	  slide.	  The	  problem	  with	  doing	  this	  is	  the	  potential	  to	  introduce	  
bias	  and	  also	  it	  makes	  future	  studies	  of	  this	  technique	  difficult.	  As	  I	  have	  shown	  in	  chapter	  3,	  
any	   test	   that	   has	   varying	   cut-­‐offs	   makes	   meta-­‐analysis	   more	   difficult.	   It	   is	   however	   a	  
promising	   new	   technique	   that	   may	   help	   pathologists	   provide	   individualised	   information	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6.1 NOBLES	  Documentation	  
6.1.1 Data	  collection	  sheet	  Visit	  1	  and	  2	  
	  




 Property of the Liver Research Group: The University of Birmingham UK. 
 NOBLES Data Collection Sheet Visit 1 Version 1.0 30th June 2011 
 
 
Clinical Data Collection sheet Visit 1 
Screening Visit 
Consent signed? 




Hospital Number  
 
Sex    M/F 
Trial ID Number  
 
Exclusion / Inclusion criteria met?  Y/N 
 
Liver disease type 
 









Liver related complications 
 
Observations Temp  HR  BP  Weight  Height 
 BMI 
 Waist circumference    Hip circumference 




Gastro / liver 
Neuro 
ECG - findings 
Blood Tests 
Fasted?  Y/N 
Obtain blood for FBC, PT and INR, U&E, LFTs (AST,ALT, Bili, GGT) AFP and Glucose (1x 4ml 
purple top, 1x3.5ml blue top, 1x4ml grey top and 1x 4ml yellow top) 
Obtain blood for fibromax panel (2x5ml Grey and 2x 5ml Yellow top) 
Obtain serum for ELF panel, Fibromax panel, sVAP-1, CK18, serum leptin, IP1-, Il-1B, MCP-1 and 
fasting insulin as well as storage (4x 6ml Red Top) 
 
Plasma for storage (2x 4ml purple top) 
 
White Cells for storage (1x4ml purple top) 
 
Liver  screen  bloods  to  be  taken  if  not  already  done  for  HbsAg,  HCV  Ab,  AMA  /  SMA  /  Ig’s,  Ferritin,  
Caeruloplasmin, A1AT 
Fibroscan result  kPa  IQR:  Probe type: 
 
Visit 2 scheduled for: 
 











 Property of the Liver Research Group: The University of Birmingham UK. 
 NOBLES Data Collection Sheet Visit 2 Version 1.0 30th June 2011 
 
 
Clinical Data Collection sheet Visit 2  




Hospital Number  
 
Sex    M/F 




Current Medications – record any changes 
 
 
Liver related complications or other significant events since last seen 
 
Observations Temp  HR  BP  Weight  Height 
 BMI 




Gastro / liver 
Neuro 
ECG - findings 
Blood Tests Fasted?  Y/N 
 
Obtain blood for FBC, PT and INR, U&E, LFTs (AST,ALT, Bili, GGT) AFP and Glucose (1x 4ml 
purple top, 1x3.5ml blue top, 1x4ml grey top and 1x 4ml yellow top) 
 
Obtain blood for fibromax panel (2x5ml Grey and 2x 5ml Yellow top) 
 
Obtain serum for ELF panel, Fibromax panel, sVAP-1, CK18, serum leptin, IP1-, Il-1B, MCP-1 and 
fasting insulin as well as storage (4x 6ml Red Top) 
 
Plasma for storage (2x 4ml purple top) 
 
White Cells for storage (1x4ml purple top) 
 






























6.2 Published	   version	   of	   Chapter	   2	   in	   Postgraduate	   Medical	   Journal	   entitled	  
“Operator	   training	   requirements	   and	   diagnostic	   accuracy	   of	   Fibroscan	   in	  
routine	  clinical	  practice”	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